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Abstract 
This thesis focused on generating a detailed understanding of the primary metabolism and its regulation in 
the novel human cell line AGE1.HN and the application of the acquired knowledge to improve 
biopharmaceutical production. The different issues that were addressed include (i) metabolic shifts during 
cultivation, (ii) metabolite channeling and metabolic fluxes during overflow metabolism, (iii) primary 
metabolism at various substrate levels and the effect of different substrate feeding on cell culture process 
and metabolism, (iv) adaptation of the metabolism to ammonia stress, (v) metabolism and metabolic 
burden imposed by recombinant α1-antitrypsin production, and (vi) improvement of metabolism and 
biopharmaceutical production in AGE1.HN. Several types of metabolic network modeling and metabolic 
flux analysis (MFA) were applied. A time resolved MFA approach was developed to analyze metabolic 
shifts over time. Stationary MFA using mass balances was used extensively to identify alterations in the 
metabolism induced by physiological perturbations. 13C tracers and 13C MFA were applied to get in-depth 
insights into metabolite channeling and compartmented fluxes in the metabolism. The presented results 
provide valuable guidance for improvement of AGE1.HN, in particular, and of the biopharmaceutical 
production in mammalian cells in general. Additionally, this thesis contributes to an improved 
understanding of metabolic regulation in human cells. 
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Zusammenfassung 
In dieser Arbeit wurden der Primärmetabolismus und dessen Regulation in der humanen Zelllinie 
AGE1.HN analysiert, wobei der Fokus auf der Anwendung des erworbenen Wissens zur Verbesserung 
der biopharmazeutischen Produktion lag. Folgende Aspekte wurden untersucht: (i) Veränderungen des 
Metabolismus im Kultivierungsverlauf, (ii) metabolische Flüsse unter Überflussbedingungen, (iii) 
Metabolismus und α1-Antitrypsin-Produktion bei verschiedenen Substratkonzentrationen, (iv) Anpassung 
des Metabolismus an Ammonium-Stress, (v) zelluläre und metabolische Adaptation an die Produktion von 
rekombinantem α1-Antitrypsin und (vi) Verbesserung des Metabolismus und der biopharmazeutischen 
Produktion in AGE1.HN. Verschiedene Arten der Modellierung von metabolischen Netzwerken sowie 
der metabolischen Flussanalyse (MFA) wurden hierbei angewendet. Eine dynamische MFA Methode 
wurde zur Analyse metabolischer Veränderungen entwickelt. Stationäre MFA wurde verwendet um 
Anpassungen des Metabolismus zu charakterisieren. 13C Markierungsexperimente sowie 13C MFA wurden 
genutzt um detaillierte Einsichten in das Channeling von Metaboliten sowie in die metabolischen Flüsse 
innerhalb und zwischen verschiedenen Kompartimenten zu erlangen. Die Ergebnisse stellen eine 
wertvolle Basis zur weiteren Verbesserung der biopharmazeutischen Produktion in AGE1.HN sowie in 
anderen Säugerzellen dar. Die vorliegende Arbeit trägt zusätzlich zu einem besseren Verständnis der 
Metabolismus-Regulation in humanen Zellen bei. 
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Aim and outline of the thesis 
The work described in this thesis was imbedded in the BMBF project SysLogics – Systems biology of cell 
culture for biologics. This project aimed at the development and refinement of system biological methods 
for the analysis of metabolic and regulatory processes in mammalian cells. Additionally, these methods 
were applied for an in-depth characterization of the physiology of the novel human cell line AGE1.HN 
which was developed for the production of challenging glycoproteins requiring complex human-type 
glycostructures. A thorough knowledge of the dynamics of cellular metabolism and related regulatory 
processes is mandatory for setting up models that might eventually allow the performance of the cells 
under varying conditions to be predicted. 
The pre-defined goals of this thesis were (i) the development and refinement of methods for metabolic 
flux analysis in industrially relevant, mammalian cell culture processes and (ii) the application of these 
methods to study the central metabolism in the AGE1.HN cell line and derived producer clones.  
A general introduction to metabolic flux analysis and its significance for system biological research in 
mammalian cells is provided in chapter 1. Additionally, application examples of metabolic flux analysis in 
different mammalian cells are reviewed. 
When we started to work with the new cell line AGE1.HN, almost nothing was known about the 
metabolism in these cells. In chapter 2, the first characterization of the AGE1.HN cell line concerning 
growth, metabolic profiles, and intracellular metabolism is presented. For an improved analysis of the 
metabolic shifts that were observed during cultivation, we additionally developed a flexible metabolic flux 
analysis method, called time resolved metabolic flux analysis, which is suitable for analyzing fluxes in 
industrially relevant cell culture processes in which the cellular metabolism has to adapt to a changing 
environment. Metabolism and metabolic shifts during batch cultivation of AGE1.HN were analyzed by 
this dynamic method and compared to flux estimates obtained by stationary metabolic flux analysis. We 
were able to identify the main events triggering alterations in the metabolism.  
Very detailed insights into the metabolism of AGE1.HN during overflow conditions were obtained by 
employing labeling experiments using 13C labeled substrates and by performing 13C metabolic flux analysis. 
The data are presented in chapter 3. We were able to verify connections between different metabolite 
pools and the activity of central metabolic pathways was unraveled. Additionally, the results were useful to 
get further hints for an optimization of the cell line and its cultivation. One finding which was particularly 
interesting was the observed low connectivity between cytosolic pyruvate and mitochondrial pyruvate 
pools during overflow conditions.  
The adaptation of the primary metabolism of AGE1.HN to various substrate levels was analyzed in a 
following study which is presented in chapter 4. An important finding of this analysis was an increasingly 
inefficient metabolism with increasing pyruvate load. We were able to show in cultivations of an α1-
antitrypsin producing cell clone, AGE1.HN.AAT, applying different feeding profiles that reduction of 
pyruvate load improves metabolic efficiency and increases α1-antitrypsin production.  
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The accumulation of toxic waste products during cell culture processes is still a factor that limits the 
productivity. Chapter 5 focuses on the detailed analysis of the effects of elevated ammonia concentrations 
on growth, metabolism, and α1-antitrypsin production in AGE1.HN.AAT cells. We were able to unravel 
the adaptation mechanism of this cell line to high ammonia conditions which is accomplished by global 
flux rearrangement in the amino acid metabolism leading to increased fixation of free ammonia in specific 
amino acids.  
What are the specific cellular properties responsible for high-level glycoprotein production in selected 
producer clones? This question is addressed in chapter 6 by comparing the high producing cell line 
AGE1.HN.AAT with the parental cell population. By analyzing dynamics of biomass constituents, 
metabolic differences, and by modeling and simulation of the metabolic burden imposed by glycoprotein 
production, we were able to identify important properties of the producer. The data pointed to further 
interesting targets for improvement of biopharmaceutical production not only in the AGE1.HN cell line 
but also in mammalian cells in general. 
Optimization of biopharmaceutical production can be performed, e.g., by genetic engineering of cell lines 
or media optimization. Based on the previous detailed studies, it was possible to design an engineering 
strategy for improving the metabolic phenotype of AGE1.HN. Besides the modification of substrate 
concentrations in the medium, as applied in the study in chapter 4, addition of specific substances having 
selected beneficial effects on cell physiology, primary metabolism, protein production, and product yields 
represents a promising strategy that is addressed in chapter 7. It is shown that addition of the flavonoid 
quercetin remarkably improves the overall performance of the cells and, eventually, the final product titer. 
Using the available analytical and developed metabolic flux analysis tools, we were able to show that 
quercetin treatment results in specific dose-dependent changes in the primary metabolism of this human 
cell line. Additionally, we were able to contribute to an improved understanding of quercetin action on 
human cells. 
In chapter 8 possible future prospects are presented and discussed. 
 
 
Chapter 1 General introduction 
The word cloud was designed at http://www.tagxedo.com 9 
1 General introduction – metabolic flux analysis in mammalian 
cells 
 
Contents in this chapter were partly published in the following reviews  
Niklas J, Heinzle E. Metabolic flux analysis in systems biology of mammalian cells. Adv Biochem Eng 
Biotechnol. 2011 Mar 24. DOI: 10.1007/10_2011_99. 
Niklas J, Schneider K, Heinzle E. Metabolic flux analysis in eukaryotes. Curr Opin Biotechnol. 2010 
Feb;21(1):63-9.  
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Systems biology has become an increasingly exciting field in biological science. An increasing number of 
research institutions and groups are focusing on this field, and various public and private funding agencies 
and companies are substantially supporting research in this field. The major reason for this substantial 
investment is the anticipated increase in understanding the functioning of biological systems that is 
expected to strongly support the creation of new and improved therapies, drugs, as well as 
biotechnological processes (Alberghina and Westerhoff 2005; Choi 2007). The enormous booming of this 
area is heavily driven by the breathtaking progress in molecular biology combined with the development 
of large-scale experiments whose data collection and analysis only became possible with the new 
bioinformatic methods and tools. Bioinformatics has made it possible to store relevant data on databases 
that are quickly accessible by everybody at any time on a global scale. In parallel, techniques of 
mechanistic modeling are evolving that permit structured development of mathematical models and their 
solution on a larger scale. It is primarily these models that are essential in the process of conceptual 
clarification and that allow testing the power of prediction. 
Mammalian cells are model organisms that are used to help understanding diseases like cancer or 
neurological diseases (Villoslada et al. 2009) and identifying suitable drug targets. Mammalian cells, 
particularly human cells, are of increasing relevance for testing the metabolism and toxicity of drug 
candidates (Beckers et al. 2010; Niklas et al. 2009; Noor et al. 2009). Another major application of 
mammalian cells is in the production of biopharmaceuticals (O'Callaghan and James 2008), in particular of 
proteins such as antibodies, but also of vaccines and viral carriers for gene therapy (Genzel and Reichl 
2009; Wurm 2004). Hereby, a solid systems understanding will assist in improving product quality, e.g., 
correct human glycosylation, and product titers, e.g., by systems-supported media design or model-driven 
genetic modifications. Engineering of producing cells will be supported by a new discipline, synthetic 
biology, that helps designing new biological systems or elements thereof, e.g., new promoters, switches, or 
sensors (Koide et al. 2009; Weber and Fussenegger 2007). In order to understand and improve production 
processes or to understand toxic effects, methods are needed that can describe the different phenotypes 
of the cells under different conditions. Metabolic fluxes or intracellular reaction rates represent an 
endpoint of a metabolic network reflecting all types of network events including regulation at different 
levels, i.e., gene, protein, and metabolic interactions (Niklas et al. 2010; Sauer 2006), making it a very 
powerful method for systems biology research (Fig. 1-1).  
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Fig. 1-1 Interactions on the various levels of the cellular hierarchy (Niklas and Heinzle 2011). 
 
The analysis of metabolic fluxes has been employed extensively in the past to understand, design, and 
optimize a number of cell types and biological processes (Boghigian et al. 2010; Niklas et al. 2010; Quek et 
al. 2010). Metabolic flux analysis (MFA) provides a quantitative description of in vivo intracellular reaction 
rates in metabolic networks describing activities of intracellular enzymes and whole pathways (Wittmann 
2007). Fluxes can be quantified either by using metabolite balancing, often also called flux balance analysis 
(FBA), or by 13C MFA, which involves the use of 13C isotope-labeled substrates (Wiechert and de Graaf 
1996).  
Flux analysis using metabolite balancing for microorganisms was described as early as 1978 (Aiba and 
Matsuoka 1978). It has been and still is the most commonly applied method for the analysis of the 
metabolism of mammalian cells (Bonarius et al. 1996; Niklas et al. 2009; Quek et al. 2010; Sidorenko et al. 
2008). The accuracy of flux estimates can be improved compared to pure metabolite balancing by using 
13C tracers in metabolic flux studies and later incorporation of the resulting labeling information stored in 
the metabolites into the flux calculation. Different mathematical methods that have been developed in the 
past have significantly contributed to the applicability of 13C flux analysis. Zupke and Stephanopoulos 
introduced the concept of atom mapping matrices (AMM) for the modeling of isotope distributions in 
metabolic networks (Zupke and Stephanopoulos 1994). A following important advancement was the 
introduction of isotopomer mapping matrices (IMM) by Schmidt et al. (Schmidt et al. 1997), which 
Chapter 1 General introduction 
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allowed using the complete information of the isotopomer distributions of metabolites and the elegant use 
of matrices for solving complex isotopomer models. Another method is based on local isotopomer 
balances and allows the estimation of local flux split ratios (Fischer et al. 2004; Nanchen et al. 2007; Sauer 
et al. 1997). This method is generally very suitable for high-throughput because of its easy calculation. Flux 
split ratios can be used directly and interpreted biologically, or can serve as additional constraints for FBA. 
Metabolic flux screening on a miniaturized scale using mass spectrometry was shown to be a promising 
method for high-throughput analysis of cellular phenotypes (Velagapudi et al. 2007). Whereas earlier 
labeling patterns were mostly analyzed by NMR (Sonntag et al. 1993; Zupke and Stephanopoulos 1995), in 
the late 1990s, GC-MS was proposed as a possible competitive technique and mass isotopomer 
distributions obtained from GC-MS measurements can be sufficient for detailed analysis of metabolic 
fluxes (Wittmann and Heinzle 1999). In 1999 Wiechert et al. provided an elegant procedure for solving 
isotopomer balances and introduced the concept of cumulative isotopomers (cumomers) (Wiechert et al. 
1999). Another significant improvement for flux calculation was presented by Antoniewicz et al. 
(Antoniewicz et al. 2007). They introduced an efficient decomposition algorithm that identifies the 
minimum amount of information needed to simulate the isotopic labeling in a reaction network. This so-
called elementary metabolite unit (EMU) framework significantly reduces the computation time needed 
for flux estimation. Another milestone, in particular, for studying compartmented systems is the 
introduction of specific fluorescence resonance energy transfer (FRET) techniques (Niittylae et al. 2009). 
The determination of individual compartmental concentrations by using FRET nanosensors that can be 
combined with 13C flux analysis might allow studying even fluxes between compartments and different 
cells, providing deeper insights into metabolic compartmentation in eukaryotic cells in future studies. As 
can be seen in the literature, MFA was mostly applied in biotechnology to increase the productivity of 
producing microorganisms (Becker et al. 2005; Kiefer et al. 2004; Wittmann and Heinzle 2002). In  
mammalian cells, it is still less established owing to their higher complexity, particularly, concerning 
compartmentation, complex medium requirements, and unbalanced growth behavior. However, there 
have been a number of interesting studies applying MFA in the past, mainly in the areas of cell culture 
technology and toxicology/medicine (Forbes et al. 2006; Maier et al. 2009; Niklas et al. 2009; Srivastava 
and Chan 2008; Vo and Palsson 2006). These studies are mostly performed under the assumption of 
metabolic steady state, which is a prerequisite for stationary MFA. In mammalian cells the question 
remains whether a true steady state and balanced growth behavior can be achieved. In particular, in batch 
cultures in which the medium composition changes and the cellular metabolism has to adapt to a changing 
environment, true metabolic steady state will not be achieved. Mammalian cells change their metabolism 
as a response to different substrate concentrations, e.g., low and high glucose concentrations (Sanfeliu et 
al. 1997). There are different possibilities to deal with this challenge of usually unbalanced growth. In most 
cases mean fluxes are calculated for the exponential growth phase of the cells, and during this phase 
metabolic steady state is assumed, which is often a fair assumption (Niklas et al. 2009; Sidorenko et al. 
2008). Another possibility is to examine metabolism and flux distributions over time using dynamic 
approaches (Llaneras and Pico 2007; Niklas et al. 2011d). If specific short time effects on the metabolism 
Chapter 1 General introduction 
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are to be investigated, e.g., effects of certain compounds, transient 13C flux analysis would be an 
interesting but still very sophisticated method (Maier et al. 2009). For reliable 13C metabolic profiling in 
mammalian cell culture processes, which usually takes several days, a special medium design could be an 
option to come close to metabolic and isotopic steady state allowing stationary 13C flux analysis 
(Deshpande et al. 2009). Different flux estimation methods applied to mammalian cells are depicted and 
compared in Fig. 1-2. 
 
 
Fig. 1-2 Methods of whole cell metabolic flux distribution measurement in mammalian cell systems with required 
knowledge and measurements and their advantages and disadvantages. a(Sidorenko et al. 2008), b(Niklas et al. 2009), 
c(Niklas et al. 2011d), d(Metallo et al. 2009), e(Maier et al. 2009). This figure was published in Niklas et al. (Niklas et 
al. 2010). 
1.1 Theoretical aspects: methods for MFA 
Different MFA methods are available as discussed before. A typical workflow of a stationary 13C MFA is 
depicted in Fig. 1-3. If metabolite balancing is applied without the use of any tracers, only the 
measurement of labeling patterns would be excluded from the workflow. Another main difference 
between metabolite balancing methodology and 13C MFA is computation. Flux calculations can be straight 
forward using metabolite balancing as described in section 1.1.1 In 13C MFA (1.1.2), metabolite balancing 
is extended by carbon isotopomer balances resulting in a nonlinear least squares problem. This can be 
solved, e.g., by using efficient numerical optimization techniques (Weitzel et al. 2007; Yang et al. 2008). 
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Fig. 1-3 Exemplary workflow of an experiment for metabolic flux analysis (Niklas and Heinzle 2011). 
1.1.1 Stoichiometric models and metabolite balancing in mammalian cells 
The metabolite balancing or flux balancing technique is the MFA method that has been applied most 
often for the analysis of animal cell metabolism. The stoichiometric models used for flux balancing can 
also be applied for in silico prediction of network characteristics (e.g., maximal yields, optimal pathways, 
minimum substrate requirements) (Fong et al. 2005; Kromer et al. 2006; Wahl et al. 2008) or prediction of 
optimal genetic modifications using different algorithms (Melzer et al. 2009; Patil et al. 2005; Segre et al. 
2002; Suthers et al. 2007; Trinh et al. 2009). The importance of these targeted optimization approaches is 
rapidly increasing, which is also caused by an increasing availability of genomic information as well as 
genome-scale models of different mammalian species (Duarte et al. 2007; Quek and Nielsen 2008; 
Selvarasu et al. 2010). The general metabolite balancing methodology is depicted in Fig. 1-4. The first step 
is to set up a network that describes the part of the metabolism to be investigated. Metabolic network 
models of the central metabolism of mammalian cells have been described and applied in a number of 
studies (Niklas et al. 2009; Quek et al. 2010; Sidorenko et al. 2008; Srivastava and Chan 2008; Wahl et al. 
2008). As an example, a model of the human central metabolism is presented in Fig. 1-5. An important 
database that can be used to set up metabolic networks is the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway database (http://www.kegg.com). If a metabolic network consists of N 
fluxes and M internal metabolites, it has F = N – M degrees of freedom, meaning that F fluxes have to be 
measured to determine all remaining fluxes (Nielsen 2003). The calculation of metabolic fluxes in an 
overdetermined network (more measurements than necessary) results in a set of calculated fluxes that 
represents a least squares solution. In this case, it can also be checked if measurements are consistent 
meaning that the balance around each metabolite is zero. The network is underdetermined if not enough 
measurements are available, which can also be seen by calculating the rank of the stoichiometric matrix. If 
the rank is lower than the number of internal metabolites, the network is underdetermined. In this case 
the network has to be simplified or specific fluxes must be assumed a priori. If insufficient fluxes are 
Chapter 1 General introduction 
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measured, this can sometimes be easily solved by measuring extra rates. Other options exist to calculate 
fluxes in underdetermined parts of the network which would extend the metabolite balancing method. 
Thermodynamic constraints can be used indicating that certain reactions do not take place or can only 
proceed in one direction (Beard et al. 2004). Expression data or measurements of in vitro enzyme activities 
can be used to exclude specific reactions in the network (Akesson et al. 2004; Korke et al. 2004; Vriezen 
and van Dijken 1998; Wahl et al. 2008). Another possibility is to use specific objective functions such as, 
e.g., maximizing energy production to find flux distributions that optimize the applied objective function 
(Savinell and Palsson 1992a, 1992b). Probably, the best possibility is the use of labeled substrates (13C 
tracers) and analysis of resulting labeling patterns in metabolites providing additional information about 
cellular metabolism. The labeling of specific metabolites can be used, for example, to get information 
about fluxes at branch points like the glycolysis/pentose phosphate pathway (PPP) split (Lee et al. 1998). 
13C MFA is further explained in the next paragraph. 
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Fig. 1-4 Procedure of metabolic flux analysis using the metabolite balancing technique. BM biomass, M metabolite, S 
substrate, P product, r reaction rates, A stoichiometric matrix, (A)# pseudo inverse of the matrix (Niklas and Heinzle 
2011). 
 
The metabolic network model in Fig. 1-5 for flux balancing in human cells and general aspects of 
modeling metabolic networks in mammalian cells will be explained in this section. The metabolic network 
can be divided into the following parts: 
Central energy metabolism The main pathways of the energy metabolism are represented, i.e., glycolysis, 
oxidative decarboxylation, TCA-cycle, electron transport chain, and oxidative phosphorylation. Since it is 
not known for some reactions in the model whether NADH or NADPH take part and due to possible 
activity of nicotinamide nucleotide transhydrogenases, NADH and NADPH were lumped together. The 
Chapter 1 General introduction 
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excess of NAD(P)H and FADH2 considering their consumption and production in all reactions permits 
the estimation of the total ATP excess. However, the P/O ratio which is the amount of ATP formed per 
NADH oxidized is usually not exactly known. In the literature, different P/O values were assumed or 
estimated (Martens 2007; Miller et al. 1987; Wahl et al. 2008; Xie and Wang 1996a). The calculated ATP 
excess in the presented model example (Fig. 1-5) represents an estimate of the amount of ATP that is 
needed in the cell, e.g., for maintenance and transport reactions but also for so-called substrate or futile 
cycles (Russell 2007).  
Pentose phosphate pathway The PPP consists of an oxidative and a nonoxidative branch. The split between 
glycolysis and PPP and the reversible reactions of the non-oxidative part cannot be resolved by metabolite 
balancing alone. Therefore, PPP is usually assumed to be responsible only for nucleic acid synthesis in 
pure metabolite balancing studies and the nonoxidative part is neglected. However, there are possibilities 
for obtaining some information concerning the glycolysis/PPP split by using additional 13C tracer 
experiments (Lee et al. 1998), which can be included in the metabolic flux calculation. 
Amino acid metabolism The metabolism of proteinogenic amino acids is usually modeled by selected 
degradation pathways. Where several pathways are possible the most probable and suitable pathway can 
be chosen or additional experiments (e.g., enzyme activity measurements) can be performed to evaluate 
this. Since metabolite balancing can only be used to calculate net fluxes, there are no data concerning 
reversibility as for example in the synthesis and degradation of nonessential amino acids such as alanine 
and glutamate. The degradation flux of essential amino acids should usually be close to zero or higher, but 
never below zero. Values below zero would indicate that there are errors in the metabolite measurement 
or in the applied anabolic demand.  
Further reactions The reactions catalyzed by the enzymes malic enzyme (cytosolic and mitochondrial), 
phosphoenolpyruvate carboxykinase, and pyruvate carboxylase represent parallel or reversible pathways 
and also cannot be distinguished by pure metabolite balancing. Again this can be solved by assuming 
activities for some of these enzymes, by taking data from other experiments, or by lumping all these 
reactions together into one reaction representing the sum of all these fluxes converting 
malate/oxaloacetate to pyruvate as was done in the model in Fig. 1-5. 
Synthesis of biomass Fluxes to biomass can be represented as five fluxes to the major macromolecules of the 
cell, i.e., proteins, carbohydrates, DNA, RNA, and lipids. Hereby, the lipid fraction also contains the 
cholesterol part of the cells. These anabolic fluxes are calculated using the specific anabolic demand of the 
cells, which is derived from the biomass composition of the cells. In most flux studies, the biomass 
composition is assumed constant. However, in detailed studies concerning cellular biomass dynamics, it 
was shown that this composition and also the total biomass of the cells (e.g., dry weight) can vary during 
cultivation or at different growth conditions (Jang and Barford 2000; Nielsen et al. 1997). The methods 
that are usually used to determine cellular macromolecules are, however, time-consuming and require 
relatively large quantities of sample material making it usually not possible to determine the biomass 
composition in every flux analysis experiment which would, strictly speaking, be required. 
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Fig. 1-5 Exemplary stoichiometric metabolic network model of a human cell (Niklas and Heinzle 2011). ETC 
electron transport chain, OP oxidative phosphorylation, PPP pentose phosphate pathway, TCA tricarboxylic acid, 
AcC acetyl coenzyme A, AKG a-ketoglutarate, ATP adenosine triphosphate, ATPtot total ATP, ATPwOP ATP without 
oxidative phosphorylation, Carbo carbohydrates, Cit citrate, F6P fructose 6-phosphate, FADH2 flavin adenine 
dinucleotide, Fum fumarate, G6P glucose 6-phosphate, GAP glyceraldehyde 3-phosphate, Gal galactose, Glc glucose, 
Lac lactate, Mal malate, NADH nicotinamide adenine dinucleotide, OAA oxaloacetate, P5P pentose 5-phosphate, Pyr 
pyruvate, SuC succinyl coenzyme A, standard abbreviations for amino acids. Indices: m mitochondrial, ex 
extracellular. 
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1.1.2 13C Metabolic Flux Analysis 
In mammalian cells, relevant information can already be obtained by the metabolite balancing 
methodology since the number of measurable uptake and production fluxes of metabolites is large. 
However, there are several cases in which the balancing technique is insufficient. In particular, certain 
circular pathways, reversible reactions, and alternative pathways cannot be resolved (Fig. 1-6). Most 
important underdetermined parts in the metabolic network of mammalian cells are typically the PPP split, 
the anaplerotic/gluconeogenic fluxes around pyruvate/phosphoenolpyruvate/malate/oxaloacetate, and 
reversibility of uptake and production of substrate metabolites. Specific metabolic compartmentations, 
such as, e.g., different intracellular pools of metabolites as suggested for pyruvate (Zwingmann et al. 
2001), are other parts that cannot be resolved just by balancing. In some situations, it might be possible to 
use well-defined constraints to solve some underdetermined parts. Mass balances of cofactors, e.g., ATP 
and NAD(P)H, irreversibility of reactions, or specific objective functions have been proposed and 
reviewed as additional constraints (Bonarius et al. 1997). However, balancing of the energy metabolites 
(ATP, NAD(P)H) does not seem generally applicable since this would require knowing all energy-
producing and -consuming reactions as well as all conversion reactions between the energy metabolites 
(Wiechert 2001). In addition, the P/O ratio can vary and can usually not be determined precisely (Sauer 
and Bailey 1999), substrate or futile cycles might impair results, e.g., in the anaplerosis (Petersen et al. 
2000), and for some reactions it is just not known which co-metabolite, NADH or NADPH, is used. E.g., 
malic enzyme and isocitrate dehydrogenase enzymes can utilize NADH or NADPH 
(http://www.kegg.com). In case of PPP split, it would be possible to get some estimates about its activity 
by balancing NADPH. However, transhydrogenation reactions can occur in the cells transferring reducing 
equivalents between NADPH and NADH, which would falsify PPP estimates. In a study comparing 
results obtained by metabolite balancing with those from 13C MFA, discrepancies were found concerning 
PPP split (Schmidt et al. 1998). All the shortcomings and limitations of the metabolite balancing method 
can be overcome by getting more information through application of isotopically labeled 13C tracers. 
These tracers are 13C labeled substrates that are taken up by the cell, and the labeled carbon atoms are 
distributed through the cellular metabolism in a clearly defined way (Fig. 1-7). Depending on the activity 
of enzymes and metabolic pathways, this will result in specific labeling patterns in metabolites. These 
chemically identical compounds with different isotope composition are referred to as isotopomers. As 
depicted in Fig. 1-7, labeling in extracellular and intracellular metabolites can be measured but also the 
labeling in macromolecule building blocks, e.g., amino acids in proteins, provides equivalent information. 
Extracellular metabolites can be easily measured since these are directly present in the medium, usually, in 
high abundance. 
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Fig. 1-6 Cases in which the metabolite balancing technique is limited and examples in the metabolism (Niklas and 
Heinzle 2011). M metabolite.  
 
However, measurement of intracellular metabolites requires reliable quenching of the metabolism and 
appropriate extraction methods. This is fairly established for adherent cells (Hofmann et al. 2008; Maier et 
al. 2008) but still much more complicated for suspension cells (Dietmair et al. 2010). Measurement of the 
labeling in monomers of macromolecules, as is often done in studies on prokaryotes (Becker et al. 2005), 
is usually not suitable for flux analysis in mammalian cells. This is because mammalian cells generally have 
much lower growth rates than microorganisms and, therefore, slow macromolecule turnover and slow 
labeling incorporation.  
The measurement of labeling patterns in metabolites can be performed by nuclear magnetic resonance 
(NMR) measurements, gas chromatography mass spectrometry (GC-MS), liquid chromatography mass 
spectrometry (LC-MS), (Sauer et al. 1997; Wittmann 2007; Wittmann and Heinzle 1999; Christensen and 
Nielsen 1999; Des Rosiers et al. 2004; Kelleher 2001; Maaheimo et al. 2001; Matsuda et al. 2003; 
Wittmann et al. 2002), matrix-assisted laser desorption ionization-time of flight mass spectrometry 
(MALDI-ToF MS) (Wittmann and Heinzle 2001a, 2001b), capillary electrophoresis MS (Toya et al. 2007), 
or membrane inlet MS (Yang et al. 2006b). Recently, it was demonstrated that gas chromatography 
combustion-isotope ratio mass spectrometry (GC–C–IRMS) is another interesting method for labeling 
quantification in 13C MFA with a low labeling degree of tracer substrate, which is interesting for 
performing MFA in larger scale cultivations like industrial pilot scale fermentations (Heinzle et al. 2008; 
Yuan et al. 2010). Compared to NMR, MS seems to be more attractive, which is mainly due to higher 
sensitivity and rapid data accumulation (Wittmann 2002). Certain potential problems of MS that would 
impair flux analysis, like isotope effects or naturally occurring isotopes particularly in atoms other than 
carbon, can be solved efficiently using specific correction methods (Dauner and Sauer 2000; Heinzle et al. 
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2008; Moseley 2010; van Winden et al. 2002; Wahl et al. 2004; Wittmann and Heinzle 1999; Yang et al. 
2009).  
 
Fig. 1-7 13C tracer experiment 
(Niklas and Heinzle 2011). The 
labeling of the tracer is distributed 
through the metabolism resulting in 
specifically labeled intracellular 
metabolites (Mint), extracellular 
metabolites (Mext), and biomass 
(BM) components. Measurement of 
labeling patterns can be performed 
directly in intracellular or 
extracellular metabolites but also in 
macromolecule building blocks of 
biomass constituents.  
 
 
 
 
 
 
 
 
 
 
 
For 13C MFA, the carbon atom transitions in the metabolic network of the cell have to be modeled. The 
concept of AMM, which is a systematic formulation of atom transfers (Zupke and Stephanopoulos 1994), 
was further expanded by the IMM concept (Schmidt et al. 1997). This allowed calculating mass and NMR 
spectra directly from isotopomer abundance (Wittmann and Heinzle 2008). The introduction of 
cumomers (Wiechert et al. 1999) and later EMUs (Antoniewicz et al. 2007) improved computation of 
fluxes. The computational part in 13C MFA can be performed by using available software packages (Quek 
et al. 2009; Wiechert et al. 2001; Zamboni et al. 2005). Further description of 13C MFA can also be found 
in several review articles (Sauer 2006; Wittmann 2007; Sauer 2004; Wiechert 2001; Wittmann and Heinzle 
2008). 13C MFA can be further divided into stationary and dynamic approaches, which both have been 
applied successfully in mammalian cells (Goudar et al. 2010; Maier et al. 2008; Metallo et al. 2009; Niklas 
et al. 2011c). Metabolic steady state is a prerequisite for stationary 13C MFA. This is still a challenge, in 
particular, for suspension cells used in industrial production. Appropriate medium design can be an option 
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also enabling detailed 13C MFA in suspension cells during exponential growth (Deshpande et al. 2009). 
For adherent cells, the problem of instationarity can be overcome by using transient 13C MFA as 
demonstrated on hepatic cells (Hofmann et al. 2008; Maier et al. 2009; Maier et al. 2008). The tracers that 
are mostly applied in 13C MFA on mammalian cells are different glucose and glutamine tracers since these 
metabolites are the main substrates of mammalian cells (Eagle 1959). Depending on the question of the 
study and the applied metabolic network structure, different tracers or combinations of tracers will be best 
suitable (Metallo et al. 2009). 
1.2 Application of MFA in systems biology of mammalian cells 
1.2.1 Optimization of cell culture processes 
Mammalian cells are extensively used for the production of vaccines (Genzel and Reichl 2009) and 
therapeutic proteins requiring specific post-translational glycosylation (Seth et al. 2006; Wurm 2004). The 
number of biopharmaceuticals available for treatment of severe diseases as well as the quantity produced 
is steadily growing (Pavlou and Reichert 2004). Therapeutic proteins are mainly expressed in Chinese 
hamster ovary (CHO) cells, but also other cell lines are commonly employed, such as murine myeloma, 
hybridoma, baby hamster kidney (BHK), or human embryo kidney cells (HEK-293) (Chu and Robinson 
2001; Wurm 2004). New, engineered human cell lines also represent very promising production systems, 
e.g., the cell lines AGE1.HN (Niklas et al. 2011d) and PER.C6 (Pau et al. 2001). Vaccine production is 
conventionally carried out in embryonated chicken eggs. However, especially in the last decade, several 
cell culture-derived vaccines have been established (Genzel and Reichl 2009). Much effort has been made 
to optimize cell culture processes to increase productivity and product quality. This includes on the one 
hand optimization of the cultivation and on the other hand targeted engineering of the cell. Different 
cellular pathways that are associated with superior characteristics concerning cell growth and production 
were engineered. This includes central metabolism, protein synthesis and secretion, protein glycosylation, 
post-translational modifications, cell cycle control, and apoptosis (Godia and Cairo 2002; Lim et al. 2010; 
Seth et al. 2006). Optimization of the metabolism of the producer cell is mandatory for different reasons. 
On the one hand efficient energy metabolism is important. In particular, the production of recombinant 
proteins requires a great deal of energy. On the other hand final product titers are directly dependent on 
integral viable cell density and lifespan of the culture, which can be increased when the substrate usage of 
the cell is very efficient. In an ideal scenario this would mean that the cell does not accumulate toxic waste 
products, which would decrease the lifespan of the culture, and substrates are taken up just to fulfill the 
cellular demand. Analyses of the metabolism and metabolic flux studies have significantly contributed in 
the past to understanding and optimizing the metabolism of mammalian cells. In this section metabolic 
flux studies in hybridoma and myeloma cells, CHO cells, and cell lines that are used for vaccine 
production are reviewed. 
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1.2.1.1 MFA in hybridoma and myeloma cells 
Hybridoma and myeloma cells are widely employed for the production of monoclonal antibodies (Chu 
and Robinson 2001). In many studies, MFA was used to understand the metabolism of these cells. Savinell 
and Palsson (Savinell and Palsson 1992a, 1992b) applied linear optimization theory to understand the 
influences of fluxes on overall cell behavior and to analyze limitations. They concluded that neither 
antibody production nor maintenance demand for ATP limited cell growth. Medium design represents 
one of the most important issues in optimizing cell culture processes, which is also reflected by many 
metabolic flux studies in this area. Xie and Wang (Xie and Wang 1996b, 1997) presented a balancing 
approach to design culture media for fed-batch cultures that integrated substrates, products, pH, 
osmolarity, and cell growth. They also estimated stoichiometric ATP production in batch and fed-batch 
cultures of hybridoma cells (Xie and Wang 1996a). Another interesting study focused on regulation of 
fluxes in the central metabolism of myeloma cells (Vriezen and van Dijken 1998). By determining fluxes 
and enzyme activities in the central metabolism, the regulation of metabolic fluxes could be shown to 
occur mainly through modulation of enzyme activity. Determination of metabolic fluxes for multiple 
steady states in hybridoma continuous culture indicated that the performance could be improved by 
inducing specific cellular metabolic shifts leading to favourable flux distribution (Follstad et al. 1999). 
Europa et al. performed fed-batch cultivations that were then switched to continuous mode (Europa et al. 
2000). This approach enabled reaching a more desirable steady state with higher concentrations of cells 
and product. Additionally, from analyses of hybridoma cells at different physiological states, it was 
reported that the amino acid metabolism is very important in reducing lactate production (Gambhir et al. 
2003). In an earlier metabolite balancing study using additional constraints to resolve underdetermined 
parts in the metabolic network, Bonarius et al. found that around 90% of the glucose was channeled 
through PPP, which was very surprising (Bonarius et al. 1996). In a following study using 13CO2 mass 
spectrometry in combination with 13C lactate NMR spectroscopy and metabolite balancing, it was found 
that just 20% is channeled through PPP (Bonarius et al. 2001). This shows that different methods can 
yield very different results. As mentioned before, cofactor balance constraints must be used very carefully. 
In particular for estimation of PPP, constraints based on 13C labeling might be much more realistic since 
the labeling measurement is usually very accurate and carbon transition in the reactions is exactly 
determined. Another interesting aspect that was analyzed by Bonarius et al. using MFA was the cellular 
response to oxidative and reductive stress (Bonarius et al. 2000). They reported that particularly 
dehydrogenase reactions producing NAD(P)H were decreased under oxygen limitation. In a recent study, 
it was reported that antibody production in hybridoma cells could be increased by enhancing specific 
fluxes through the addition of specific metabolites to the medium (Omasa et al. 2010). Fluxes between 
malate and pyruvate were increased by the addition of the intermediates pyruvate, malate, and citrate, 
resulting in increased ATP and antibody production. This is a good example showing how metabolic flux 
data can be used to improve the metabolic phenotype in a cell culture process. Another important step is 
the construction of mathematical models that can be used to predict growth, metabolism, and product 
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formation during the cultivation. Dorka et al. utilized an approach based on MFA to model batch and fed-
batch cultures of hybridoma cells (Dorka et al. 2009). Genome-scale modeling and in silico simulations for 
fed-batch cultures of hybridoma cells were recently carried out suggesting that the applied methodology 
might serve as a valuable tool for targeted optimization in the future (Selvarasu et al. 2009b). 
1.2.1.2 MFA in CHO cells 
CHO cells (Puck et al. 1958) represent the main workhorse for the industrial production of 
biopharmaceuticals (Chu and Robinson 2001). In several studies, the metabolism of these cells under 
different conditions was analyzed. CHO cells are often cultured in media supplemented with specific 
hydrolysates that contain many peptides, which makes MFA more complicated. Nyberg et al. (Nyberg et 
al. 1999b) reported that these potential substrates must be balanced for accurate metabolic flux estimates. 
In another study, metabolic effects on the glycosylation of recombinant protein were reported. Particularly 
glutamine limitation seemed to influence glycosylation remarkably (Nyberg et al. 1999a). Altamirano et al. 
published several results on medium design and favourable fed-batch strategies for CHO (Altamirano et 
al. 2006; Altamirano et al. 2001; Altamirano et al. 2004). MFA was performed, in particular, to understand 
lactate consumption in CHO cells grown on galactose. It was found that lactate was not used as a fuel in 
the TCA cycle (Altamirano et al. 2006). A very important aspect in mammalian cell culture processes is the 
optimization of the bioreactor operation. Goudar et al. presented an approach for quasi real-time 
estimation of metabolic fluxes (Goudar et al. 2006). Cellular physiology and metabolism can be monitored 
by combining on-line and off-line data to calculate metabolic fluxes. This methodology can help in 
optimizing the cultivation process. Recently, the same group analyzed metabolic fluxes of CHO cells in 
perfusion culture by applying metabolite balancing and 2D-NMR spectroscopy (Goudar et al. 2010). Flux 
data obtained by metabolite balancing in this case corresponded well with flux information from 2D-
NMR spectroscopy. Recently, a study was published in which MFA was performed for the late non-
growth phase in CHO cultivation (Sengupta et al. 2010). In this case a combination of metabolite 
balancing and isotopomer analysis was used. The most surprising finding in this study was that almost all 
of the consumed glucose was channeled through PPP. This result is in contrast with several publications  
that determined different flux distributions in the growth phase of CHO or other cells (Goudar et al. 
2010; Lee et al. 1998; Maier et al. 2008; Mancuso et al. 1994; Metallo et al. 2009; Vo and Palsson 2006). 
1.2.1.3 MFA in cell lines for production of vaccines and viral vectors 
Another promising and important application of mammalian cell culture is the production of vaccines 
(Audsley and Tannock 2008; Genzel and Reichl 2009). A number of cell lines were identified to be 
suitable for high-yield vaccine manufacturing (Genzel et al. 2010), e.g., madin darby canine kidney 
(MDCK) cells (Kessler et al. 1999), HEK-293 cells (Le Ru et al. 2010), or specifically engineered cell lines 
such as PER.C6 or AGE1.CR (Jordan et al. 2009; Pau et al. 2001). Optimization of cell culture processes 
for vaccine production is still mainly done by trial and error. Detailed metabolic studies might help 
substantially to understand cell culture based vaccine production (Ritter et al. 2010) and enable targeted 
optimization. Wahl et al. investigated an influenza vaccine production process in MDCK cells using a 
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segregated growth model for distinct growth phases in the batch process. Comparison of observed 
metabolic fluxes with theoretical minimum requirements revealed large optimization potential for this 
process (Wahl et al. 2008). Flux analysis of MDCK in glutamine-containing media and media in which 
glutamine was replaced by pyruvate was presented in another publication (Sidorenko et al. 2008). 
Ammonia and lactate release were remarkably reduced in a high pyruvate medium without further 
dramatic changes in the central metabolism. Henry and co-workers showed that MFA can provide a basis 
to develop a feeding strategy for perfusion cultures of HEK-293 cells for production of adenovirus 
vectors (Henry et al. 2005). Martinez et al. compared metabolic states of HEK-293 cells during growth 
and adenovirus production to optimize media according to the cellular demand (Martinez et al. 2010). 
Higher cell densities and increased adenovirus production were achieved. 
1.2.2 MFA in medical research 
MFA was mostly applied in the past by bioengineers to understand phenotypes of producer cells. But 
another very important field in which MFA can contribute substantially is the medical sector. Defects in 
mitochondrial function contribute to many physiological diseases. Ramakrishna et al. (Ramakrishna et al. 
2001) stated that FBA of mitochondrial energy metabolism might be a useful methodology to characterize 
the pathophysiology of mitochondrial diseases. The strength of metabolic flux data, as mentioned in the 
beginning of this chapter and shown in Fig. 1-1, is the integration of all interactions at different levels of 
the cellular hierarchy. Therefore, specific flux patterns that reflect a certain physiological response might 
be indicators for specific diseases or genetic defects. Lee et al. proposed that MFA could be a very useful 
tool for tissue engineering (Lee et al. 1999). By applying MFA, it is possible to obtain a very 
comprehensive view of the metabolic state, and flux estimates under different conditions can be used to 
monitor and optimize tissue function. Forbes and co-workers described an interesting method that uses 
isotopomer path tracing to quantify fluxes in metabolic models containing reversible reactions and applied 
MFA to analyze the effects of estradiol on breast cancer cells (Forbes et al. 2001; Forbes et al. 2006). 
Metabolic fluxes were calculated from extracellular fluxes and isotope enrichment data generated by 
NMR. They observed that breast cancer cells are dependent on PPP and glutamine consumption for 
estradiol-stimulated biosynthesis and concluded that these pathways might be possible targets for 
estrogen-independent breast cancer therapy. Brain function and, in particular, physiological and 
pathophysiological regulation of neural metabolism were investigated in several metabolic studies. 
Zwingmann et al. investigated glial metabolism using 13C-NMR (Zwingmann and Leibfritz 2003). They 
concluded that the observed metabolic flexibility of astrocytes might buffer the brain tissue against 
extracellular cytotoxic stimuli and metabolic impairments. In another study, the coupling between 
metabolic pathways of astrocytes and neurons was modeled and investigated by FBA (Cakir et al. 2007). 
By using the reconstructed model, effects of hypoxia could be fairly well predicted. This shows how 
stoichiometric models can be used in medical metabolic flux modeling. Teixeira et al. investigated the 
metabolism of astrocytes by combining 13C-NMR spectroscopy and MFA (Teixeira et al. 2008). In a 
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subsequent study, the method was applied to analyze metabolic alterations induced by ischaemia in 
astrocytes (Amaral et al. 2010). 
1.2.3 MFA in toxicology 
The analysis of effects of drugs and chemicals on cellular metabolism is another very promising 
application of MFA and highly relevant for toxicological research. Toxicity of drugs is one of the leading 
causes of attrition at all stages of the drug development process (Kramer et al. 2007) and is mainly 
detected late in the pipeline where also most of the costs are incurred (Kola and Landis 2004). 
Identification of toxicity early in the drug development process would save a lot of money. Metabonomics 
is a system approach for studying in vivo metabolic profiles and has emerged in the last decade as a very 
powerful technique for studying drug toxicity, disease processes, and gene function (Nicholson et al. 2002; 
O'Connell and Watkins 2010; Winnike et al. 2010). MFA, which provides potentially more information 
than metabolic profiling, is, however, still not routinely used in toxicity studies, which might be mainly due 
to its presently low throughput. Some studies have focused on developing and adapting MFA methods 
and setups for high-throughput screening (Balcarcel and Clark 2003; Fischer et al. 2004; Hollemeyer et al. 
2007; Sauer 2004; Velagapudi et al. 2007; Wittmann et al. 2004). Balcarcel et al. (Balcarcel and Clark 2003) 
presented a method called High-Throughput Metabolic Screening that can be used for faster screening of 
the overall activity of metabolic pathways in mammalian cells. In a recent study it was shown that MFA 
can be applied in a high-throughput setup to analyze subtoxic drug effects (Niklas et al. 2009). Several 
changes in the metabolism of Hep G2 cells could be detected upon exposure to subtoxic drug levels. In 
the future it might be possible to use MFA in a high-throughput format to detect specific metabolic 
signatures or flux patterns that are associated with specific toxicity mechanisms. Other studies analyzed 
effects of different compounds on cellular metabolism without focusing on high-throughput application 
of the applied methods. Srivastava and co-workers applied MFA to identify the toxicity mechanism of free 
fatty acids and metabolic changes in Hep G2 cells (Srivastava and Chan 2008). They observed that free 
fatty acid toxicity is associated with the limitation of cysteine import causing reduced glutathione synthesis. 
Another very promising MFA method was implemented by Maier et al. to quantify statin effects on 
hepatic cholesterol synthesis (Maier et al. 2009). Transient 13C flux analysis was applied to study effects of 
atorvastatin at a therapeutic concentration. 
Summarizing this section, it can be seen that there have been some interesting applications of MFA to 
identify toxicity mechanisms and metabolic effects of compounds. However, these methods must be 
applicable in high-throughput format to be attractive for larger scale toxicity screening. Additionally, the 
analysis has to be more detailed calling for improved analytical methods. Specific flux patterns and 
signatures for different toxicity mechanisms must be identified and clearly defined in the future, which 
would lead to a better understanding of toxicity at the metabolome level. Then it might be possible to 
elucidate possible side effects of compounds early in the drug development process. 
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1.3 Conclusions 
MFA is a very important method for understanding the metabolism of mammalian cells under various 
conditions. The acquired knowledge can be used to optimize cell culture media and cellular phenotypes, to 
define favourable feeding strategies, as well as to understand mechanisms of toxicity and diseases. In 
suspension cells that are employed in industrial production, mainly MFA using metabolite balancing was 
applied. 13C MFA cannot be directly applied in industrially relevant processes since metabolic steady state 
is not reached. As presented in some studies, continuous cultures are an option to enable detailed 
stationary 13C flux studies. Dynamic methods are very promising tools to describe the dynamic and 
adaptive behavior of the cells during batch and fed-batch processes. Since they are still fairly complex and 
laborious, they are not yet widely applied. 13C MFA is relatively established in tissues and adherent cells 
where the flux experiment can be performed at a short time scale and metabolic and isotopic steady state 
may be reached very fast. Transient 13C flux analysis represents a very interesting method that may in 
many cases solve the problem of changing metabolism during cultivation of mammalian cells. The 
application examples presented in this chapter indicate that MFA can contribute significantly in many 
areas in which the metabolism of mammalian cells is of interest. However, MFA method development has 
to be intensified in the future to enable broader application in mammalian cell culture and to permit 
robust and realistic studies. Compartmentation of the metabolism is an issue that is often only 
rudimentarily considered in metabolic flux studies but is very important, especially, for 13C MFA. 
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2 Quantitative characterization of  metabolism and metabolic 
shifts during growth of  the new human cell line AGE1.HN 
using time resolved metabolic flux analysis. 
2.1 Abstract 
For the improved production of vaccines and therapeutic proteins, a detailed understanding of the 
metabolic dynamics during batch or fed-batch production is requested. To study the new human cell line 
AGE1.HN, a flexible metabolic flux analysis method was developed that is considering dynamic changes 
in growth and metabolism during cultivation. This method comprises analysis of formation of cellular 
components as well as conversion of major substrates and products, spline fitting of dynamic data, and 
flux estimation using metabolite balancing. During batch cultivation of AGE1.HN, three distinct phases 
were observed, an initial one with consumption of pyruvate and high glycolytic activity, a second 
characterized by a highly efficient metabolism with very little energy spilling waste production, and a third 
with glutamine limitation and decreasing viability. Main events triggering changes in cellular metabolism 
were depletion of pyruvate and glutamine. Potential targets for the improvement identified from the 
analysis are (i) reduction of overflow metabolism in the beginning of cultivation, e.g., accomplished by 
reduction of pyruvate content in the medium, and (ii) prolongation of phase 2 with its highly efficient 
energy metabolism applying, e.g., specific feeding strategies. The method presented allows fast and reliable 
metabolic flux analysis during the development of producer cells and production processes from 
microtiter plate to large scale reactors with moderate analytical and computational effort. It seems well 
suited to guide media optimization and genetic engineering of producing cell lines. 
 
 
 
 
 
 
 
 
 
 
 
This chapter was published as 
Niklas J, Schräder E, Sandig V, Noll T, Heinzle E. Quantitative characterization of metabolism and 
metabolic shifts during growth of the new human cell line AGE1.HN using time resolved metabolic flux 
analysis. Bioprocess Biosyst Eng. 2011 Jun;34(5):533-45.  
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2.2 Introduction 
Cell culture products represent currently the most important and most promising source for new 
biopharmaceuticals. The majority of recombinant biopharmaceuticals are produced by mammalian cell 
culture and this fraction is steadily increasing (Ferrer-Miralles et al. 2009; O'Callaghan and James 2008; 
Wurm 2004). The projected sales volume for therapeutic proteins by 2010 is USD 70 billion (Pavlou and 
Reichert 2004; Walsh 2006). Commonly employed production cell lines are, e.g., Chinese Hamster Ovary 
(CHO) cells or murine lymphoid cells. These production systems must be capable of generating high 
quantities of proteins to enable the administration of high doses required in clinical application (Dinnis 
and James 2005; Rose et al. 2008; Sandig et al. 2005). A number of approaches were applied to optimize 
product yields (Kumar et al. 2007), e.g., cell cycle arrest and control of apoptosis (al-Rubeai and Singh 
1998; Fogolin et al. 2004; Trummer et al. 2006; Yoon et al. 2003) or addition of nutrient supplements 
(Eyer et al. 1995; Oh et al. 2005; Sung et al. 2004). However, there is still room for improvement. New 
production cell lines are entering the market due to demands for higher product quality (e.g., 
glycosylation), efficiency, productivity, and robustness. Cell lines created from primary cells represent 
promising new production systems. These cell lines overcome typical limitations of other cells, e.g., serum 
requirements or attachment dependence, and eliminate also the repeated safety testing required for each 
new batch of primary tissue (Jordan et al. 2009). Concerning manufacturing of therapeutic proteins, 
engineered human cell lines may have in particular another unique advantage over standard producer cell 
lines, as, e.g., CHO cells, because of their genuine human post-translational modification machinery. The 
cell line AGE1.HN represents such a new human cell line which was immortalized and engineered for 
apoptosis resistance and can be used for production of recombinant proteins but also for viruses and viral 
vectors. However, further targeted optimization would be promoted by a profound knowledge of growth 
and metabolism of the cells. In order to find optimized cultivation conditions and targets for metabolic 
engineering for improved production, metabolic flux analysis seems most suited since it represents the 
functional end point of genome, proteome, and metabolome interactions (Nielsen 2003; Sauer 2006). This 
methodology has revealed valuable insights into the metabolism of several mammalian cell systems 
(Balcarcel and Clark 2003; Bonarius et al. 1996; Niklas et al. 2009; Sidorenko et al. 2008; Wahl et al. 2008). 
A requirement for reliable stationary metabolic flux analysis is metabolic steady state that is usually not 
reached due to complex growth requirements. It seems generally possible to optimize the medium such 
that metabolic steady state is reached during a longer period (Deshpande et al. 2009). However, if the 
metabolism of cells in a conventional medium should be investigated, dynamic changes of the cellular 
metabolism commonly observed in cell culture have to be monitored and considered (Altamirano et al. 
2006). One way to deal with this challenge is to focus just on the exponential growth phase of the cells 
where in some cases metabolic steady state can be observed (Niklas et al. 2009). Another possibility is to 
divide the growth of the cells in different metabolic phases and calculate the flux distribution for each 
phase (Altamirano et al. 2006). The third possibility is to compute instantaneous flux distributions during 
the whole cultivation (Llaneras and Pico 2007). Most detailed information can be obtained using 13C-
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substrate labeling techniques. This can be accomplished either by assuming intracellular steady state of 
metabolites (Bonarius et al. 2001) or by analyzing intracellular metabolite and isotopomer dynamics. The 
latter requires much more sophisticated analytical methods and is much more laborious both for analysis 
as well as modeling and computation (Hofmann et al. 2008; Maier et al. 2008). In this study, we 
quantitatively analyze dynamics of growth and metabolism of the new human cell line AGE1.HN using a 
dynamic flux analysis method. The presented method of metabolic flux analysis is well suited to monitor 
and investigate metabolic shifts caused by environmental changes that occur during batch cultivation of 
mammalian cells. It does not require any kinetic model and is, therefore, widely applicable. Estimated flux 
dynamics were compared to results obtained from stationary metabolic flux analysis in different metabolic 
phases. We analyzed parental AGE1.HN cells in this study to gain detailed quantitative knowledge and 
understanding of growth behavior, cellular metabolism, as well as its dynamics. The results are, therefore, 
expected to be useful for rational development of optimal growth media, for further optimization and 
engineering of the cell line to obtain higher cell densities in a process, for all derived producer cells, and 
for the design of other producer cell lines. 
2.3 Materials and methods 
2.3.1 Cell line.  
The AGE1.HN cell line was developed from primary cells from a human brain tissue sample. The primary 
cells were immortalized with an expression plasmid containing the adenoviral E1 A and B genes of human 
adenovirus type 5 driven by the human pGK and the endogenous E1B promoter, respectively. While the 
E1A induces progression of the cell cycle, the E1B proteins prevent apoptosis caused by E1A through 
interaction with p53 and bax. The cell line was further modified to express the structural and regulatory 
protein pIX from human adenovirus type 5. This modification changes cell metabolism, enhances 
productivity for secreted proteins, and modulates susceptibility to a variety of viruses. The AGE1.HN 
cells express marker genes representative for cells of neuronal lineage and lack expression of glial markers. 
The cell line was adapted to robust growth in suspension in both serum/protein-free and chemically 
defined culture media and has been proven to grow efficiently in shaker, spinner, roller, and stirred tank 
bioreactors. The entire development work for the generation of the AGE1.HN line was carried out in a 
dedicated cell culture suite and the complete development history was recorded. The documentation for 
all media and supplements used in the AGE1.HN cell line development is in compliance with the 
stipulations of EMEA 410/01. The AGE1.HN cell line is proprietary to ProBioGen AG (Berlin, 
Germany) covered by patent application 06807777.5-2406.  
2.3.2 Cell culture and experimental procedure. 
The cells were cultured in baffled shake flasks (Corning, NY, USA) at 37°C on a shaker (2 inches orbit, 
ES-X, Kühner, Basel, Switzerland) enclosed in a 5% CO2 supplied, humidified (80%) incubator (Mytron, 
Heilbad Heiligenstadt, Germany). The preculture was carried out in a 250 ml baffled shake flask in 42-
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Max-UB-medium, which is serum-free and was especially developed for the AGE1.HN cell line. The 
medium composition is presented in Table S1. The cells were centrifuged (800 1/min, 7 min, 22°C, 
Megafuge, Heraeus Instruments, Hanau, Germany) and the supernatant discarded. The pellet was 
resuspended in 42-Max-UB-medium without glucose and glutamine. Four 125 ml baffled shake flasks 
were inoculated yielding an initial cell density of about 4 × 105 cells/ml. Glucose and glutamine were 
finally added. The final culture volume was 54 ml. Samples (1.6 ml) were taken every day. 500 µl were 
directly used for cell counting. The rest was centrifuged (1,500 1/min, 5 min, 22°C, Megafuge, Heraeus 
Instruments, Hanau, Germany), the supernatant transferred into fresh tubes and frozen (-20°C). The 
analysis of several cultivation parameters was carried out using an automated cell culture analyzer (Cedex 
AS20, Innovatis, Bielefeld, Germany) which determines cell density, viability (Trypan Blue exclusion 
method), size, morphology, and aggregation rate. Dissolved oxygen was always above 80% in the applied 
setup, which was determined in an additional cultivation using the OXY-4 mini system (PreSens - 
Precision Sensing GmbH, Regensburg, Germany) described earlier (Deshpande and Heinzle 2009). 
2.3.3 Quantification of metabolites.  
Glucose, lactate, and pyruvate in the supernatant were analyzed using high-pressure liquid 
chromatography (HPLC) as described previously (Niklas et al. 2009). Quantification of proteinogenic 
amino acids was performed by another HPLC-method (Kromer et al. 2005). The measured metabolite 
concentrations as well as cell density were corrected for evaporation using (1). The determined 
evaporation rate kE in the applied setup was 0.0356 h-1. 
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ccorr represents the corrected concentration and cmeas the measured concentration. 
Glutamine hydrolysis was observed to be a first order process having a rate constant kG of 0.00198 h-1 in 
the applied medium (pH 7.4, 37°C). The actual glutamine uptake rate rGln was calculated employing 
polynomials of degree 5 in Matlab 7.5 (The Mathworks, Natick, MA, USA) using 
)r[Gln]k(
dt
[Gln]d
lnGG +×−=          (2) 
2.3.4 Metabolic network.  
A metabolic network model (Fig. 2-1) was set up using the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway database for Homo sapiens as well as other published metabolic network information 
(Duarte et al. 2007). The enzymes that were included into the model are given in Table S4 of the 
supplementary material section. The stoichiometric matrix of the model had the dimensions 41 × 70 and a 
rank of 41. It is presented in the supplementary material (Table S5). 
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Fig. 2-1 Metabolic network used for metabolic flux analysis. PPP pentose phosphate pathway, TCA tricarboxylic 
acid, ETC electron transport chain, OP oxidative phosphorylation, Carbo carbohydrates, Glc glucose, Gal galactose, 
Lac lactate, Pyr pyruvate, G6P glucose 6-phosphate, P5P pentose 5-phosphate, F6P fructose 6-phosphate, GAP 
glyceraldehyde 3-phosphate, AcC acetyl coenzyme A, Cit citrate, AKG a-ketoglutarate, SuC succinyl coenzyme A, 
Fum fumarate, Mal malate, OAA oxaloacetate, ATP adenosine triphosphate, ATPwOP ATP without oxidative 
phosphorylation, ATPtot total ATP, ATPexc ATP excess, NADH nicotinamide adenine dinucleotide, FADH2 flavin 
adenine dinucleotide, standard abbreviations for amino acids. Indices: m mitochondrial, ex extracellular.  
 
Central energy metabolism. The main pathways of the energy metabolism, glycolysis, oxidative 
decarboxylation, TCA cycle, electron transport chain, and oxidative phosphorylation, are represented. Due 
to the possible action of nicotinamide nucleotide transhydrogenases and the fact that for some reactions it 
is not known whether NADH or NADPH take part, NADH and NADPH were lumped together. The 
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excess of NAD(P)H and FADH2 from all reactions considered in the model was calculated. For oxidative 
phosphorylation, it was assumed that per NAD(P)H and FADH2 2.5 ATP and 1.5 ATP are produced, 
respectively. The excess of ATP (ATPtot) was calculated considering the demand or production of all 
reactions. However, the energy needed for transport of metabolites and maintenance was not included in 
the ATP-balance. 
Pentose phosphate pathway. Pentose phosphate pathway/glycolysis split can not be resolved by 
metabolite balancing alone and was assumed to be just responsible for nucleic acid synthesis. 
Amino acid metabolism. The metabolism of proteinogenic amino acids is represented by selected 
degradation pathways. In cases where several pathways are possible, the most probable and suitable 
pathway was chosen (Table S4 of supplementary material and Fig. 2-1).  
Other reactions. Since it is not possible to distinguish between the reactions catalyzed by the enzymes 
phosphoenolpyruvate carboxykinase, malic enzyme (malate dehydrogenase, oxaloacetate decarboxylating), 
and pyruvate carboxylase with the method applied in this study, just one reaction from malate to pyruvate 
was included which represents the sum of the fluxes through these enzymes.  
Synthesis of biomass. The biomass fluxes are represented as five fluxes to the major macromolecules of 
the cell. Cytosolic acetyl coenzyme A, which is needed for the synthesis of fatty acids and lipids, is 
assumed to be solely derived from citrate that is transported through the citrate/malate shuttle and 
converted through the citrate lyase to acetyl coenzyme A and malate. Further precursors that were 
considered for the synthesis of lipids are glyceraldehyde 3-phosphate and serine. Carbohydrates were 
taken as polyglucose and are, therefore, derived from glucose 6-phosphate. The precursors considered for 
nucleic acid synthesis are ribose 5-phosphate, glycine, and aspartate. For proteins, a certain amount of 
each proteinogenic amino acid is needed per cell, which was calculated using the amino acid composition 
of total cellular protein determined in this study (described below).  
Transport of metabolites. As mentioned above, the energy demand for transport was not included in 
the ATP balance. From calculated fluxes, a rough estimate could, however, be derived using literature 
knowledge, e.g., about amino acid transport (Hyde et al. 2003). The mitochondrial transporters included in 
the model are the pyruvate carrier, citrate/malate shuttle, glutamate/aspartate shuttle, and the ADP/ATP 
transporter (Berg et al. 2003; Kaplan 2001). For further metabolites entering the mitochondria, no specific 
transport mechanisms were assumed. 
Anabolic demand of AGE1.HN. Macromolecules. The applied macromolecular composition of the cells 
was: Proteins, 70.6%; lipids, 9.2%; carbohydrates, 7.1%; DNA, 1.4%; RNA, 5.8%; rest/ash, 5.9%. The 
lipid composition was determined once using 4.9 × 108 cells, harvested at a cell density of 3.4 × 106 
cells/ml (viability 97%) using a published protocol (Niklas et al. 2009). The other parts of the composition 
were taken from Bonarius et al. (1996).  
Amino acid composition. The amino acid composition of total cellular protein was determined using samples 
of 1-2 × 107 cells that were washed twice with PBS to remove amino acids from the medium. For 
hydrolysis, 6 M HCl (280 µl/107 cells) was used and incubated for 24 h at 110°C. The solution was 
neutralized using 6 M NaOH and the amino acid composition was determined using HPLC as described 
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above. The determined relative composition (n=4) was: aspartic acid/asparagine, 9.25 ± 0.6%; glutamic 
acid/glutamine, 12.83 ± 0.48%; serine, 6.19 ± 0.12%; histidine, 2.18 ± 0.12%; glycine, 9.45 ± 0.67%; 
threonine, 4.94 ± 0.1%; arginine, 5.19 ± 0.23%; alanine, 8.06 ± 0.09%; tyrosine, 1.9 ± 0.04%; valine, 6.14 
± 0.13%; phenylalanine, 3.56 ± 0.08%; isoleucine, 4.49 ± 0.09%; leucine, 8.71 ± 0.1%; lysine, 7.5 ± 
0.17%; proline, 3.99 ± 0.12%. Methionine, tryptophan, and cysteine are degraded by the applied hydrolytic 
method. Relative amounts for these amino acids were taken from literature (Savinell and Palsson 1992a): 
methionine, 1.7%; tryptophan, 1.1%; cysteine, 2.8%. 
Cell dry weight estimation. The cell dry weight of mammalian cells in culture is not constant and increases 
with increasing growth rate (Frame and Hu 1990; Nielsen et al. 1997). It was shown, that the volume of 
cells is proportional to their dry weight and can be used as an indirect measure of the biomass 
concentration in the culture (Frame and Hu 1990). In this study, cell size was determined using an 
automated cell culture analyzer (Cedex AS20, Innovatis, Bielefeld, Germany) providing an accurate 
determination of the cell diameter. Assuming that the cells are spherical, the respective cell volume was 
calculated. The correlation between dry cell weight, DCW (pg), and cell volume, CV (µm3), determined in 
a control experiment using the procedure described previously (Niklas et al. 2009), was 
DCW = 0.25 × CV. This relationship was used for calculation of biomass concentrations. The anabolic 
demand of the cells is shown in Table 2-1. 
 
Table 2-1 Anabolic demand of AGE1.HN. 
Macromolecule Anabolic demand [µmol/gbiomass] 
Carbohydrates 438.3 
DNA 45.3 
RNA 180.3 
Lipids 128.1 
Proteins 6,433.0 
 
2.3.5 Metabolic flux analysis.  
The two different procedures applied for calculation of metabolic fluxes are depicted in Fig. 2-2. For the 
calculation of metabolic fluxes over time (dynamic method), splines were fitted to the measured data for 
biomass and extracellular metabolites (Supplementary Fig. S1) using Matlab 7.5 (The Mathworks, Natick, 
MA, USA). These were used to calculate specific rates (v) for each metabolite concentration Mi over time 
using 
B
dt
dM
v
i
Mi
=           (3) 
where B represents the respective biomass in the culture. Intracellular fluxes were calculated using 
)vS(Sv mm
1
kk ×−×=
−
          (4) 
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where vm and vk represent the measured and the calculated rate vectors. Sk and Sm are corresponding 
stoichiometric matrices. 
For calculating stationary fluxes, growth was divided into different metabolic phases (Fig. 2-2). Average 
rates for each metabolite Mi were calculated assuming metabolic steady state for each phase using the 
estimated specific growth rate µ and metabolite yields: 
BΔ
MΔ
µv iMi =            (5) 
B represents the total biomass in the culture. The data was implemented into the metabolic network 
model and intracellular fluxes for each phase were subsequently calculated using equation (4).  
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Fig. 2-2 Methods applied for metabolic flux analysis. Dynamic method for calculation of the time course of 
metabolic fluxes and stationary method for calculation of mean fluxes for different metabolic phases. 
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2.4 Results 
2.4.1 Growth profile of AGE1.HN during batch cultivation.  
During the initial growth period lasting up to 160 h, the viability remained high at about 95% (Fig. 2-3). At 
160 h the viability started decreasing and the growth rate slowed down. The cell density at the end of the 
batch cultivation was about 7.5 × 106 cells/ml (Fig. 2-3). By plotting the logarithm of the cell density 
against time (not shown), distinct growth phases could be distinguished. The first lasted from 0 h to 90 h, 
the second from 90 h to 160 h, and the third from 160 h to 230 h having growth rates of 0.351 ± 0.055 
d-1, 0.279 ± 0.021 d-1, and 0.056 ± 0.011 d-1.  
 
 
Fig. 2-3 Growth of AGE1.HN. 
Viable cell density, total cell 
density, and viability during batch 
cultivation. Mean values and 
standard deviations of four 
parallel cultivations. 
 
 
 
 
 
 
 
2.4.2 Exometabolome analysis and extracellular fluxes.  
The observed growth behavior is strongly linked to metabolite profiles (Fig. 2-4, Fig. S1). Pyruvate was 
consumed during the first 90 h of the cultivation (phase 1), and lactate, glutamate, alanine, and glycine 
were produced. The uptake rates of glucose and pyruvate as well as the production rate of lactate were 
highest in the beginning and dropped until 90 h (Fig. 2-5). The lactate production stopped with pyruvate 
depletion at about 90 h indicating a coupling of these reactions (Fig. 2-5). The glutamate production rate 
was decreasing during the first phase whereas the glutamine consumption rate remained at a constant high 
value in this phase (Fig. 2-5). For most other amino acids, the uptake or production rates were highest in 
phase 1 (Fig. S2, Table S2 and Table S3).  
After 90 h (phase 2), when pyruvate was used up, lactate production stopped immediately and the cells 
started to consume glutamate as well as glycine (Fig. 2-4). The extracellular fluxes for most metabolites 
were significantly lower than in phase 1 (Fig. 2-6, Table S3). The glucose uptake rate, which was almost 
identical to the rate of glycolysis, was constant (Fig. 2-5), and the lactate production rate was very low (Fig. 
2-5, Fig. 2-6). The glutamine uptake rate was decreasing (Fig. 2-5, Table S2). At the end of phase 2, 
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glutamine was nearly completely consumed and the cells started to consume glutamate (Fig. 2-5, Table 
S2). The production rate of alanine was decreasing (Fig. 2-5, Fig. S2 and Table S2). The rates for other 
amino acids remained nearly constant or were very low (Fig. S2).  
After 160 h (phase 3), glutamine was used up which forced the cells to adapt their metabolism again. 
Glutamate consumption increased initially in this phase. Lactate production again increased slightly but 
was nevertheless very low compared to phase 1 (Fig. 2-5, Table S3). Alanine, which was constantly 
produced during phases 1 and 2, was now consumed. In addition, the cells stopped exponential growth 
and the viability dropped directly after glutamine depletion, which indicates the important role of 
glutamine as substrate for AGE1.HN. Almost all of the calculated mean extracellular fluxes (Fig. 2-6, 
Table S3) were significantly different compared to phase 1, and most of them were also significantly 
different compared to phase 2. Glutamate was completely exhausted at about 215 h (Fig. 2-4). The glucose 
consumption rate was constantly decreasing until glucose was completely depleted at the end of the 
cultivation at 230 h (Fig. 2-4 and Fig. 2-5).  
In general, the standard errors for extracellular fluxes were high in the beginning and decreased with time 
(Fig. 2-5). This is due to the small differences in substrate concentrations in the beginning of the 
cultivation. The integral yield of cells per glucose was around 340 cells/nmol which is a favourable feature 
of AGE1.HN since it is higher compared to the corresponding yield in CHO cells which is typically 
ranging between 60 and 100 cells/nmol of glucose consumed (Deshpande et al. 2009; Kim and Lee 2007). 
 
 
Fig. 2-4 Cultivation profile of AGE1.HN. 
Mean values and standard deviations for cell 
mass and selected metabolites of four 
parallel cultivations are depicted. Further 
metabolites are depicted in Fig. S1 of the 
supplementary material. The first line (90 h) 
indicates the end of the first metabolic 
phase when pyruvate is depleted, the second 
line (160 h) the end of the second metabolic 
phase when glutamine is depleted. 
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2.4.3 Metabolic flux analysis – intracellular fluxes.  
Intracellular fluxes were calculated using the stoichiometric network model depicted in Fig. 2-1.  
Glycolysis. The highest flux through the glycolytic pathway was observed in phase 1 (Fig. 2-6 and Table S3). 
Then it steadily decreased until 90 h (Fig. 2-5 and Fig. S2). In phase 2, glycolytic activity was significantly 
lower and remained nearly constant. In phase 3, glycolytic flux was slightly decreasing until the end of the 
cultivation (Fig. 2-5 and Fig. S2) but was not significantly different from phase 2 (Fig. 2-6 and Table S3).  
Pyruvate dehydrogenase activity. The calculated fluxes through the pyruvate carrier (Pyr-Pyrm, Fig. 2-5 and Fig. 
2-6) and through the pyruvate dehydrogenase complex (Pyrm-AcCm) were low in the beginning, i.e., not 
significantly different from zero (Table S3) and increased in phase 1. In phase 2, pyruvate dehydrogenase 
activity remained constant and was significantly higher compared to phase 1 (Fig. 2-5,   Fig. 2-6 and Table 
S3). Since lactate production was approximately 0 in phase 2, most of the pyruvate was entering the TCA 
cycle via pyruvate dehydrogenase. This flux was still high in phase 3 but slightly decreasing (Fig. 2-5).  
TCA cycle and anaplerosis. The activity of the TCA cycle in phase 1 was significantly lower than in phases 2 
and 3 (Fig. 2-5, Fig. 2-6 and Table S3). No lactate was produced from pyruvate in phase 2. Therefore, a 
large fraction of pyruvate entered the TCA cycle and fluxes through the upper part as well as the lower 
part of the TCA cycle were very high in this phase (Fig. 2-5, Fig. 2-6 and Table S3). The anaplerotic flux 
through the enzyme glutamate dehydrogenase (Glu-AKGm) was decreasing during the cultivation 
matching the decrease in available extracellular glutamine (Fig. 2-5). The aspartate aminotransferase flux 
(Asp-OAAm) was highest in phase 1 and decreased thereafter. During phase 2, this flux remained constant 
until it decreased again in phase 3 (Fig. S3). Fluxes through the TCA cycle in phase 3 were similar to those 
in phase 2 but decreasing towards the end (Fig. 2-5, Fig. 2-6 and Table S3). Glutamine was depleted and 
glutamate was taken up instead (Fig. 2-4). However, the flux through glutamate dehydrogenase was very 
low in phase 3 which shows that acetyl coenzyme A derived from pyruvate was by far the most important 
fuel for TCA cycle after glutamine depletion. The calculated flux from malate to pyruvate (Malm-Pyrm) was 
very high in the beginning of phase 1. In the following phases, this flux dropped and was significantly 
lower (Fig. 2-5,   Fig. 2-6 and Table S3). Interestingly, the TCA cycle was additionally fed by the 
degradation of the branched chain amino acids isoleucin, leucin, and valine during phase 1. In the other 
phases, degradation of these amino acids to form intermediates of TCA cycle was not significantly 
different from zero.  
Electron transport chain/oxidative phosphorylation. In accordance to the time courses for FADH2 and 
NAD(P)H production, the activity of the oxidative phosphorylation (ATPOP) was low in phase 1 and then 
increased to a constant level during phase 2 until the middle of phase 3 and subsequently decreased 
(Fig. S3 and Table S3). The ATP-balance for all reactions included in the network without oxidative 
phosphorylation (ATPwOP) indicates that the ATP demand was also highest in phases 1 and 2 and lowest 
in phase 3.  
Amino acid metabolism. The fluxes through glutamine synthetase (Gln-Glu) and glutamate dehydrogenase 
(Glu-AKGm) were almost constant in phase 1 and then decreased during the cultivation, since glutamine 
and glutamate were successively depleted (Fig. 2-5, Fig. 2-6 and Table S3). The glutamate pool was 
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additionally fed by degradation of arginine (Arg-Glu, Fig. S3 and Table S3). In phases 1 and 2 less 
asparagine was taken up than needed for protein synthesis which was then synthesized through the 
asparagine synthase from aspartate (Asn-Asp, Fig. S3 and Table S3). Aspartate was feeding into the TCA 
cycle during the whole cultivation through the aspartate aminotransferase catalyzed reaction leading to 
oxaloacetate (Asp-OAAm). This flux was decreasing over time (Fig. S3). Since glycine was produced in 
phase 1 and then only slightly taken up (Fig. 2-4), it had to be produced via glycine 
hydroxymethyltransferase indicated by Gly-Ser in Fig. S3 and Table S3. This flux significantly decreased 
with time because glycine was taken up in phases 2 and 3 where, additionally, the anabolic demand 
decreased because of slower growth. The flux through serine dehydratase (Ser-Pyr) also significantly 
decreased (Fig. S3 and Table S3). In accordance with the time course of proline production (Fig. 2-5), the 
flux from glutamate to proline (Pro-Glu, Fig. S3 and Table S3) was highest in phase 1 and then decreased. 
Other degradation rates of amino acids were very low indicating that the uptake of these amino acids was 
just matching the anabolic demand of the cells.  
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Fig. 2-5 Selected metabolic fluxes of AGE1.HN over time related to biomass. Mean values and confidence intervals 
(90%) of four parallel cultivations. The fluxes (y-axis) are given in µmol/g/h and the time (x-axis) in days. The first 
line (90 h) indicates the end of the first metabolic phase when pyruvate is consumed, the second line (160 h) the end 
of the second metabolic phase when glutamine is consumed. Negative values indicate fluxes in the opposite direction 
of the arrow. Further extracellular and intracellular fluxes are depicted in Fig. S2 and Fig. S3 of the supplementary 
material. 
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Fig. 2-6 Average metabolic flux distribution of AGE1.HN in each metabolic phase. Arrow width indicates flux 
strength. Flux symbols selected for this figure are shown in the flux map of phase 1 and are defined in the metabolic 
network (Fig. 2-1). Same experiment as shown in Fig. 2-5. Further data are provided in Table S3 of the 
supplementary material. 
2.5 Discussion 
2.5.1 Metabolism in AGE1.HN.  
Metabolism and metabolic shifts of the new human cell line AGE1.HN were quantitatively analyzed in 
this study using time resolved metabolic flux analysis and stationary metabolic flux analysis in different 
phases during batch cultivation. Our results indicate that pyruvate uptake during phase 1 in combination 
with high levels of other substrates resulted in an inefficient metabolic phenotype characterized by 
overflow metabolism leading to waste product formation. In phase 2, the metabolism was switching to a 
most efficient state characterized by low substrate uptake rates and no lactate formation. The data indicate 
that a decrease in substrate levels occurring during the cultivation resulted in a slowdown of glycolysis 
during phase 1. Additional experiments using different pyruvate concentrations in the medium support 
the conclusion that there is a strong link between pyruvate in the medium and lactate production in 
AGE1.HN (Niklas et al. 2011b). Another possibility would be that the cells could secrete lactate only until 
a certain concentration is reached and would then stop the production. However, in other experiments 
that were performed using high lactate start concentrations (about 8 mM), it was observed that the cells 
were producing almost the same amount of lactate as in experiments where lactate start concentration was 
0. This indicates that pyruvate depletion seems to be an important factor for cessation of lactate 
production. This particular phenotype was so far not observed in other mammalian cells (Altamirano et al. 
2006; Gambhir et al. 2003; Niklas et al. 2009; Sidorenko et al. 2008). 
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During exponential growth of mammalian cells under non-limiting substrate levels, inefficient substrate 
utilization was reported for several other mammalian cell lines (Bonarius et al. 2001; Le Ru et al. 2010; 
Niklas et al. 2009; Sidorenko et al. 2008). Usually, only a small amount of intracellular pyruvate is entering 
the TCA cycle under these conditions, which is considered very unfavourable. Increasing flux through 
pyruvate dehydrogenase represents an optimization target for the cultivation of many mammalian cells, 
but the mechanisms and molecular reasons are still poorly understood (Modak et al. 2002; Zeng et al. 
2002). In a recent study on HEK-293 cells, pyruvate dehydrogenase activity was reported to be around 
22% of glycolytic activity (Le Ru et al. 2010). Very low or even no activity of the pyruvate dehydrogenase 
complex was reported in other studies on different mammalian cells (Neermann and Wagner 1996; 
Sidorenko et al. 2008). In AGE1.HN cells, this was observed only during the first phase. During phases 2 
and 3, pyruvate dehydrogenase activity was high. In MDCK cells, it was found that an addition of 
pyruvate in a glutamine depleted medium resulted even in an increase in the flux from pyruvate into the 
TCA cycle (Sidorenko et al. 2008). In AGE1.HN, it seems that available pyruvate has an opposite effect 
triggering the conversion of pyruvate to lactate. High uptake rates of glucose and pyruvate, as observed in 
phase 1, might lead to an increase of the intracellular pyruvate pool triggering overflow metabolism into 
lactate/alanine, eventually resulting in an increased secretion of these waste metabolites. This might be 
changed by increasing reactions connecting TCA cycle and glycolysis, e.g., by stimulating pyruvate 
dehydrogenase and pyruvate carboxylase fluxes (Elias et al. 2003; Irani et al. 1999). However, the success 
of this strategy can not be predicted a priori. Increase of fluxes into the TCA cycle must be accompanied 
by an increase in oxidative phosphorylation activity, which might not always be possible. Another strategy 
that is working in the opposite direction would be decreasing the substrate uptake rates, e.g., by knock 
down of transporters (Paredes et al. 1999) or decreasing the lactate production, e.g., by knock down of 
lactate dehydrogenase (Kim and Lee 2007).  
2.5.2 Comparison of selected metabolic fluxes in AGE1.HN with those in other 
cells.  
Selected metabolic fluxes in AGE1.HN that were calculated by the stationary method for different phases 
are compared to fluxes published for other mammalian cells (Table 2-2). Glucose uptake and lactate 
production rates were generally lower in AGE1.HN than in other cells. Pyruvate represents an 
extracellular metabolite that was often neglected in other studies (Altamirano et al. 2006; Bonarius et al. 
2001). However, as shown in this study and in MDCK cells (Genzel et al. 2005; Sidorenko et al. 2008) or 
CHO cells (Omasa et al. 2010), it is a very interesting metabolite that can induce huge changes in the 
metabolism. In AGE1.HN cells, pyruvate uptake rate was far lower than in MDCK cells that were grown 
in high pyruvate medium (Table 2-2, M2). However, the ratio of pyruvate uptake per glucose uptake was 
similar. The second phase in AGE1.HN showed a very efficient metabolism concerning substrate usage as 
already discussed before. The cells were proliferating without lactate production. Pyruvate dehydrogenase 
(PDH) activity was high. In all other cell lines, high lactate production was observed during the phases 
that were analyzed by MFA except for CHO cells in presence of galactose after glucose depletion. In 
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order to reach higher cell densities in cultivations of AGE.HN, the second phase could be prolonged by 
feeding of glutamine. PDH activity in AGE1.HN was low in phase 1 and high in phases 2 and 3. A similar 
situation was observed in CHO cells (Altamirano et al. 2006) which exhibited low PDH activity and 
overflow metabolism during growth on glucose. After glucose depletion, these cells were consuming 
lactate in the presence of galactose having high PDH activity. No PDH activity was reported for MDCK 
cells in glutamine containing medium. In medium without glutamine and high pyruvate concentration, low 
PDH activity was found in these cells. The absolute flux through PDH was highest in continuously 
cultured hybridoma cells (Bonarius et al. 2001), but the metabolism was by far not as efficient as in phase 
2 of AGE1.HN since there was high glucose consumption and waste product formation. Absolute 
glutamate dehydrogenase (GDH) activity of AGE1.HN during phases 1 and 2 was lower than in other cell 
lines, but the relative activity compared to the glucose uptake rate was quite similar in MDCK and CHO 
cultures. Upper and lower TCA cycle activity in phases 2 and 3 was comparable to the activity in CHO 
cells with glucose medium (S1 in Table 2-2) and in MDCK cells (M2 in Table 2-2) cultured without 
glutamine. For hybridoma cells, higher TCA cycle activity was reported.  
 
Table 2-2 Comparison of selected metabolic fluxes in AGE1.HN during different metabolic phases (P1-3) with 
fluxes published for other mammalian cell lines. 
  Flux [µmol g
-1 h-1] 
 AGE1.HN MDCKa CHOb Hybridomac 
  P1 P2 P3 M1 M2 S1 S2   
Glc uptake 123.0 56.6 33.7 1,108.7 476.6 322.5 43.8d 674.6 
Pyr uptake 28.7 0.9 0.4 0.0 111.0 nd nd nd 
Lac production 236.3 4.5 14.3 2,188.0 965.0 612.5 -68.8 1,030.0 
Gln uptake 37.1 23.5 2.1 70.9 0.9 0.0 0.0 146.9 
Glu production 4.0 -2.4 -2.9 -42.1 -22.1 -56.3 -56.8 1.2 
PDH 12.2 88.1 56.8 0.0 33.1 35.5 174.6 355.7 
GDH 13.2 8.3 1.7 64.7 42.8 28.1 14.0 110.1 
Upper TCA  -4.0 66.4 57.7 -27.3 43.5 35.5 148.8 312.5 
Lower TCA  9.2 74.7 59.3 54.3 63.0 78.9 195.8 441.1 
Fluxes are given in µmol/g/h. Literature fluxes that were given per cell were normalized to biomass by assuming a 
cell dry weight of 800 pg/cell for MDCK cells (Wahl et al. 2008) and 400 pg/cell for CHO and hybridoma cells 
(Bonarius et al. 1996; Xie and Wang 1994). MDCK murine darby canine kidney, M1 glutamine containing medium, 
M2 medium with high pyruvate concentration and without glutamine, CHO chinese hamster ovary, S1 stage 1 of 
cultivation, S2 stage 2 of cultivation when glucose is exhausted, Glc glucose, Pyr pyruvate, Lac lactate, Gln glutamine, 
Glu glutamate, PDH pyruvate dehydrogenase, GDH glutamate dehydrogenase, upper TCA activity of the upper 
tricarboxylic acid cycle represented by the flux from citrate to α-ketoglutarate, lower TCA activity of the lower TCA 
cycle represented by the α-ketoglutarate dehydrogenase flux, nd not determined. aMDCK cell culture (Sidorenko et al. 
2008), bCHO cell culture (Altamirano et al. 2006), cContinuous culture of hybridoma cells (Bonarius et al. 2001), 
dGalactose uptake.  
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The main differences between the metabolic phases of AGE1.HN are summarized in Fig. 2-7. The results 
indicate further targets for improving the metabolic phenotype of these cells to reach higher cell densities 
as well as to obtain a more efficient utilization of the nutrients. The high overflow metabolism in the 
beginning of the cultivation with channeling of pyruvate to lactate could be decreased. This could be 
accomplished by genetic engineering, e.g., by deletion of lactate dehydrogenase (Chen et al. 2001) or 
introduction of pyruvate carboxylase (Elias et al. 2003), further medium optimization, e.g., reduced 
concentrations of pyruvate, or by application of new feeding strategies (Omasa et al. 2010). The observed 
metabolism in phase 2 indicates the potential of this cell line to grow very efficiently having minimum 
formation of waste products and minimum energy spilling (Russell 2007).  Therefore, it seems promising 
to change environmental conditions, i.e., media, substrate feeding, as well as enzyme expression such as to 
approach the efficient metabolic state of phase 2 during a process. Studies on enzyme expression and 
detailed labeling experiments in combination with 13C metabolic flux analysis would provide additional 
hints for the best way to further improve the cell line. 
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Fig. 2-7 Summary of metabolic shifts during batch cultivation of AGE1.HN.  
2.5.3 Time resolved vs. stationary flux analysis.  
The applied dynamic method is well suited to analyze and monitor metabolic shifts during the cultivation. 
Cell growth, cell size, extracellular, as well as intracellular fluxes of mammalian cells in a cell culture 
process are highly dynamic which is caused by environmental changes. Therefore, the presented method 
that is considering the dynamics of all included metabolites and biomass is best suited to understand and 
finally model the process. Stationary metabolic flux analysis, which was applied extensively in the past 
(Sidorenko et al. 2008; Xie and Wang 1996b), is only suited to describe the mean metabolism during a 
certain phase which is a significant disadvantage since changes during the phase considered are neglected 
(Niklas et al. 2010). However, if the pseudo steady state assumption during a phase is justified, it can give 
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a useful overview of its average metabolism (Quek et al. 2010). The information obtained by flux balance 
analysis can be validated (Zupke and Stephanopoulos 1995) or further enriched by specific labeling 
information (Bonarius et al. 1998b) to resolve reversible, cyclic, or parallel fluxes as, e.g., pentose 
phosphate pathway split (Lee et al. 1998; Velagapudi et al. 2007). 
2.6 Concluding remarks 
The application of a dynamic metabolic flux analysis method, as presented in this study, is well suited to 
describe the dynamic and adaptive behavior of the metabolism of mammalian cells during cultivation in 
industrially relevant media at any scale. Thus it supports the identification of targets for improved growth 
and substrate utilization based on derived metabolic flux distribution. Further improvement of the 
method could be achieved by including labeling information as, e.g., to monitor pentose phosphate 
pathway split. The presented dynamic method can be applied to almost any cultivation of a mammalian 
cell and could replace the widely applied but inflexible stationary MFA. In this study, metabolic shifts 
caused by changing environmental conditions during cultivation of AGE1.HN cells were described in 
detail (Fig. 2-7). This knowledge about the reaction of the cells to changes in the environment is a valuable 
basis for designing efficient feeding strategies and provides hints for genetic modifications. In the 
AGE1.HN cell line, major targets identified for improvement are as follows: (i) overflow metabolism 
during phase 1 should be reduced, e.g., by reduction of pyruvate content in the medium, (ii) phase 2 
should be prolonged by specific feeding strategies, e.g., of glutamine. The dynamic metabolic flux data 
presented in this study are a contribution to the attempts at understanding this cell line at a systems level. 
Such an understanding is expected to eventually support the improvement of heterologous protein 
production in derived producers. Generally, the method represents a valuable option to support today and 
future improvement of cell culture media and processes. 
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3 Metabolite channeling and compartmentation in the human 
cell line AGE1.HN determined by 13C labeling experiments and 
13C metabolic flux analysis 
3.1 Abstract 
This study focused on analyzing active pathways and the metabolic flux distribution in human neuronal 
AGE1.HN cells, which is a desirable basis for a rational design and optimization of producing cell lines 
and production processes for biopharmaceuticals. 13C-labeling experiments and 13C metabolic flux analysis 
were conducted using glucose, glutamine, alanine, and lactate tracers in parallel experiments. Connections 
between cytosolic and mitochondrial metabolite pools were verified, e.g., flux from TCA cycle metabolite 
13C to glycolytic metabolites. It was also found that lactate and alanine are produced from the same 
pyruvate pool and that consumed alanine is mainly directly metabolized and secreted as lactate. Activity of 
the pentose phosphate pathway was low being around 2.3% of the glucose uptake flux. This might be 
compensated in AGE1.HN by high mitochondrial malic enzyme flux producing NADPH. Mitochondrial 
pyruvate transport was almost zero. Instead, pyruvate carbons were channeled via oxaloacetate into the 
TCA cycle, which was mainly fed via α-ketoglutarate and oxaloacetate during the investigated phase. The 
data indicate that further optimization of this cell line should focus on the improved substrate usage which 
can be accomplished by an improved connectivity between glycolytic and mitochondrial pyruvate pools or 
by better control of the substrate uptake.  
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was published as 
Niklas J, Sandig V, Heinzle E. Metabolite channeling and compartmentation in the human cell line 
AGE1.HN determined by 13C labeling experiments and 13C metabolic flux analysis. J Biosci Bioeng. DOI: 
10.1016/j.jbiosc.2011.07.021.  
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3.2 Introduction 
In the last decade, the pharmaceutical industry has put much effort into developing and establishing 
efficient cell culture processes for the production of biopharmaceuticals to fulfill the increasing demand of 
a global market with a projected size of USD 70 billion by 2010 (O'Callaghan and James 2008; Pavlou and 
Reichert 2004; Walsh 2006). The rapid growth and success of the biologics sector is driven by high success 
rates of therapeutic proteins, especially monoclonal antibodies (O'Callaghan and James 2008; Reichert et 
al. 2005).  
The applied cellular production systems and cell culture processes must be capable of generating high 
product yields. Commonly used cell lines are CHO (Chinese hamster ovary), BHK (baby hamster kidney), 
or hybridoma cells (Dinnis and James 2005; Sandig et al. 2005). However, increasing the product yields by 
optimizing culture conditions is limited (Fogolin et al. 2004; Kumar et al. 2007; Oh et al. 2005; Trummer 
et al. 2006). Due to demands for higher productivity, efficiency, product quality (e.g., glycosylation), and 
robustness, new designer cell lines are developed and are entering the market (Rose et al. 2008; Sandig et 
al. 2005). The human cell line AGE1.HN (ProBiogen AG, Berlin, Germany) represents such a relatively 
new cell line which is well suited for the production of challenging biopharmaceuticals requiring complex 
human-type glycosylation (Blanchard et al. 2011). The rational improvement of the cell line can be 
facilitated by a thorough knowledge of growth and metabolism of the cells. In the area of systems biology 
research, the possibility is increasing of combining huge amounts of information with appropriate models 
enabling detailed knowledge and prediction of the investigated system (Kitano 2005; Westerhoff and 
Palsson 2004). A very powerful systems biology method represents metabolic flux analysis (Niklas et al. 
2010; Sauer 2006; Wittmann 2007; Niklas and Heinzle 2011). Those flux distributions or in vivo reaction 
rates represent functional end points of genome, proteome, and metabolome interactions providing 
detailed information of the investigated system (Sauer 2006). While metabolic flux analysis, especially 
using 13C labeled substrate, is widely applied in microbial biotechnology (Kiefer et al. 2004; Kim et al. 
2008; Wittmann and Heinzle 2002), it is still less established in mammalian cells (Niklas et al. 2010). Due 
to complex nutrient requirements and usually unbalanced growth behavior, metabolic flux analysis in 
mammalian cells is much more complicated. Therefore, most studies applying metabolic flux analysis to 
mammalian cells were pure metabolite balancing (Niklas et al. 2009; Wahl et al. 2008). However, there are 
possibilities to investigate the metabolism under nearly steady state conditions applying 13C metabolic flux 
analysis using special media in which the cellular metabolism is kept constant during a longer period 
(Deshpande et al. 2009).  
An interesting aspect in eukaryotic cells that needs further investigation is metabolic compartmentation 
and the in vivo dynamics of key metabolic reactions that take place in cytosol as well as mitochondria. This 
can be accomplished by using 13C metabolic flux analysis (13C MFA). In order to perform a 13C MFA, a 
thorough knowledge of the active enzymes and the connections in the metabolism of the system of 
interest is necessary, which enables the construction of a realistic carbon atom transition network. In this 
study, we performed labeling experiments using 13C tracers of glucose, glutamine, lactate, and alanine to 
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unravel metabolic connections and active pathways in AGE1.HN. A carbon atom transition network was 
constructed taking into account metabolic compartmentation. In a recent publication on the metabolism 
and its dynamics during batch cultivation of the AGE1.HN cell line, distinct metabolic phases were 
observed (Niklas et al. 2011d). The first phase in the cultivation is characterized by overflow metabolism 
and energy spilling. It was proposed that one reason for this metabolic inefficiency might be the 
connectivity between glycolysis and TCA cycle resulting in a wasting of pyruvate produced intracellularly 
and, ultimately, energy. However, the metabolic flux distribution around the pyruvate node and, in 
particular, the compartmentation of the metabolism cannot be determined just by metabolite balancing as 
applied in our previous study (Niklas et al. 2011d). In this study, 13C tracers and, subsequently, 13C 
metabolic flux analysis were applied to get insights into these normally underdetermined parts of the 
metabolism. A detailed analysis of the metabolic fluxes during overflow metabolism in AGE1.HN sheds 
light on the metabolic reasons underlying the observed metabolic inefficiency in the first growth phase of 
this cell line. It additionally provides valuable hints for (i) further improvement of the cultivation process 
or (ii) genetic modifications improving the metabolic phenotype. To ensure reliable metabolic profiling, 
only mass isotopomer distributions of lactate were used for metabolic flux analysis. A powerful tracer 
combination was applied in parallel labeling experiments using differently labeled glucose and [U-13C5] 
glutamine. We observed that the fluxes in the compartmented metabolic network can be resolved using 
the applied methodology revealing interesting aspects concerning the compartmentation of the cellular 
metabolism and the flux distribution in AGE1.HN during overflow metabolism. 
3.3 Materials and Methods 
3.3.1 Cell line 
The cell line AGE1.HN® (ProBioGen AG, Berlin, Germany) was developed from primary cells from a 
human brain tissue sample which were immortalized with an expression plasmid containing the adenoviral 
E1 A and B genes of human adenovirus type 5 driven by the human pGK and the endogenous E1B 
promoter, respectively. E1A induces progression of the cell cycle, whereas E1B proteins prevent 
apoptosis caused by E1A through interaction with p53 and bax. The cell line was further modified to 
express the structural and regulatory protein pIX from human adenovirus type 5 which changes cell 
metabolism, enhances productivity for secreted proteins, and modulates susceptibility to a variety of 
viruses. The cell line was adapted to robust growth in suspension in both serum/protein-free and 
chemically defined culture media. In this study, parental AGE1.HN cell line was used to analyze 
connections in the metabolism as well as its compartmentation unaffected by the production of a 
particular therapeutic protein. 
3.3.2 Labeling experiments 
Different tracer experiments were conducted to analyze the connections between key metabolites in the 
central metabolism. The applied tracers were [1,2-13C2] glucose (99%, Cambridge Isotope Laboratories, 
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Andover, MA, USA), [U-13C6] glucose (99%, Euriso-Top, Saarbrücken, Germany), [U-13C5] glutamine 
(99%, Cambridge Isotope Laboratories), [U-13C3] alanine (98%, Cambridge Isotope Laboratories), and [1-
13C1] lactate (20% w/w in water, Cambridge Isotope Laboratories). The glucose and glutamine tracer 
experiments were carried out as follows. The cells were cultured in baffled shake flasks (Corning, NY, 
USA) at 37°C on a shaker (2 inches orbit, ES-X, Kühner, Basel, Switzerland) enclosed in a 5% CO2 
supplied, humidified (80%) incubator (Mytron, Heilbad Heiligenstadt, Germany). The preculture was 
carried out in a 250 ml baffled shake flask in 42-Max-UB-medium (Teutocell, Bielefeld, Germany; 
substrate concentrations in the medium are given in Table S1). The cells were centrifuged (800 1/min, 7 
min, 22°C, Megafuge, Heraeus Instruments, Hanau, Germany) and the supernatant discarded. The pellet 
was resuspended in 42-Max-UB-medium without glucose and glutamine. Four 125 ml baffled shake flasks 
were inoculated reaching an initial cell density of about 4 × 105 cells/ml. Glucose and glutamine were 
finally added. The final culture volume was 54 ml. Samples (1.6 ml) were taken every day. 500 µl were 
directly used for cell counting. The rest was centrifuged (1,500 1/min, 5 min, 22°C, Megafuge, Heraeus 
Instruments, Hanau, Germany), the supernatant transferred into fresh tubes and frozen (-20°C). The 
analysis of several cultivation parameters was carried out using an automated cell culture analyzer (Cedex 
AS20, Innovatis, Bielefeld, Germany). Dissolved oxygen was measured in an additional cultivation in the 
applied culture system using the OXY-4 mini system (PreSens-Precision Sensing GmbH, Regensburg, 
Germany) (Wittmann et al. 2003). It was always higher than 80% air saturation. The cultivation conditions 
for alanine and lactate tracer experiments were as described above using an incubator supplied with 
shaking unit as well as temperature and CO2 control (Innova 4230, New Brunswick Scientific, Edison, NJ, 
USA; 2 inches orbit). The cells from the preculture were transferred in two separate tubes, centrifuged 
(500 1/min, 5 min, 25°C, Labofuge 400R Function Line, Heraeus Instruments, Hanau, Germany), the 
supernatant discarded, and the pellet resuspended in phosphate buffered saline (PBS). After another 
centrifugation, the pellets were resuspended in 42-Max-UB medium containing either 2.4 mM [U-13C3] 
alanine or 9 mM [1-13C1] lactate and not any anabolic amino acids which were determined using data 
obtained from the [U-13C6] glucose experiment described above. The cell suspensions were transferred 
into 50 ml bioreactor filter tubes (TPP, Trasadingen, Switzerland). The culture volume was 19 ml. Samples 
of 500 µl were taken every day. Cell counting was performed using an automated cell counter (Countess, 
Invitrogen, Karlsruhe, Germany). 
Metabolite concentrations and their labeling were analyzed as described below. The 13C labeling state of a 
molecule can be expressed in different ways, e.g., by using molar fractions or fractional abundances of 
single mass isotopomers (Kelleher 1999; Wittmann 2002). To describe the 13C labeling of the whole 
molecule the molar enrichment (Kelleher 1999) or summed fractional labeling (Christensen et al. 2000) 
can be used but also the so called fractional labeling (FL, mol 13C/mol total carbon) of the total molecule, 
which was also applied in other studies on cellular metabolism (Bonarius et al. 2001; Grotkjaer et al. 2004; 
Mancuso et al. 1994). The FL for each metabolite having n carbons was calculated as follows 
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where mi represents the fraction of a mass isotopomer having i 13C atoms.  
The concentration of labeled carbon atoms CLC (Unit C-mol/l) for each metabolite M having in total n 
carbon atoms was calculated using 
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This is required for the analysis of the total carbon transfer from 13C labeled substrates to products. The 
relative carbon atom transfer RCT from the respective tracer to a metabolite can finally be calculated. 
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3.3.3 Experiments applied for metabolic flux estimation 
Parallel experiments in which the tracers [1,2-13C2] glucose, [U-13C6] glucose, and [U-13C5] glutamine were 
applied were used for metabolic flux analysis. The details of the cultivation are described in the previous 
section. 
3.3.4 Quantification of metabolites 
Glucose, lactate, and pyruvate in the supernatant were analyzed using high-pressure liquid 
chromatography (HPLC) as described previously (Niklas et al. 2009). Quantification of proteinogenic 
amino acids was performed by another HPLC-method (Kromer et al. 2005). For metabolic rate 
calculation, the metabolite concentrations were corrected for evaporation and glutamine data was 
corrected for degradation as described recently (Niklas et al. 2011d). 
3.3.5 Analysis of labeling patterns 
13C-labeling of extracellular metabolites was analyzed applying gas chromatography mass spectrometry 
(GC-MS). 100 µl of the supernatants were lyophilized. 50 µl N,N-dimethylformamide was added and 
incubated at 80°C for 30 min. The metabolites were derivatized into corresponding t-butyldimethylsilyl 
derivatives using 50 µl N-methyl-N-t-butyldimethylsilyl-trifluoro-acetamide (MBDSTFA) (Wittmann et al. 
2002) followed by another incubation at 80°C for 30 min. The GC-MS measurements were carried out on 
a GC (HP 6890, Hewlett Packard, Paolo Alto, CA, USA) equipped with an HP5MS capillary column (5% 
phenyl-methyl-siloxane diphenylpolysiloxane, 30 m × 0.25 mm × 0.25 µm, Agilent Technologies, 
Waldbronn, Germany), electron impact ionization at 70 eV, and a quadrupole detector (Agilent 
Technologies). The conditions were as follows: 1 µl injected sample volume; helium carrier gas flow of 
1.1 ml/min; temperature gradient: 135°C for 7 min, 10°C/min up to 162°C, 7°C/min up to 170°C, 
10°C/min up to 325°C, 325°C for 2.5 min; inlet temperature: 140°C and heating with 720°C/min up to 
320°C; interface temperature 320°C; quadrupole temperature 150°C. For later determination of the mass 
distribution vectors the m-57 fragments of the extracellular metabolites were used which contain the 
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complete carbon skeleton (Wittmann et al. 2002). Carbon mass isotopomers were determined from the 
analyte mass isotopomer distribution using the method of Yang et al. (Yang et al. 2009). 
Mean mass isotopomer distributions for the experiments and the period considered for metabolic flux 
analysis were calculated. Fractions for each mass isotopomer mi having i labeled carbons were calculated 
from yields on biomass BM using 
∑
=
=
n
0i
i
i
m
]BM[d
]m[d
]BM[d
]m[d
f
i
         (4) 
where f represents the fraction of each mass isotopomer mi having n carbon atoms. 
3.3.6 Calculation of specific rates  
Specific rates (r) were calculated for each metabolite M using 
]BM[d
]M[d
µrM =           (5) 
where µ represents the specific growth rate. 
Assuming that the cells are spherical, the volume of the cells was calculated from the determined cell 
diameter and finally the specific biomass production was calculated using the relationship determined 
earlier (Niklas et al. 2011d). 
3.3.7 Anabolic demand of AGE1.HN  
The anabolic demand of AGE1.HN calculated from the biomass composition which was also applied in 
another study on AGE1.HN (Niklas et al. 2011d) is illustrated in Table 3-1.  
3.3.8 Flux estimation 
Inputs used for flux estimation were the measured extracellular fluxes, anabolic fluxes, as well as the 
labeling patterns of lactate. Labeling in secreted extracellular amino acids could also be used theoretically 
for flux estimation. However, these amino acids are present in the beginning of the cultivation, and 
reversibility of production and uptake of these as well as their conversion would change the extracellularly 
present labeling distribution, which then no longer reflects the intracellular labeling state. In this study, 
labeling patterns of lactate were therefore used. The advantages are as follows. Lactate is not present in 
the beginning of the cultivation, it can be directly measured, and its production reflects immediately the 
current state of the cellular metabolism. 
Fluxes were estimated in Matlab R2008 (The Mathworks, Natick, MA, USA) using the elementary 
metabolite unit concept (Antoniewicz et al. 2007). The defined biochemical reaction stoichiometry 
including carbon atom transition mechanisms was automatically compiled into the executable files 
required for carbon flux simulation and numerical flux estimation runs. A gradient-based hybrid algorithm 
is utilized for the numerical flux estimation (Yang et al. 2008). During the simulation, the measured and 
simulated variables were fitted by minimizing the sum of least squares (Wittmann and Heinzle 2002). 
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Maximum flux value was set to 500% of the glucose uptake flux. Error propagation was calculated 
applying Gaussian error propagation using Monte-Carlo simulation.   
 
Table 3-1 Anabolic demand of AGE1.HN. 
Precursor Anabolic demand [mmol/gDCW] 
G6P 0.438 
P5P 0.226 
GAP 0.097 
ACA 2.283 
Ala 0.519 
Asp 0.298 
Glu 0.413 
Gln 0.413 
Gly 0.721 
Ile 0.289 
Leu 0.560 
Pro 0.257 
Ser 0.448 
Val 0.395 
The anabolic demand was calculated from the biomass composition which was described elsewhere (Niklas et al. 
2011d). The demand for the biomass precursors included in the metabolic network (Fig. 4-2) is depicted. DCW dry 
cell weight, G6P glucose 6-phosphate, P5P pentose 5-phosphate, GAP glyceraldehyde 3-phosphate, ACA acetyl 
coenzyme A, standard abbreviations for amino acids. 
3.4 Results 
3.4.1 Metabolic connections in AGE1.HN 
A number of tracer experiments were carried out followed by analysis of fractional labeling (FL) in 
extracellular metabolites and subsequent calculation of the relative carbon atom transfer (RCT) from 
tracers to extracellular metabolites in order to unravel relevant and active connections in the metabolism. 
Fig. 3-1 depicts the RCT from different tracers to extracellular metabolites after 72 h. It can be seen that 
glucose was metabolized mainly to lactate since 76% of glucose consumed was detected in lactate. Smaller 
amounts were channeled to alanine (5%) and serine (3%). In addition, glucose carbons were also entering 
TCA cycle which can be seen by an increase in FL of glutamate and proline. On the other hand, there was 
also reflux from TCA cycle which can be deduced by the observed labeling in lactate as well as alanine 
when using [U-13C5] glutamine as tracer. Further interesting results were found by applying lactate and 
alanine tracers. It was observed that lactate was also taken up to a small extent, which can be deduced 
from a decrease in labeled extracellular lactate as well as an increase in labeled extracellular alanine (Fig. 3-
1). This shows in addition that alanine and lactate and subsequently the pyruvate pools responsible for 
their synthesis are connected. By using [U-13C3] alanine, it was found that alanine which was taken up was 
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mainly directly used for transamination entering the cytosolic pyruvate pool, converted to lactate, and 
secreted. However, another part was also entering the central metabolism, particularly the TCA cycle, 
which can be seen by an increase in labeled glutamate. This indicates, in addition, that generally most of 
the intracellular pyruvate was directly metabolized to lactate. 
 
 
Fig. 3-1 Summary of the results obtained by different tracer experiments. Given are relative carbon atom transfers 
(RCT, [%]) from each tracer to extracellular metabolites after 72 h cultivation. The results from glucose labeling 
experiments using [U-13C6] and [1,2-13C2] glucose were averaged since these present the same information. A shows 
the results using glucose and glutamine tracers, B the results from alanine and lactate tracer experiments. Glc  
glucose, Lac lactate, standard abbreviations for amino acids.  
3.4.2 Modeling 
A metabolic carbon atom transition network of human central metabolism was set up (Fig. 3-2) using the 
genome information in the Kyoto Encyclopedia of Genes and Genomes (www.kegg.com), biochemistry 
books (Berg et al. 2003; Michal 1999), and the information obtained by tracer experiments (described 
above). Uptake fluxes of metabolites that do not contribute to the carbon atoms of the metabolites in the 
central metabolism are not important for 13C metabolic flux analysis and were excluded allowing faster 
simulation and parameter estimation. These were taken as negligible if the uptake of a metabolite matched 
the anabolic demand. The reactions and carbon transfers of the model are shown in Table S2 of the 
supplementary material. Pyruvate and phosphoenolpyruvate pools as well as oxaloacetate and malate pools 
were lumped to one pyruvate pool and oxaloacetate pool in mitochondria and cytosol, respectively. As 
supported by the labeling experiments described before, reactions between cytosolic and mitochondrial 
pools of pyruvate and oxaloacetate as well as their transport reactions were modeled to be reversible. The 
model consisted in total of 13 extracellular fluxes, 13 anabolic fluxes, and 30 intracellular fluxes (16 
defined as reversible). The anabolic demand (Table 3-1) for biomass precursors that are included in the 
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model was derived from the biomass composition which was also recently applied in another study 
(Niklas et al. 2011d). 
 
Fig. 3-2 Metabolic network for 13C metabolic 
flux analysis in AGE1.HN. The carbon atom 
transition reactions of the network are given 
separately in Tab. S2. The reflux of a reversible 
reaction is indicated by the small line end of the 
arrow. Abbreviations: 3PG 3-phosphoglycerate, 
ACA acetyl coenzyme A, cPyr cytosolic 
pyruvate, E4P erythrose 4-phosphate, F6P 
fructose 6-phosphate, G6P glucose 6-phosphate, 
GAP glyceraldehyde 3-phosphate, Glc glucose, 
Lac lactate, mACA mitochondrial acetyl 
coenzyme A, mAKG mitochondrial α-
ketoglutarate, mCit mitochondrial citrate, mOAA 
mitochondrial oxaloacetate, mPyr mitochondrial 
pyruvate, mSuc mitochondrial succinate, OAA 
oxaloacetate, P5P pentose 5-phosphate, Pyr 
pyruvate,  S7P sedoheptulose 7-phosphate, 
standard abbreviations for amino acids. Indices: 
ex extracellular. 
 
 
 
 
3.4.3 Metabolic fluxes in AGE1.HN 
Uptake and secretion rates for substrates and products (Table 3-2) were calculated for the growth phase 
between 18 and 72 h of the cultivation (see Fig. S1). In this phase, the cells exhibited overflow metabolism 
characterized by production of waste metabolites, e.g., lactate, alanine, and glutamate. Standard errors 
between the three cultivations were generally low (Table 3-2). Glutamine uptake rate was about 26% of 
the glucose uptake flux. Uptake of other amino acids was generally lower. However, the summed uptake 
of the branched chain amino acids leucine, isoleucine, and valine was comparable to the glutamine uptake. 
Serine, aspartate, and arginine uptake was also significantly higher compared to the remaining amino acid 
uptake rates.  
 
Chapter 3 Metabolite channeling and compartmentation in AGE1.HN 
 57 
Table 3-2 Extracellular rates in the exponential growth phase of AGE1.HN 
 Rate [µmol/g/h] SD [µmol/g/h] 
rGlucose -144.6 5.3 
rLactate 336.8 2.8 
rPyruvate -36.9 1.3 
rAlanine 20.1 2.4 
rArginine -10.9 3.3 
rAsparagine -3.9 1.7 
rAspartate -14.0 3.5 
rCysteine -0.6 0.0 
rGlutamate 5.1 1.6 
rGlutamine -38.3 1.4 
rGlycine 0.6 2.9 
rHistidine -2.2 1.5 
rIsoleucine -11.0 2.3 
rLeucine -16.5 4.0 
rLysine -8.2 5.6 
rMethionine -4.6 1.7 
rPhenylalanine -4.6 1.9 
rProline -0.1 8.0 
rSerine -16.8 5.4 
rThreonine -5.9 2.2 
rTryptophan -1.5 0.9 
rTyrosine -3.9 1.2 
rValine -10.7 2.7 
Metabolic rates for uptake (negative value) and production (positive value) of extracellular metabolites in the 
exponential growth phase of AGE1.HN (18-72 h). Mean values and standard deviations (SD) of three parallel 
cultivations in which different tracers ([1,2-13C2] glucose, [U-13C6] glucose, and [U-13C5] glutamine) were applied. 
 
By plotting metabolite (see Fig. S2) and lactate isotopomer (see Fig. S3) concentrations against glucose 
uptake, linear correlation was observed. This indicates that the pseudo steady state assumption during the 
exponential phase is valid and that the mean metabolism during this phase can be investigated using 13C 
MFA (Deshpande et al. 2009). Detailed 13C metabolic flux analysis was performed by including the 
labeling information stored in extracellular lactate resulting from three different parallel tracer experiments 
using [1,2-13C2] glucose, [U-13C6] glucose, and [U-13C5] glutamine. The fit between simulated and measured 
extracellular fluxes as well as lactate labeling was very good (see Fig. S4). The resulting flux map is 
depicted in Fig. 3-3; detailed data including resulting errors in estimated rates is presented in Table S3 of 
the supplementary material. 
Glucose which was taken up was mainly channeled through the glycolysis. Flux through the oxidative 
branch of the pentose phosphate pathway (PPP) was just around 2.3% of the glycolytic flux. The 
estimated flux through the non-oxidative branch of the PPP was very low.  
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The cytosolic pyruvate pool (cPyr) was mainly fed by the glycolytic flux. However, pyruvate uptake flux 
was about 20% of the glucose uptake (mol/mol) showing that extracellular pyruvate was also significantly 
contributing to intracellular pyruvate. The cytosolic pyruvate was almost exclusively converted to lactate 
and alanine and secreted. Just a very low amount was further used to produce energy. Flux between 
cytosolic oxaloacetate (OAA) and cPyr was estimated to be almost completely reversible having similar 
fluxes in both directions. Pyruvate transport between mitochondria and cytosol was very low having a 
higher flux from mitochondria to cytosol. Cytosolic oxaloacetate was entering mitochondria and feeding 
the mitochondrial oxaloacetate pool (mOAA). Flux from mOAA to mitochondrial pyruvate (mPyr) was 
relatively high and the only flux feeding mPyr pool. 
The tricarboxylic acid (TCA) cycle was almost exclusively fed by substrates other than those derived from 
glucose. Glutamine uptake was about 27% (mol/mol) of the glucose uptake and glutamine was mostly 
metabolized to α-ketoglutarate feeding the TCA cycle. Other rates of anaplerotic reactions that 
significantly contributed to replenishing TCA cycle intermediates were the degradation of aspartate to 
mOAA as well as the degradation of the branched chain amino acids leucine, isoleucine, and valine. In 
total, carbon flux through the upper TCA cycle (citrate synthase) and lower TCA cycle (mAKG up to 
mOAA) was around 33% of the glucose uptake flux. Just the flux through the isocitrate dehydrogenase 
(mCit to mAKG) was lower which was caused by the citrate lyase catalyzed conversion of citrate 
producing cytosolic oxaloacetate and acetyl coenzyme A (ACA) that is needed for lipid biosynthesis. 
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Fig. 3-3 Metabolic flux map for AGE1.HN during the first 3 days of batch cultivation. Fluxes are given in 
µmol/gbiomass/h. Flux strength is additionally indicated by the arrow width. Net fluxes could be determined very 
precisely in the metabolic network by using the applied tracer combination (Table S3). Fluxes to biomass and most 
extracellular fluxes are not depicted in this map. Abbreviations are defined in Fig. 3-2 (metabolic network). 
Reversibility for fluxes between cytosolic oxaloacetate (OAA) and cytosolic pyruvate (cPyr) as well as for exchange 
of cytosolic and mitochondrial pyruvate (cPyr-mPyr) is depicted. For other reversible fluxes the net fluxes could be 
determined precisely but not their reversibility (see Table S3). Therefore, just the net fluxes are presented for these 
reactions. 
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3.5 Discussion 
3.5.1 Metabolic connections in AGE1.HN 
In the first part of this study, labeling experiments were conducted to identify active pathways in 
AGE1.HN (Fig. 3-1). Channeling of glucose carbons mainly to lactate in permanent cell lines is 
commonly observed in mammalian cell culture (Altamirano et al. 2006; Bonarius et al. 2001; Sidorenko et 
al. 2008) and was also described for AGE1.HN in a recent study in which metabolic dynamics during 
growth were investigated (Niklas et al. 2011d). During the growth phase which was considered for 
metabolic flux analysis in this study, around 80% of the glucose carbons were channeled to the waste 
products lactate and alanine showing that the metabolism was not working efficiently (Fig. 3-1). This 
inefficient use of sugar carbons and energy which is stored in the wasted metabolites was already identified 
in the past as an optimization target and engineering approaches focused on optimizing this (Kim and Lee 
2007). In AGE1.HN, only a very low amount of the glucose carbons were found later in the secreted 
amino acids glutamate and proline. This indicates, additionally, that glucose was not an important source 
for the TCA cycle during the investigated metabolic phase. On the other hand, a significant percentage of 
the consumed glutamine carbons were found later in lactate indicating reflux from the TCA cycle and a 
connection between mitochondrial and cytosolic metabolite pools. The lactate labeling experiment 
revealed that lactate production and uptake was to a certain extent reversible. This shows that it might also 
be possible in the future to design the cultivation process such that lactate, which is produced during a 
first phase, can be taken up again and be used as an energy source as it was presented for CHO cells 
(Altamirano et al. 2006). Alanine was also reversibly produced and taken up as unraveled by the alanine 
tracer experiment. Interestingly, the percentage of alanine carbons which were channeled to lactate was 
almost identical to the percentage of glucose carbons that were found later in lactate. This indicates that 
both metabolites, i.e., glucose and alanine, were feeding into the same pyruvate pool since the fate of their 
carbons seems almost identical. This is somehow in contrast to earlier reports in which a strict separation 
of the glycolytic pyruvate pool that only produces lactate and the pyruvate pool involved in alanine 
metabolism was proposed. Zwingmann et al. described the phenomenon of alanine uptake and direct 
conversion and secretion of lactate in astrocytes (Zwingmann et al. 2001). Their observation was that 
alanine which is taken up by the cells is only converted to lactate and nothing is channeled into central 
metabolism. Bouzier et al. analyzed lactate and glucose metabolism in C6 glioma cells and presented 
results that supported the concept of two separate pyruvate and lactate pools (Bouzier et al. 1998).  This 
seems to be clearly not the case in AGE1.HN since all these metabolite pools are connected, and alanine 
carbons derived from consumed alanine were also entering central metabolism at a similar percentage as 
glucose carbons.  
3.5.2 Metabolic fluxes in AGE1.HN 
Metabolic flux distribution in AGE1.HN was computed by integrating data from glucose and glutamine 
tracer experiments. By applying different tracers in parallel experiments, a lot of information can already 
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be obtained solely from the labeling in lactate, as applied in this study, since it is directly derived from 
probably the most important metabolic hub in the cells, i.e., pyruvate. Similarly, the significance of 
information increase by parallel labeling experiments was shown for 13C metabolic flux analysis using CO2 
label analysis (Yang et al. 2006b, 2006a). The metabolic flux distribution of AGE1.HN (18-72 h of the 
cultivation) shows some interesting differences compared to metabolic fluxes published for other cells. 
Relative pentose phosphate pathway (PPP) activity in AGE1.HN was low being around 2.3% of the 
glucose uptake flux (Fig. 3-3). In other mammalian cells, comparably low activities have been reported 
(Lee et al. 1998; Mancuso et al. 1994; Vo and Palsson 2006). Slightly higher relative PPP activity was 
presented in metabolic flux studies on HEK-293 cells (Le Ru et al. 2010) and hybridoma cells (Bonarius et 
al. 2001) being 15% and 20%, respectively. In some studies, surprisingly high PPP activities of even 
approximately 40% were reported (Goudar et al. 2010; Maier et al. 2008). Generally, PPP activity depends 
on the demand for NADPH, nucleotides, and specific sugars, which again depends on the growth 
conditions and growth rate of the cells. Additionally, the NADPH supply can also be accomplished by the 
activity of malic enzyme or transhydrogenases. Malic enzyme isoforms are differentially expressed in the 
cytosol and mitochondria having different isoforms that prefer NADH or NADPH (Pongratz et al. 2007). 
Especially in neuronal cells, it was reported that the malic enzyme and, in particular, the mitochondrial one 
might be highly enriched and play a key role in the mitochondrial metabolism of brain cells (McKenna 
2007). In our study, relatively high activity of the mitochondrial flux from oxaloacetate (mOAA) to 
pyruvate (mPyr) was estimated indicating an important role of this flux in this neuronal cell line. This 
flux’s principal contribution was to fill up the mitochondrial pyruvate pool, and it can also contribute to 
NAD(P)H supply in this cell line. The cytosolic fluxes between oxaloacetate (OAA) and pyruvate (cPyr) 
were estimated to be highly reversible and the net flux was very low. In other cells, this cytosolic flux was 
working in the same direction (OAA to cPyr) but was estimated to be higher (Bonarius et al. 2001; 
Goudar et al. 2010; Le Ru et al. 2010). In CHO and hybridoma cells, mitochondrial malic enzyme was 
working in the other direction compared to AGE1.HN converting pyruvate to oxaloacetate (Bonarius et 
al. 2001; Goudar et al. 2010). This might also explain the different PPP activities in AGE1.HN cells 
compared to CHO and hybridoma cells, since the malic enzyme flux contributes to the supply of 
NADPH for biosynthesis.  
Another interesting finding in this study was that the TCA cycle was almost exclusively fed by substrates 
other than glucose. Pyruvate transport between cytosol and mitochondria was almost zero. Total TCA 
cycle activity was approximately 30% (mol/mol) of the glucose uptake flux. In other cells, e.g., in MDCK 
or CHO cells, very low TCA cycle activity was found compared to the glycolytic flux (Sidorenko et al. 
2008), especially, during the exponential growth phase (Altamirano et al. 2006). However, in other cells, 
the feeding of the TCA cycle was mostly accomplished through the entry of glycolytic pyruvate into 
mitochondria (Bonarius et al. 2001; Goudar et al. 2010; Le Ru et al. 2010); other anaplerotic fluxes played 
a minor role (Bonarius et al. 2001; Goudar et al. 2010). In HEK-293 cells, the anaplerotic fluxes feeding 
the TCA cycle were approximately similar compared to the mitochondrial pyruvate transport (Le Ru et al. 
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2010). In spite of almost no pyruvate transport from cytosol to mitochondria, the flux through pyruvate 
dehydrogenase was high in AGE1.HN being around 20% (mol/mol) of the glucose uptake flux (Fig. 3-3).  
3.5.3 Targets for improvement of metabolic efficiency 
The metabolic phase that was investigated is characterized by an overflow of substrates and high 
production of waste metabolites resulting in spilling of carbon energy. The inefficient use of glucose and 
pyruvate carbons is, therefore, an optimization target for the AGE1.HN cell line. In particular, the 
connectivity between the pathways glycolysis and TCA cycle is very low. Fluxes into the cytosolic pyruvate 
pool were high but the pyruvate could not be efficiently channeled into mitochondria. Pyruvate transport 
between the compartments seems one of the major problems of this cell line under the applied conditions 
since it was almost zero. This could be solved in the future by genetic engineering approaches focusing on 
improved pyruvate transport into mitochondria or further conversion of pyruvate to oxaloacetate which 
might facilitate its transport and usage. Insertion of an additional pyruvate carboxylase gene might be an 
interesting option to improve flux from cytosol to mitochondria of AGE1.HN, as it was also tried in 
other cell lines (Elias et al. 2003; Irani et al. 1999). In particular, the finding that the main metabolic 
connection between cytosol and mitochondria in AGE1.HN cells seems to be the transport of 
oxaloacetate/malate makes this engineering strategy really interesting. The other possibility, which was 
also proposed earlier (Niklas et al. 2011d), is the reduction of substrate uptake minimizing the flow into 
the intracellular cytosolic pyruvate pool, which would most probably lead to a more efficient use of the 
nutrients. This can be done, e.g., by using efficient feeding strategies restricting substrate uptake or by 
applying genetic engineering strategies focusing on reduction of substrate uptake or waste product 
formation (Noguchi et al. 2000; Paredes et al. 1999; Wlaschin and Hu 2007). 
The presented metabolic network and experimental platform for AGE1.HN cells also provides an 
important basis for further experiments to understand the effects of different environmental or genetic 
perturbations on cellular metabolism and its compartmentation as well as for the comparison of different 
producer cell lines. 
3.6 Acknowledgements 
This work has been financially supported by the BMBF project SysLogics - Systems biology of cell culture 
for biologics (FKZ 0315275A-F). We thank the Institute of Cell Culture Technology (University of 
Bielefeld, Germany) headed by Prof. Dr. Thomas Noll and especially Eva Schräder for most valuable help 
and experimental support. We thank Michel Fritz for valuable support for the HPLC and GC-MS analysis. 
3.7 Supplementary material 
The supplementary material for this chapter is available online:  
http://www.sciencedirect.com/science/article/pii/S1389172311002982.  
 
Chapter 4 Primary metabolism and α1-antitrypsin production in AGE1.HN at various substrate levels 
 63 
4 Primary metabolism in the new human cell line AGE1.HN at 
various substrate levels: increased metabolic efficiency and α1-
antitrypsin production at reduced pyruvate load 
4.1 Abstract 
Metabolic responses of the new neuronal human cell line AGE1.HN to various substrate levels were 
analyzed in this study showing that reduced substrate and especially pyruvate load improves metabolic 
efficiency, leading to improved growth and α1-antitrypsin (A1AT) production. The adaptation of the 
metabolism to different pyruvate and glutamine concentrations was analyzed in detail using a full factorial 
design. The most important finding was an increasingly inefficient use of substrates as well as reduction of 
cell proliferation with increasing pyruvate concentrations in the medium. Cultivations with different 
feeding profiles showed that the highest viable cell density and A1AT concentration (167% of batch) was 
reached in the culture with the lowest glucose level and without pyruvate feeding. Analysis of metabolic 
fluxes in the differently fed cultures revealed a more efficient metabolic phenotype in the cultures without 
pyruvate feeding. The measured in vitro enzyme activities of the selected enzymes involved in pyruvate 
metabolism were lower in AGE1.HN compared with CHO cells, which might explain the higher 
sensitivity and different adaptation of AGE1.HN to increased pyruvate concentrations. The results 
indicate on the one hand that increasing the connectivity between glycolysis and the TCA cycle might 
improve substrate use and, ultimately, the production of A1AT. On the other hand, a better balanced 
substrate uptake promises a reduction of energy spilling which is increased with increasing substrate levels 
in this cell line. Overall, the results of this study provide important insights into the regulation of primary 
metabolism and into the adaptation of AGE1.HN to different substrate levels, providing guidance for 
further optimization of production cell lines and applied process conditions. 
 
 
 
 
 
 
 
 
This chapter was published as 
Niklas J, Priesnitz C, Rose T, Sandig V, Heinzle E. Primary metabolism in the new human cell line 
AGE1.HN at various substrate levels: increased metabolic efficiency and α1-antitrypsin production at 
reduced pyruvate load. Appl Microbiol Biotechnol. 2011. DOI: 10.1007/s00253-011-3526-6.  
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4.2 Introduction 
Mammalian cells represent nowadays the predominant system for the production of recombinant proteins 
for clinical applications because of their ability to secrete properly folded and glycosylated proteins. 
Around 70% of recombinant therapeutic proteins are produced using cell culture processes, and this 
number is further increasing (O'Callaghan and James 2008). Intensive research in the past led to enormous 
improvement of the performance of mammalian cells (Wurm 2004). This was mainly enabled through 
better understanding and modification of parameters that influence productivity like cell growth, gene 
expression (Korke et al. 2004), metabolism (Bonarius et al. 2001; Cruz et al. 1999), protein secretion 
(Omasa et al. 2008), or repression of apoptosis (al-Rubeai and Singh 1998; Arden and Betenbaugh 2006; 
Nivitchanyong et al. 2007). For specific therapeutic glycoproteins with complex glycosylation, human cell 
lines may have an advantage compared to animal-derived cell lines since these human cells have a genuine 
human glycosylation system. The engineered cell line AGE1.HN represents such a very promising human-
derived production system. In some initial studies, it was shown that these cells are well suited for the 
production of complex glycoproteins (Blanchard et al. 2011). 
The neutrophil elastase inhibitor α1-antitrypsin (A1AT) represents a glycoprotein requiring N-
glycosylation at three sites (Carrell et al. 1981). In the clinic, A1AT is required to treat patients having 
A1AT deficiency, an inherited disease that can result in lung emphysema and liver dysfunction (Kelly et al. 
2010; Petrache et al. 2009). Patients with lung disease can be treated with A1AT augmentation therapy 
decreasing the mortality risk (A1AT-Group 1998). In spite of the fact that recombinant A1AT was 
produced in different prokaryotic and eukaryotic expression systems, there are currently only plasma-
derived products licensed by the US FDA for intravenous treatment of A1AT deficiency (Karnaukhova et 
al. 2006). An alternative source for A1AT would be highly desirable since A1AT augmentation therapy is 
currently very expensive and not cost-effective (Gildea et al. 2003). A1AT derived from AGE1.HN cells 
has similar anti-inflammatory activity as commercial A1AT from human plasma (Blanchard et al. 2011), 
showing that the AGE.HN cell line is an alternative and favorable expression system for large-scale 
production of recombinant human A1AT. 
The final product titer in a therapeutic protein production process in cell culture is related to high viable 
cell density and culture longevity (Kumar et al. 2007). In order to obtain high cell densities in a targeted 
development process, detailed knowledge of the metabolism of the producing cell system is desirable 
(Niklas et al. 2010). Metabolism of cells can be analyzed by metabolic profiling where, e.g., time courses of 
metabolites are interpreted or by different methods of metabolic flux analysis where intracellular reaction 
rates are analyzed (Niklas and Heinzle 2011; Niklas et al. 2010). Analysis of the cellular fluxome has shed 
light on the metabolism and its regulation not only in several mammalian cells (Bonarius et al. 2001; 
Gambhir et al. 2003; Niklas et al. 2009; Niklas et al. 2011d; Sidorenko et al. 2008; Teixeira et al. 2008) but 
also in microorganisms (Selvarasu et al. 2009a; Wittmann and Heinzle 2002) or plants (Heinzle et al. 
2007). 
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In a metabolic flux study on parental AGE1.HN cells, changes in the metabolic fluxes during batch 
cultivation of the parental AGE1.HN cell line were analyzed (Niklas et al. 2011d). It was found that 
during cultivation, the metabolism in AGE1.HN was switching from an inefficient metabolic state 
characterized by waste product formation to a very efficient metabolic state with minimum energy spilling. 
The main event that was triggering this change in the metabolism was concluded to be the reduction in 
extracellular substrate levels including the depletion of pyruvate. Reduction of the glutamine level and 
finally its depletion was another perturbation occurring during batch cultivation, which led again not only 
to a metabolic shift but also to a stop of growth and reduction of viability. It seems interesting to 
investigate the effects of pyruvate and glutamine on growth, metabolism, and glycoprotein production in 
more detail. In particular, pyruvate was often not considered and sometimes even not measured in 
metabolic studies on mammalian cells. However, it was shown that pyruvate can be used to introduce 
beneficial changes in the metabolism of several mammalian production cells (Genzel et al. 2005; Omasa et 
al. 2010). Genzel et al. (Genzel et al. 2005) showed that high pyruvate concentrations in the medium can 
be used to replace glutamine resulting in similar growth and lower ammonia production in cultivations of 
MDCK, BHK21, and CHO-K1 cells. These mammalian cells could even grow in media containing up to 
37 mM pyruvate. Omasa et al. found that the addition of pyruvate to cultivations of CHO cells resulted in 
an increased tricarboxylic acid (TCA) cycle activity accompanied by increased ATP and antibody 
production rates (Omasa et al. 2010). The studies mentioned show that it is interesting to investigate the 
effects of different substrate levels and especially different pyruvate concentrations on the metabolism in 
order to acquire an improved understanding of the cellular utilization of the substrates and their influence 
on cell growth and productivity. This improved understanding can eventually lead to the identification of 
promising targets for further metabolic engineering and for rational improvement of the production 
process. 
With the aim of understanding the influence of major substrates on the metabolism and growth of 
AGE1.HN, different substrate levels were examined. The effects of start concentrations of pyruvate and 
glutamine on growth and metabolism of AGE1.HN in batch cultivation were studied using a full factorial 
design experiment. Based on these results, feeding experiments were carried out in which glucose, 
pyruvate, and glutamine were fed during the cultivation in order to maintain the substrate levels in a 
certain concentration range. Metabolic flux analysis using the metabolite balancing method was 
additionally performed for the differently fed cultures in order to analyze the differences in substrate use. 
The results of the study lead directly to further engineering strategies for the improvement of 
biopharmaceutical production in the human AGE1.HN cell line. 
4.3 Material and methods 
4.3.1 Cell lines and cell culture 
The AGE1.HN® cell line (ProBioGen AG, Berlin, Germany) was developed from primary cells from a 
human brain tissue sample. A more detailed description of the cell line was published recently (Niklas et 
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al. 2011d). In this study, the parental AGE1.HN cell line as well as a derived production cell line 
(AGE1.HN.AAT) which produces the therapeutic protein A1AT were applied. Parental AGE1.HN cells 
were transfected with an expression vector containing the human A1AT gene driven by a human 
CMV/EF1 hybrid promoter (ProBioGen AG). The high-producing AGE1.HN.AAT cell line was derived 
after selection with puromycin. AGE.HN cells were cultivated in the serum-free 42-Max-UB medium 
(Teutocell AG, Bielefeld, Germany). T-CHO ATIII cells producing recombinant anti-thrombin III were 
obtained from Helmholtz Center for Infection Research (Braunschweig, Germany) and were cultured 
using serum-free CHO-S-SFM II medium (GIBCO, Invitrogen, Darmstadt, Germany). Standard 
cultivations of all cell lines were carried out in shake flasks (125 or 250 ml; Corning, NY, USA) at 37°C in 
an incubator containing shaking unit (Innova 4230, New Brunswick Scientific, Edison, NJ, USA, 2-in. 
orbit) with constant 5% CO2 supply at 185 rpm. 
4.3.2 Analytical methods 
Cell counting was performed using an automated cell counter (Countess, Invitrogen, Karlsruhe, Germany) 
or a hemocytometer. Viability was assessed by applying the Trypan blue exclusion method. The pH in the 
samples was determined using a MP 220 pH meter (Mettler-Toledo, Giessen, Germany). Sugars, lactate, 
and pyruvate in the supernatant were analyzed using high-pressure liquid chromatography (HPLC) as 
described previously (Niklas et al. 2009). For the feeding experiments, glucose concentration was 
additionally measured using the Glucose-UV Assay Kit (Roche, Darmstadt, Germany) according to the 
manual. Quantification of proteinogenic amino acids was performed by HPLC using the method of 
Kromer et al. (Kromer et al. 2005). Ammonia was quantified using the ammonia assay kit of Sigma-
Aldrich (Steinheim, Germany) according to the kit’s instructions. The measurement was performed in a 
photometer (Novaspec, Pharmacia Biotech, LittleChalfont, England). The concentration of active A1AT 
was determined using the trypsin inhibitory assay. Calibration was done using standards with different 
A1AT concentrations (0.5-0.001 mg/ml in phosphate buffered saline (PBS); A1AT from human plasma 
was acquired from Sigma-Aldrich). The samples were diluted with PBS (1:20 to 1:60). Of the samples and 
standard solutions 50 µl was mixed with a trypsin solution (0.1 mg/ml in an activity buffer containing 
15 mM Tris, 100 mM NaCl, 0.01% (v/v) Triton X-100 at pH 7.6) and incubated for 10 min at 37°C. Of 
these solutions 10 µl was pipetted into the wells of a 96-well plate and 90 µl of a BAPNA solution (Nα-
benzoyl-L-arginine 4-nitroanilide hydrochloride, Sigma-Aldrich) was added to each well. The BAPNA 
solution was prepared by mixing 11 µl of BAPNA stock solution (500 mM in DMSO) with 1,989 µl 
activity buffer. The plate was incubated at 37°C for 1 h and the absorption finally measured at 405 nm 
(iEMS Reader MF, Labsystems, Helsinki, Finland). 
4.3.3 Study of the effects of pyruvate and glutamine concentrations 
The effects of pyruvate and glutamine on the metabolism of parental AGE1.HN cells were analyzed in a 
three-level full factorial design for both factors (glutamine and pyruvate), resulting in 32 cultivations. The 
applied pyruvate concentrations were 2, 5, and 9 mM; the glutamine concentrations were 5, 7.5, and 10 
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mM. The preculture was performed in normal 42-Max-UB medium (2 mM pyruvate, 5 mM glutamine). 
The cells were harvested by centrifugation (500 rpm, 5 min, 25°C, Labofuge 400R Function Line, Heraeus 
Instruments, Hanau, Germany) and the supernatant discarded. The cell pellet was resuspended in the 
medium without glutamine and pyruvate. The cell suspension was uniformly distributed into 50-ml 
bioreactor filter tubes (TPP, Trasadingen, Switzerland) and the supplements (glutamine, pyruvate) were 
added. The culture volume was 20 ml. Samples of 300 µl were taken every day. Of the samples, 50 µl was 
used directly for cell counting. The rest was centrifuged (8,000 rpm, 5 min, 25°C, Biofuge Pico, Heraeus 
Instruments), the supernatant transferred into tubes and frozen (-20°C) for later exometabolome analysis. 
4.3.4 Cultivation of AGE1.HN.AAT using different substrate feeding 
The effects of different feeding profiles of glucose and pyruvate on growth, metabolism, and product 
formation (A1AT) were analyzed. The preculture (42-Max-UB medium; 2 mM pyruvate, 2 mM glutamine) 
was harvested by centrifugation (500 rpm, 5 min, 25°C, Labofuge 400R Function Line, Heraeus 
Instruments) and the supernatant discarded. The pellets were washed once with PBS (37°C, centrifugation 
as before) and the cells were finally resuspended in 42-Max-UB medium without glucose and glutamine. 
After cell counting, the cell suspension was transferred into 50-ml bioreactor filter tubes (TPP) and the 
supplements were added. Glutamine (stock solution 200 mM) was added to a final concentration of 2 mM 
in all cultures and glucose (stock solution 200 g/l) was supplemented such that the concentration was 
1 g/l (feeds 1 and 2) or 2 g/l (feeds 3 and 4). The total cultivation volume was 16 ml. The following 
cultivations were carried out: (1) Control (Batch), normal batch cultivation using the standard cultivation 
conditions; (2) feed 1 (high Glc), glucose controlled at high level (up to 2 g/l and mostly above 0.2 g/l); 
(3) feed 2 (high Glc+Pyr), glucose controlled at high level (up to 2 g/l and mostly above 0.2 g/l) and 
when glucose was fed pyruvate was added such that the pyruvate concentration in the medium was 
increased by about 2 mM; (4) feed 3 (low Glc), glucose controlled at low level (up to 1 g/l and mostly 
above 0.1 g/l); (5) feed 4 (low Glc+Pyr), glucose controlled at low level (up to 1 g/l and mostly above 
0.1 g/l) and when glucose was fed pyruvate was added such that the pyruvate concentration in the 
medium was increased by about 1 mM. In all cultivations, glutamine was fed to avoid limitation. Samples 
for metabolite analysis were taken every day. Glucose was measured in the cultures more often to avoid 
any limitation and to maintain the planned feeding profile by adjusting the feeding amount.  
4.3.5 Metabolic flux analysis 
Metabolic fluxes in AGE1.HN upon different substrate feeding were calculated for the phase between 72 
and 169 h in which the main differences in the metabolism were observed. Stationary metabolic flux 
analysis was applied as described in detail in a recent publication (Niklas et al. 2011d). The metabolic 
network that was used recently to analyze metabolic shifts in the parental AGE1.HN cell line (Niklas et al. 
2011d) was slightly modified and extended so that it contains additionally the production of A1AT and its 
precursor demand. The amino acid demand for A1AT was derived directly from its amino acid sequence. 
The average glycosylation of A1AT was taken from the literature (Kolarich et al. 2006). To glycosylate one 
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A1AT protein having three N-glycosylation sites, the following sugar combination is needed: average 
glycosylation (three sites) = 12.69 N-acetylglucosamine + 9 mannose + 6.69 galactose + 6.681 N-
acetylneuraminic acid + 0.321 fucose. The stoichiometry to synthesize 1 mol of fully glycosylated and 
active A1AT was included into the metabolic network model and can be seen in the stoichiometric matrix 
which is presented in the supplementary material (Table S1). A scheme of the applied metabolic network 
is depicted in Fig. 4-1. 
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Fig. 4-1 Simplified scheme of the metabolic network model for calculation of metabolic fluxes in AGE1.HN 
(modified and extended version of a metabolic network model which was published previously (Niklas et al. 2011b)). 
Dotted lines indicate fluxes to biomass (BM), solid lines extracellular or intracellular fluxes. Flux numbers are 
depicted for extracellular and intracellular reactions. The stoichiometric matrix of the model is given in the 
supplementary material (Table S1). PPP pentose phosphate pathway, TCA tricarboxylic acid, BM biomass, AA all 
amino acids, A1AT α1-antitrypsin, Glc glucose, Gal galactose, Lac lactate, Pyr pyruvate, G6P glucose 6-phosphate, 
P5P pentose 5-phosphate, F6P fructose 6-phosphate, GAP glyceraldehyde 3-phosphate, AcC acetyl coenzyme A, Cit 
citrate, AKG α-ketoglutarate, SuC succinyl coenzyme A, Fum fumarate, Mal malate, OAA oxaloacetate, standard 
abbreviations for amino acids. Indices: m mitochondrial, ex extracellular. 
4.3.6 Enzyme assays 
Enzyme activity measurements were carried out in cuvettes using a UV/vis photometer (Helios α, 
Spectronic Unicam, Cambridge, England) set at 37°C. For performing enzyme assays, 50 µl of cell 
suspension (10 µl for lactate dehydrogenase (LDH) assay) was pipetted in each cuvette and 950 µl of the 
respective assay solution (37°C) was added (990 µl for LDH assay). Chemicals (analytical grade) were 
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purchased from Sigma-Aldrich, Fluka (Buchs, Switzerland), and Merck (Darmstadt, Germany). PBS buffer  
was acquired from PAA Laboratories (Pasching, Austria). The assay solutions for different enzymes were 
as follows. Malic enzyme (ME): 890 µl PBS, 10 µl MgCl2 (200 mM), 10 µl NADP+ (100 mM), and 40 µl 
malate (1 M). LDH: 960 µl PBS, 25 µl NADH (15 mM), and 5 µl pyruvate (500 mM). Pyruvate carboxylase 
(PC): 830 µl PBS, 10 µl MgCl2 (1 M), 15 µl acetyl coenzyme A (50 mM), 10 µl KHCO3 (1 M), 40 µl 5,5’-
dithio-bis-(2-nitrobenzoic acid) (DTNB, 5 mM), 20 µl pyruvate (2 M), 25 µl ATP (100 mM), and 0.3 U 
citrate synthase. Phosphoenolpyruvate carboxykinase (PEPCK): 834 µl PBS, 15 µl NADH (10 mM) 1 µl MgCl2 
(1 M), 10 µl phosphoenolpyruvate (PEP) (100 mM), 75 µl inosine diphosphate (20 mM), 10 µl malate 
dehydrogenase (>12 U), and 5 µl KHCO3 (1 M). The cells were harvested in the exponential growth phase 
by centrifugation (5 min, 500 rpm, 25°C, Labofuge 400R, Heraeus Instruments). The supernatant was 
discarded and the pellet resuspended in PBS (37°C). This washing step was repeated and finally the pellet 
was resuspended in PBS and the cell density was determined. The cell suspension was diluted to yield a 
cell density of ~5 × 106 cells/ml. The cells were disrupted by adding a Triton X-100 solution (5% v/v) 
such that the final concentration in the cell suspension was 0.05% (v/v) followed by incubation at 37°C for 
10 min. This treatment was earlier found sufficient to permeabilize cellular and mitochondrial membranes 
(Niklas et al. 2011a). The cells were transferred into the cuvettes and the enzyme assay solution was added. 
The change in absorbance was finally monitored for 15 min. The specific enzyme activities per cell (SA) 
were calculated using 
 
CDt
A
SA
××
=
ε∆
∆
          [1] 
where A represents absorbance, CD the respective cell density, and t is time. For NAD(P)H-dependent 
measurements, the extinction coefficient, ε 340, of 6.22 l mmol-1 cm-1 was used; for the DTNB-dependent 
measurements the extinction coefficient, ε 412, of 13.6 l mmol-1 cm-1. 
4.4 Results 
4.4.1 Growth and metabolic profiles at different initial pyruvate and glutamine 
concentrations 
AGE1.HN cells were grown in batch culture using media with different pyruvate (Pyr) and glutamine 
(Gln) concentrations in a full factorial design experiment to analyze the effects of both metabolites on 
growth and metabolism. Changes in cell density and in selected metabolite concentrations during 
cultivation are shown in the surface plots in Fig. 4-2 and in Table S2 of the supplementary material. The 
growth and metabolic profiles of all nine cultivations are depicted in the supplementary material (Fig. S1). 
Increasing Pyr concentrations led to a decrease in cell proliferation as well as total glucose and glutamine 
uptake and uptake of most amino acids (Fig. 4-2). Pyruvate uptake was highest in media having 5 mM Pyr 
as start concentration and was similar at high (9 mM) and low (2 mM) Pyr in the medium. Total lactate 
production was also highest in the 5 mM Pyr cultivations, but only slightly lower in the cultivations with 9 
and 2 mM Pyr. The lactate/glucose quotient (∆Lac/∆Glc) that is also depicted in Fig. 4-2 as well as the 
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quotient of C-mol of produced lactate per C-mol of the consumed substrates glucose and pyruvate 
(CLac/[CGlc+CPyr]) indicate clearly a Pyr-dependent increase in the relative lactate production per 
consumed substrates. In the 9 mM Pyr cultivations, a CLac/(CGlc+CPyr) quotient of even around 1 was 
observed. Additionally, glutamate and alanine production was influenced by an increasing Pyr 
concentration. An increase in the Gln concentration does not influence the cell proliferation, but led to an 
increase in the production of alanine, glutamate, and ammonia as well as a decrease in the uptake of 
asparagine and the branched chain amino acid isoleucine (Fig. 4-2, Table S2). Changes in extracellular 
metabolite concentrations per cell in the respective culture are depicted for some selected metabolites in 
Fig. 4-3. The data indicate that glucose and pyruvate uptake as well as the production of lactate per cell 
were increased depending on Pyr and were only little influenced by changing Gln concentration. Alanine 
and glutamate production as well as glutamine uptake per cell were increased with increasing Gln and Pyr 
consumption. 
 
 
Fig. 4-2 Effects of different pyruvate (Pyr) and glutamine (Gln) concentrations in the medium on growth and 
extracellular metabolite levels (M) in AGE1.HN. Maximum changes, ∆M = |Maximum (M) – Minimum (M)|, in 
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viable and total cell density (VCD, TCD) and extracellular metabolite levels (Glc glucose, Lac lactate, standard 
abbreviations for amino acids) are depicted. Additionally, the total Lac/Glc quotient (∆Lac/∆Glc) and the quotient 
of C-mol of produced lactate per C-mol of consumed glucose and pyruvate (CLac/[CGlc+CPyr]) in the different 
cultivations are presented. Detailed data are additionally given in Table S2. Growth and metabolic profiles are 
depicted in Fig. S1. 
 
 
 
 
Fig. 4-3 Effects of different 
pyruvate (Pyr) and glutamine 
(Gln) concentrations in the 
medium on metabolite uptake or 
production per total cell density 
(TCD). Maximum changes, ∆M, 
in extracellular metabolite levels 
per total cell density in each 
cultivation are depicted (Glc 
glucose, Lac lactate, standard 
abbreviations for amino acids). 
Growth and metabolic profiles are 
depicted in Fig. S1. 
 
 
 
 
 
 
4.4.2 Effects of different substrate feeding on growth and A1AT production 
In the experiments described before with different pyruvate and glutamine concentrations, one of the 
most interesting aspects was the fact that increasing pyruvate concentrations led to low growth 
performance and high energy spilling, as indicated by high waste product formation. This effect of higher 
substrate load leading to energy wasting was further investigated by applying different feeding profiles. For 
these experiments, AGE1.HN cells producing the therapeutic glycoprotein A1AT were used to provide 
additional insights into the product formation under varying conditions of substrate supply. Different 
substrate feeding rates and different substrate concentrations in the medium might result in a different 
intracellular pyruvate supply and further changes in the cellular metabolism and product formation. The 
applied feeding profiles are depicted in Fig. 4-4. Different supplies of glucose and pyruvate were tested in 
the four feeding experiments. Growth and metabolite profiles (only most important metabolites) are 
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depicted in Fig. 4-5. Initially, growth and metabolism were similar in the fed-batch cultures and the batch 
cultivation. In a second phase after 72 h of cultivation, metabolism was clearly different depending on the 
applied feeding profile. The lower initial glucose concentration combined with feeding always resulted in 
higher cell density, increased culture longevity, and higher A1AT concentration compared with the batch 
cultivation. The highest viable cell density (146% of the batch cultivation) was achieved in the low-glucose 
culture without pyruvate feeding (Feed 3) in which also the highest A1AT concentration (167% of batch 
cultivation) was measured (Fig. 4-5). In the cultures that were also fed with pyruvate (feeds 2 and 4), 
lactate production was slightly higher after 72 h. Alanine and glutamate production were clearly increased 
compared with the cultures without the addition of pyruvate. Furthermore, A1AT production was lower 
in the cultures which were additionally 
fed with pyruvate.  
 
 
Fig. 4-4 Profiles of glucose (Glc), glutamine 
(Gln), and pyruvate (Pyr) concentrations 
during cultivations of the AGE1.HN.AAT 
cell line with different feeding profiles. 
Control (batch), normal batch cultivation 
using standard cultivation conditions; feed 1 
(high Glc), glucose controlled at high level 
(up to 2 g/l and mostly above 0.2 g/l); feed 
2 (high Glc+Pyr), glucose controlled at high 
level (up to 2 g/l and mostly above 0.2 g/l). 
When glucose was fed, pyruvate was added 
such that the pyruvate concentration in the 
medium was increased by about 2 mM; feed 
3 (low Glc), glucose controlled at low level 
(up to 1 g/l and mostly above 0.1 g/l); feed 
4 (low Glc+Pyr), glucose controlled at low 
level (up to 1 g/l and mostly above 0.1 g/l). 
When glucose was fed, pyruvate was added 
such that the pyruvate concentration in the 
medium was increased by about 1 mM. 
Glutamine was additionally fed to avoid 
limitation. 
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Fig. 4-5 Growth and metabolic profile of AGE1.HN.AAT cells during cultivation. The same experiment as in Fig. 
4-4 where the applied feeding profiles are depicted. TCD total cell density, VCD viable cell density, A1AT α1-
antitrypsin, Lac lactate, standard abbreviations for amino acids. 
4.4.3 Metabolic changes upon different substrate feeding 
In order to understand the main metabolic differences caused by different feeding of the substrates 
glucose and pyruvate, stationary metabolic flux analysis was performed for the phase between 72 and 169 
h of the cultivation (Fig. 4-6, Table S3) in which the main differences in metabolite and growth profiles 
were observed (Fig. 4-5 and Fig. S2). It was found that the glucose uptake rate and glycolytic fluxes (v32, 
Fig. 4-6) were only slightly reduced when pyruvate was fed as an additional carbon source (feed 2 and feed 
4). Lactate production rate (v3, Fig. 4-6) was clearly increased in the cultures with pyruvate feeding. 
Mitochondrial pyruvate transport seemed to be slightly reduced with pyruvate feeding and with lower 
glucose concentration in the medium (v34, Fig. 4-6). The activity of the upper and lower TCA cycle (v36, v38, 
Fig. 4-6) was unaffected by pyruvate feeding (feed 2 and feed 4) but was decreased in the cultures fed with 
low glucose levels (feed 3 and feed 4). The TCA cycle was mainly fed by pyruvate. Glutamate carbons 
were entering the TCA cycle to a lower extent and solely through transaminase-catalyzed conversion 
(v52+v55, Fig. 4-6). Glutamate dehydrogenase was working in the direction of glutamate (v58, Fig. 4-6). This 
flux was clearly increased in the low-glucose cultures and slightly decreased when additionally pyruvate 
was fed. Net flux from glutamate to α-ketoglutarate (v58-[v52+v55]) was increased with pyruvate feeding 
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(feed 2 and feed 4) and lower in the low-glucose cultures (feed 3 and feed 4) compared with the high-
glucose cultures (feed 1 and feed 2). This flux was generally around 12% of the pyruvate transport flux 
(v34). Glutamate and alanine production rates (v5 and v10, Fig. 4-6) were increased depending on pyruvate, 
as also observed for the lactate production rate. The highest A1AT production rate was found in the 
culture feed 3 in which glucose was maintained at a low level and pyruvate was not fed. 
 
 
Fig. 4-6 Metabolic flux distribution of AGE1.HN during cultivations in which different feeding profiles (F1 – F4 
correspond to feed 1-feed 4 of Fig. 4-4) were applied. The same experiment as shown in Figs. 4-4 and 4-5. Fluxes 
were calculated for the phase between 72 and 169 h. Negative values indicate fluxes in the opposite direction of the 
arrow. Detailed data are additionally presented in Table S3. The metabolic network including the flux numbers of the 
reactions and the abbreviations can be seen in Fig. 4-1. 
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4.4.4 Comparative analysis of in vitro activities of selected anaplerotic enzymes 
In vitro activities of important enzymes of the pyruvate metabolism were measured in parental (AGE1.HN 
Par) and A1AT-producing (AGE1.HN.AAT) AGE1.HN cells and compared with the corresponding 
enzyme activity in a CHO cell line (T-CHO ATIII cells producing recombinant anti-thrombin III; Table 
4-1). ME activity was slightly lower, whereas PC and PEPCK activities in AGE1.HN were by far lower 
than in CHO. LDH activity was slightly higher in AGE1.HN cell lines compared with CHO cells. 
 
Table 4-1 In vitro activities of the enzymes malic enzyme (ME), pyruvate carboxylase (PC), phosphoenolpyruvate 
carboxykinase (PEPCK), and lactate dehydrogenase (LDH) in parental (AGE1.HN Par) and A1AT producing 
(AGE1.HN.AAT) AGE1.HN cells as well as in T-CHO ATIII cells.  
 ME  PC  PEPCK  LDH  
AGE1.HN Par 81.5 ±8.4 77.0 ±9.4 2,582.9 ±32.5 14,337.8 ±510.4 
AGE1.HN.AAT 97.7 ±2.3 183.0 ±15.9 2,676.7 ±25.4 14,255.9 ±403.0 
T-CHO ATIII 143.3 ±5.5 515.3 ±20.8 7,143.5 ±284.2 12,504.1 ±337.6 
Activities were measured in the exponential growth phase of the cells. Mean values and standard deviations of two 
measurements. Specific enzyme activities are given in fmol/cell/h. 
 
4.5 Discussion 
In the first part of this study, growth and metabolic profiles of AGE1.HN cells cultured with increasing 
pyruvate and glutamine concentrations were analyzed. In a recent study on metabolic dynamics, it was 
proposed that pyruvate and glutamine supply might induce characteristic changes in the metabolism of 
AGE1.HN (Niklas et al. 2011d). This was based on flux changes analyzed during batch cultivation. In 
order to investigate the influence of both substrate metabolites in detail, increased pyruvate and glutamine 
concentrations were applied in a full factorial design experiment and growth and metabolite 
concentrations were monitored. The dependency of the production and uptake of other metabolites on 
extracellular pyruvate and glutamine levels could be determined.  
Increased glutamine concentrations did not cause significant changes in cell proliferation, but led to 
specific changes in the uptake and production of other amino acids and amino group donors as well as an 
increase in ammonia production (Table S1). Increased alanine production caused by increased glutamine 
concentration in the medium aids reducing ammonia intoxication. Transamination reactions, transferring 
amino groups from aspartate or glutamate to pyruvate, yielding alanine, may play a role in ammonia 
detoxification. Also, in other studies, increased alanine production in the presence of high ammonia 
concentrations was reported (Hansen and Emborg 1994; Miller et al. 1988; Ozturk et al. 1992). In 
AGE1.HN, it was additionally found that glutamine depletion is associated with a direct decrease in 
viability, showing its importance for this cell line (Niklas et al. 2011d). After glutamine depletion, the 
metabolism tries to compensate this by a higher uptake of the amino group donors glutamate and alanine, 
but this is not enough to sustain the growth rate and viability (Niklas et al. 2011d). Glutamine feeding 
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seems essential to maintain the viability and growth of AGE1.HN, as will also be outlined later in the 
discussion. 
The cell interior of mammalian cells is compartmentalized and highly organized. To overcome diffusive 
barriers in the cell, enzymes of a metabolic pathway are sometimes associated physically and build static 
multienzyme complexes, so-called metabolons, resulting in a channeling of the metabolites through this 
pathway (Ovadi and Saks 2004). Glycolytic channeling and the association of glycolytic enzymes has been 
reported earlier (Graham et al. 2007). This might result in a direct conversion of glucose down to lactate, 
preventing an efficient use of glucose-derived pyruvate in the mitochondria. Additional cytoplasmic 
pyruvate pools could exist (Zwingmann et al. 2001), and this pyruvate might be transported more 
efficiently into mitochondria and might be further metabolized in oxidative decarboxylation and TCA 
cycle. Omasa et al. found that the ATP and antibody production rates of hybridoma cells could be 
increased by adding specific metabolites, i.e., pyruvate, malate, and citrate (Omasa et al. 2010). In 
particular, pyruvate enrichment caused an improvement of the energy metabolism (e.g., increase in TCA 
cycle fluxes) and a significant increase in product formation. In AGE1.HN cells, it seems that pyruvate 
has an opposite effect since growth and energy metabolism became less efficient with increasing pyruvate 
supply in the medium. In particular, lactate production per consumed substrate (glucose and pyruvate) 
increased. This indicates that pyruvate taken up from the medium is not differently and not more 
efficiently used than pyruvate derived through glycolysis. The performance of AGE1.HN is not improved 
by using additional pyruvate in the medium. Increasing pyruvate concentrations led to a less efficient 
metabolic phenotype with increased production of the waste metabolites lactate, alanine, and glutamate. 
This influence of pyruvate on the waste metabolite production was also proposed in a dynamic analysis of 
the metabolism of this cell line (Niklas et al. 2011d). Interestingly, an increase in the pyruvate supply was 
directly accompanied by an increase in lactate production per substrate that was taken up, resulting in an 
almost complete conversion of the substrates to lactate when 9 mM pyruvate was used in the medium 
(Fig. 4-2). This might also explain the almost complete stop of proliferation at the highest pyruvate 
concentration. The cells were not proliferating but were metabolizing the substrates, almost not producing 
any biomass but just waste metabolites. This indicates clearly that a reduction in the pyruvate load is 
beneficial for the growth of AGE1.HN and most probably also for later recombinant protein production.  
However, the pyruvate load and especially intracellular pyruvate load is dependent not only on the 
pyruvate concentration in the medium and its uptake but also on the cellular glucose uptake and the 
glucose amount which is metabolized through glycolysis. Generally, substrate level reduction seems 
beneficial to improve the efficiency of metabolism of AGE1.HN. Since pyruvate is efficiently taken up by 
the cells (Niklas et al. 2011d), the high pyruvate concentrations applied in this experiment (Fig. 4-2) mimic 
also the situation in which the cell has to cope with high intracellular pyruvate concentrations. It can be 
clearly seen in this study that the cells are not able to use the additional substrates efficiently by adapting 
their uptake or by increasing pyruvate flux into the TCA cycle which could result in better growth. 
Increased channeling of pyruvate into the TCA cycle depends on the possibility of increasing pyruvate 
transport, pyruvate dehydrogenase activity, anaplerotic reactions, and respiration activity. However, this 
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does not seem possible since the growth performance of the cells was clearly decreasing with increased 
substrate availability.  
Another interesting application of high pyruvate concentrations in the medium was published by Genzel 
et al. (Genzel et al. 2005). It was reported that the replacement of glutamine by high pyruvate 
concentrations (e.g., 10 mM) seems to be an interesting strategy to reduce ammonia formation for some 
mammalian cell lines. However, when we tried to culture the human cell line AGE1.HN in media without 
glutamine, the cells did not grow even when increased concentrations of pyruvate were supplied (data not 
shown). Cultivation of the cells in media in which glutamine was replaced by glutamate was also not 
successful (data not shown). This might be caused by low or absent glutamine synthetase activity that was 
reported for other human cells (Bell et al. 1995; Street et al. 1993).  
The strong influence of pyruvate on the energy spilling in AGE1.HN might also partly be explained by 
the lower activity of anaplerotic enzymes, e.g., malic enzyme, pyruvate carboxylase, and 
phosphoenolpyruvate carboxykinase compared with CHO cells (Table 4-1). As shown by Genzel et al. 
(Genzel et al. 2005) other mammalian cells (but not human cells) grow comparably well in media having 
low or high pyruvate concentrations, which might be explained by a higher enzymatic capacity to convert 
pyruvate and channel its carbons into TCA cycle associated with a higher respiratory activity. In a 
subsequent metabolic flux study on MDCK cells in normal medium or medium having high pyruvate 
concentration and no glutamine, it was suggested that most of the glucose consumed was excreted as 
lactate under high pyruvate conditions whereas pyruvate seemed to directly enter TCA cycle (Sidorenko et 
al. 2008). This is also different compared with AGE1.HN. The results of the feeding experiment (Fig. 4-4 
and 4-5) and especially the metabolite balancing flux analysis (Fig. 4-6) showed that additional pyruvate 
does not lead to an increase in TCA cycle fluxes and was not beneficial for A1AT production. As 
mentioned before, anaplerotic reactions connecting glycolysis and the TCA cycle, the pyruvate 
dehydrogenase activity, or respiratory capacity might be the bottleneck resulting in the observed 
phenotype. The low in vitro activities of the measured anaplerotic enzymes (Table 4-1) and inefficient 
pyruvate use can be an indication that a genetic engineering strategy, as was applied in other mammalian 
cells, might also be interesting for the improvement of the AGE1.HN cell line, namely, the introduction 
of an additional pyruvate carboxylase gene (Elias et al. 2003; Irani et al. 1999). However, this will only lead 
to a significant improvement if oxidative phosphorylation is not the limiting step.  
The results of this study led to another strategy. A reduction in the substrate load (decrease in glucose 
concentration and no pyruvate feeding) resulted in improved culture longevity, more efficient metabolism, 
and finally higher product concentration. Substrate feeding should be balanced in fed-batch processes of 
AGE1.HN to maintain a most efficient metabolism. However, according to the data of the feeding 
experiments in which waste product formation was also just partially reduced even at lowest glucose 
feeding, strategies focusing on inhibition/reduction of substrate uptake should be considered. This may 
lead to lower accumulation of toxic waste products, higher cell densities, and product concentrations in 
the cultivation. Some genetic engineering in the past on mammalian cells focused also on the reduction of 
excessive substrate uptake, leading to an improved metabolism in the modified cells (Altamirano et al. 
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2000; Wlaschin and Hu 2007). Based on the results of this contribution, we have worked out a targeted 
engineering strategy for this cell line which focuses on a more efficient substrate usage, and work is 
underway showing the influence of this strategy on glycoprotein production in AGE1.HN.  
Regarding the general findings concerning primary metabolism in AGE1.HN, it can be concluded that 
certain aspects are similar compared with the metabolic behavior of other mammalian cells, e.g., overflow 
metabolism in the beginning of the cultivation with high waste product formation, whereas other 
important metabolic parameters are completely different. In particular, pyruvate utilization and pyruvate 
metabolism are different in AGE1.HN compared with, e.g., CHO or MDCK cells, as was outlined before 
in the discussion. 
Differences in the metabolism and in the metabolic machinery of different production cell lines might also 
originate from their specific origin. Enzyme and transporter properties as well as metabolic requirements 
of the cells depend on the tissue from which they originate (Wang et al. 2010). The cells in these tissues 
have a certain enzyme expression, e.g., different glucose transporters (Elsas and Longo 1992; Thorens and 
Mueckler 2010) or different expression of glycolytic and gluconeogenic enzymes (Lawrence et al. 1986), 
which depends also on their nutritional environment present in the respective part of the body (Mather 
and Pollock 2011). Different substrate levels in different tissues and even parts of tissues (Mather and 
Pollock 2011) result in cells adapted to their environment fulfilling specific tasks (Gebhardt 1992). Cells 
derived from different tissues might have therefore different metabolic properties, and their enzyme 
expression as well as the ability to adapt the enzyme expression to varying situations might differ. 
However, one has to keep in mind that production cells are immortalized and their metabolic behavior 
changes compared with the tissue situation. Nevertheless, these changes might be constrained to a certain 
extent depending on the tissue type from which the cells originate, e.g., by epigenetic mechanisms. 
In summary, the following conclusions can be drawn from the different experiments which were 
performed in this study. Pyruvate enrichment in the medium leads to an inefficient metabolism 
characterized by high energy spilling and lowered cell proliferation. Reduced substrate levels and no 
pyruvate feeding resulted in higher efficiency of substrate use as well as higher viable cell densities and 
A1AT concentrations. Pyruvate addition does not increase TCA cycle fluxes in AGE1.HN, contrary to 
reports using other mammalian cells. Generally, pyruvate utilization in AGE1.HN cells as well as fluxes 
around the pyruvate node seem to be significantly different compared with the other mammalian cells 
currently employed in biopharmaceutical production. The in vitro activity of the measured anaplerotic 
enzymes in AGE1.HN is lower compared with CHO cells and can be an interesting genetic engineering 
target for the improvement of AGE1.HN since pyruvate is not efficiently entering the TCA cycle. 
However, the most promising strategy in our opinion is the engineering of the cells toward a more 
balanced substrate uptake. Work is underway showing the effects of this engineering strategy on the 
production in AGE1.HN cells. The findings of this study provide a rational basis for further targeted 
improvement of the cellular metabolism and the cultivation process conditions for production cells. 
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5 Metabolic flux rearrangement in the amino acid metabolism 
reduces ammonia stress in the α1-antitrypsin producing human 
AGE1.HN cell line 
5.1 Abstract 
This study focuses on metabolic changes in the neuronal human cell line AGE1.HN upon increased 
ammonia stress. Batch cultivations of α1-antitrypsin (A1AT) producing AGE1.HN cells were carried out 
in media with initial ammonia concentrations ranging from 0 to 5 mM. Growth, A1AT production, 
metabolite dynamics, and finally metabolic fluxes calculated by metabolite balancing were compared. 
Growth and A1AT production decreased with increasing ammonia concentration. The maximum A1AT 
concentration decreased from 0.63 g/L to 0.51 g/L. Central energy metabolism remained relatively 
unaffected exhibiting only slightly increased glycolytic flux at high initial ammonia concentration in the 
medium. However, amino acid metabolism was significantly changed. Fluxes through transaminases 
involved in amino acid degradation were reduced concurrently with a reduced uptake of amino acids. On 
the other hand, fluxes through transaminases catalyzing the formation of amino acids, i.e., alanine and 
phosphoserine, were increased leading to increased storage of excess nitrogen in extracellular alanine and 
serine. Glutamate dehydrogenase flux was reversed and increasingly fixing free ammonia with increasing 
ammonia concentration. Urea production additionally observed was associated with arginine uptake by the 
cells and did not increase at high ammonia stress. It was therefore not used as nitrogen sink to remove 
excess ammonia. The results indicate that the AGE1.HN cell line can adapt to ammonia concentrations 
usually present during the cultivation process to a large extent by changing metabolism but with slightly 
reduced A1AT production and growth. 
 
 
 
 
 
 
 
 
 
 
 
This chapter was submitted as 
Priesnitz C*, Niklas J*, Rose T, Sandig V, Heinzle E. Metabolic flux rearrangement in the amino acid 
metabolism reduces ammonia stress in the α1-antitrypsin producing human AGE1.HN cell line.  
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5.2 Introduction 
In the last decades mammalian cell cultures have gained more and more importance in biotechnological 
and pharmaceutical industries. Apart from the use of mammalian cells in the prediction of toxicity (Noor 
et al. 2009), they have become increasingly popular for the production of biopharmaceuticals (Wurm 
2004). This has been mainly due to their ability to introduce correct posttranslattional modifications on 
the expressed proteins. Now, the number of therapeutic proteins produced in mammalian cells exceeds 
the number produced in bacteria (Walsh 2010). The most important posttranslational modifications are 
N- and O-linked glycosylation. Glycosylation plays an important role for protein stability, ligand binding, 
immunogenicity, and serum half-life (Walsh 2006). Much effort has been put into optimizing productivity 
and product quality by applying different strategies like engineering cell metabolism, protein secretion, 
apoptosis resistance, and glycosylation (Lim et al. 2010). One major factor that still limits productivity is 
the accumulation of toxic byproducts like lactate and ammonia in the cell culture medium. Ammonia 
results on the one hand from chemical decomposition of glutamine (Tritsch and Moore 1962), which is an 
important component in most cell culture media, and on the other hand from metabolic deamination 
reactions. The effects of increased ammonia concentrations on different mammalian cells were examined 
by several groups (Mirabet et al. 1997; Ozturk et al. 1992; Schneider et al. 1996). The large variation of the 
influence of ammonia on different cells described in the literature shows that it is important to analyze the 
effects of elevated ammonia levels for every cell line separately and that it is not possible to completely 
transfer results obtained for one cell line to another. The effects range from decreased cell growth and 
reduced productivity to alterations in the glycosylation pattern and inhibition of virus multiplication 
(Andersen and Goochee 1995; Borys et al. 1994; Hong et al. 2010; Koyama and Uchida 1989; Thorens 
and Vassalli 1986; Yang and Butler 2000, 2002) and are, at least, partly attributed to changes in the 
intracellular pH and changes in UDP-hexose levels (Ryll et al. 1994). To overcome these negative effects 
of ammonia on cell growth, productivity, and product quality, the reduction of the ammonia accumulation 
in the media is a major goal. To achieve this, a variety of different approaches was proposed including 
(over)expression of the glutamine synthetase (Bell et al. 1995; Cockett et al. 1990), controlled feeding of 
glutamine (Eyer et al. 1995; Glacken et al. 1986), feeding of glutamine according to the demand for 
biosynthesis (Xie and Wang 1994) or depending on the oxygen uptake rate (Eyer et al. 1995), co-culturing 
CHO cells with HepG2 cells (Choi et al. 2000), substitution of glutamine by glutamate, asparagine 
(Kurano et al. 1990), or α-ketoglutarate (Hassell et al. 1991), and adaptation of cells to high ammonia 
concentrations (Schumpp and Schlaeger 1992). Most of the investigations available deal with the effects of 
elevated ammonia levels in hybridoma and myeloma cells used for the production of monoclonal 
antibodies  (McQueen and Bailey 1990; Miller et al. 1988; Ozturk et al. 1992; Reuveny et al. 1986), and 
comparatively few publications can be found about the effects in CHO cells (Yang and Butler 2000), 
BHK cells (Cruz et al. 2000), or other mammalian cell lines, although, they are among the most prominent 
cell lines for production of therapeutic proteins. In most publications, the investigated parameters were 
just cell growth and productivity, and only in some studies changes in extracellular metabolites were 
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additionally analyzed. Detailed studies on the effects of elevated ammonia concentrations on central 
metabolism and intracellular fluxes are hardly available (Bonarius et al. 1998a; Nadeau et al. 2000). 
The main goal of the presented study was a detailed analysis of the effects of elevated ammonia 
concentrations on growth, metabolism, and glycoprotein production in the human cell line AGE1.HN 
(ProBioGen, Berlin, Germany) that was specifically designed for production of biopharmaceuticals 
requiring complex human-type glycosylation (Blanchard et al. 2011).  In this study, an AGE1.HN cell line 
was used that is producing α1-antitrypsin (A1AT). This glycoprotein, which is produced in vivo in the 
human liver, has three N-glycosylation sites and requires complex glycosylation (Carrell et al. 1981; 
Kolarich et al. 2006). A1AT is an important biopharmaceutical that is required for augmentation therapy 
in A1AT deficiency, a hereditary disorder which may result in a shortened lifetime mainly caused by 
chronic respiratory insufficiency (Tonelli and Brantly 2010). So far, only plasma-derived human A1AT is 
approved for augmentation therapy, whereas the production of stable and active recombinant or 
transgenic A1AT in several non-human hosts was impeded by impurities or lower stability mainly caused 
by wrong glycosylation of the produced A1AT compared to the plasma-derived version (Karnaukhova et 
al. 2006). 
In this study, the following questions were addressed: (i) what is the effect of ammonia on cell growth, 
A1AT formation, A1AT quality/activity, (ii) how does the metabolism of AGE1.HN change upon high 
ammonia supply and how is ammonia detoxified, and (iii) should further engineering focus on ammonia 
metabolism? The results are important for further rational improvement of human production cell lines 
based on a thorough understanding of cellular physiology. 
5.3 Material and methods 
5.3.1 Cell line 
The AGE1.HN® cell line (ProBioGen AG, Berlin, Germany) was derived from a primary human tissue 
sample from the periventricular zone of a fetal brain. The cells were immortalized using an expression 
plasmid which contained the adenoviral genes E1 A and B of the human Adenovirus 5. These genes are 
driven by the human pGK and the endogenous E1B promoter, respectively. Furthermore, the cell line 
was improved by expressing the protein pIX of the human Adenovirus 5. This modification leads to 
changes in the metabolism, enhanced productivity of secreted proteins, and increased the susceptibility to 
various viruses. AGE1.HN cells were transfected with an expression vector containing human A1AT 
(ProBioGen AG) under the control of a specific CMV/EF1 hybrid promoter (ProBioGen AG). High 
producer cells were selected with puromycin. Recently, it was shown that the AGE1.HN cell line can 
produce fully active A1AT with its complex glycosylation pattern (Blanchard et al. 2011). 
5.3.2 Cell culture and experimental procedure 
The cells were cultured in shake flasks (Corning, NY, USA) or 50 ml bioreactors (TPP, Trasadingen, 
Switzerland) at 37°C in a 5% CO2 supplied shake-incubator (185 1/min, 2 inch shaking orbit, Innova 
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4230, New Brunswick Scientific, Edison, NJ, USA). The preculture was carried out in a 250 ml shake flask 
in serum-free 42-Max-UB-medium (Teutocell AG, Bielefeld, Germany). The cells were centrifuged (500 
1/min, 5 min, 22°C, Labofuge, Heraeus Instruments, Hanau, Germany) and the supernatant discarded. 
The pellet was resuspended in 30 ml PBS (37°C, PAA Laboratories, Pasching, Austria) and centrifuged 
again. After discarding the supernatant, the pellet was resuspended in 42-Max-UB-medium supplemented 
with 2 mM glutamine. Three 50 ml bioreactors were inoculated yielding an initial cell density of about 9 × 
105 cells/ml. Through the addition of PBS or PBS containing NH4Cl (125 mM and 250 mM), ammonium 
concentrations of 0 mM, 2.5 mM, and 5 mM were achieved. The final culture volume was 18 ml. Samples 
(300 µl) were taken every day. 30 µl were used for cell counting. The rest was centrifuged (10,000 1/min, 5 
min, 22°C, Biofuge pico, Heraeus Instruments, Hanau, Germany) and the supernatant transferred into 
fresh tubes. Of the samples 70 µl were used for pH determination (MP 220 pH meter, Mettler-Toledo, 
Giessen, Germany), 20 µl were used for ammonia measurements, and the rest was frozen (-20°C). The 
analysis of cultivation parameters was carried out using an automated cell counter (Countess, Invitrogen, 
Karlsruhe, Germany) which determines cell density, viability (Trypan Blue exclusion method), and cell 
size.  
5.3.3 Quantification of metabolites 
Glucose, lactate, and pyruvate in the supernatant were analyzed using high-pressure liquid 
chromatography (HPLC) as described previously (Niklas et al. 2009). Quantification of proteinogenic 
amino acids was performed by another HPLC-method (Kromer et al. 2005). Glutamine data was 
corrected for degradation as described recently (Niklas et al. 2011d). 
5.3.4 Quantification of ammonia and α1-antitrypsin 
Ammonia was quantified using an ammonia assay kit (Sigma-Aldrich, Steinheim, Germany) according to 
the instructions. The sample volume was 20 µl and the absorption was measured in a spectrophotometer 
at 340 nm (iEMS Reader MF, Labsystems, Helsinki, Finland). The produced α1-antitrypsin was quantified 
using an activity assay. The assay is based on the inhibition of trypsin by α1-antitrypsin. The unbound 
trypsin was quantified via the cleavage of BAPNA (Nα-benzoyl-L-arginine 4-nitroanilide hydrochloride, 
Sigma-Aldrich, Steinheim, Germany) that releases benzoyl-arginine and p-nitroaniline that was quantified 
photometrically. The assay was carried out as follows. For the trypsin working solution, 50 µl of trypsin (1 
g/l in phosphate buffered saline (PBS); Sigma-Aldrich, Steinheim, Germany) were diluted with 450 µl 
activity buffer (15 mM Tris, 100 mM NaCl, 0.01% Triton-X 100, pH 7.6). For the BAPNA working 
solution, 11 µl of BAPNA (500 mM in DMSO; Sigma-Aldrich, Steinheim, Germany) were diluted with 
1,989 µl activity buffer. The samples were diluted twenty to sixtyfold with PBS. In a 96-well plate, 50 µl of 
the diluted samples were mixed with 15 µl of trypsin working solution and the plate was incubated for 10 
min at 37°C. 10 µl of the sample-trypsin mixtures were transferred into the wells of a new 96-well plate. 
90 µl BAPNA working solution was added. The plate was incubated for 60 min at 37°C. For 
quantification, a standard curve was recorded using α1-antitrypsin (derived from human plasma; Sigma-
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Aldrich, Steinheim, Germany) solutions having concentrations between 0.5 g/l and 0.001 g/l. The 
absorption was measured at 414 nm (iEMS Reader MF, Labsystems, Helsinki, Finland). Samples and 
standards were measured in triplicates. 
5.3.5 Quantification of urea 
Urea was quantified using an HPLC method described by Clark et al (Clark et al. 2007). Samples were 
diluted with distilled water (1:10) and a calibration curve was recorded with samples of known urea 
concentration.  
5.3.6 Metabolic flux analysis. 
Metabolic rates, Fi, for each extracellular metabolite, Mi, were calculated from the specific growth rate, µ, 
and concentration changes of metabolites, ∆CMi, as well as of biomass, ∆CBM, for the growth phase 
between 0 and 74 h using 
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where C denotes concentration. To get a realistic representation of the accuracy of the calculated 
extracellular fluxes, the standard deviation of Fi was estimated by using the determined average standard 
deviation of the metabolite analysis in Monte-Carlo simulation. Anabolic fluxes were calculated using the 
anabolic demand which was recently presented in another metabolic flux study on AGE1.HN cells (Niklas 
et al. 2011d). The metabolic network model (single cell, two compartment model (Niklas et al. 2010)) 
which was used for calculation of intracellular fluxes is schematically depicted in Fig. 5-1. The 
stoichiometry of the network can be seen in the stoichiometric matrix which is given in the supplementary 
material (Table S1). The network consists in total of 27 extracellular fluxes, 5 anabolic fluxes and 41 
intracellular fluxes. The rank of the stoichiometric matrix is 42. The intracellular fluxes in the 
overdetermined system were calculated using Matlab 7.5.0 (Version R2007b, The Mathworks, Natick, MA, 
USA) assuming pseudo steady-state. Standard methods applying Monte-Carlo simulation to calculate error 
propagation in the network were used (Niklas and Heinzle 2011). Consistency check of the model and 
calculated fluxes which represent a least-square solution was done by calculation of the redundancy matrix 
(Quek et al. 2010; van der Heijden et al. 1994). The specific change of metabolic fluxes, FC, upon 
cultivation of AGE1.HN at increased ammonia concentrations was calculated by 
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Sensitivity of metabolic fluxes, FS, to changing ammonia concentrations was finally calculated using 
equation 3 
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FCSD
FC
FS =            [3] 
 
where SDFC represents the standard deviation of FC calculated by Monte-Carlo simulation using Matlab. 
It was defined that FS > 1 indicates a significant change in metabolic flux. FC > 0 indicates higher 
substrate uptake or lower product secretion rates, FC < 0 reduced substrate uptake or increased product 
secretion rates. 
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Fig. 5-1 Metabolic network model applied for metabolic flux analysis. The detailed stoichiometry of the model can 
be seen in the stoichiometric matrix, which is supplied in the supplementary material section. Flux numbers are given 
on the respective arrow. Direction of the arrow indicates in which direction the fluxes were defined. Dashed lines 
indicate anabolic fluxes. BM biomass, PPP pentose phosphate pathway, TCA tricarboxylic acid, AA all amino acids, 
A1AT α1-antitrypsin, Glc glucose, Gal galactose, Lac lactate, Pyr pyruvate, G6P glucose 6-phosphate, P5P pentose 5-
phosphate, F6P fructose 6-phosphate, GAP glyceraldehyde 3-phosphate, AcC acetyl coenzyme A, Cit citrate, AKG 
α-ketoglutarate, SuC succinyl coenzyme A, Fum fumarate, Mal, malate, OAA oxaloacetate, standard abbreviations for 
amino acids. Indices: ex extracellular, TA transaminase reaction, m mitochondrial. Flux numbers are defined in Table 
5-1 and Table 5-2. 
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5.4 Results  
5.4.1 Influence of ammonia on growth and A1AT production  
Growth of AGE1.HN cells was influenced by the ammonia concentration in the medium (Fig. 5-2). Start 
concentrations of 2.5 mM ammonia did not affect the growth rate but clearly reduced the maximum cell 
density whereas ammonia concentrations of 5 mM reduced the growth rate as well as maximum cell 
density. With increasing ammonia start concentrations the viability dropped earlier. The ammonia 
secretion itself was also influenced by the ammonia concentration in the media. The higher the ammonia 
start concentration, the lower was the net ammonia secretion. In the cultivation starting with no ammonia, 
the ammonia concentration reached 6.5 mM after 10 days whereas in the 2.5 mM and in the 5 mM 
ammonia cultivation only 4.5 mM and 4.3 mM ammonia were produced in the same time period, 
respectively. The A1AT production decreased with increasing ammonia concentrations in the medium. In 
the control cultivation, 0.63 g/l A1AT were produced, which is a high concentration for such a complex 
glycoprotein in a batch process. At 5 mM initial ammonia concentration, this value was reduced by nearly 
20% to 0.51 g/l. 
 
 
Fig. 5-2 Growth profile of 
AGE1.HN.AAT cells in media with 
different ammonia start concentrations. 
TCD total cell density, VCD viable cell 
density, A1AT α1-antitrypsin. 
 
 
 
 
 
 
 
 
 
 
 
 
5.4.2 Dynamics of extracellular metabolite concentrations 
The metabolism of the AGE1.HN cell line under normal batch cultivation conditions can be divided into 
distinct phases (Niklas et al. 2011d). This also applies for the cultivation with different ammonia start 
concentrations. The time courses of the most important metabolites are depicted in Fig. 5-3 and additional 
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ones in Fig. S1 of the supplementary material. In the presented cultivations, generally, two main metabolic 
phases can be distinguished. The first one is lasting from 0-74 h and is characterized by the presence of all 
substrates and resulting overflow metabolism. The second phase (after 74 h) starts with depletion of 
glutamine and pyruvate and is characterized by decreased growth but also less waste product formation. 
Taking into account the slightly decreased proliferation in the cultivations with higher ammonia start 
concentrations, no clear difference can be observed directly in the time courses for most extracellular 
amino acids. However, the decrease of extracellular glucose was similar in all three cultivations indicating 
higher glucose uptake per cell at high ammonia conditions. Total lactate concentration was slightly higher 
in the control cultivation compared to the 2.5 mM and 5 mM ammonia cultivations. Total extracellular 
alanine concentration was increased with increasing start concentration of ammonia. Production of 
alanine took place only in the first metabolic phase (0-74 h); in the second phase (after 74 h), in which 
glutamine and pyruvate were consumed, alanine was taken up by the cells. Similarly, glutamate was 
produced in phase I and consumed in phase II. The extracellular glutamate concentration was clearly 
increased with increasing ammonia levels in the medium (Fig. 5-3). The specific production rates in phase 
I were, however, not significantly changed (Table 5-1). The production of the C5 amino acid proline, 
which can be synthesized from glutamate, was increased with increasing initial ammonia concentration.  
Interestingly, we also observed relatively high production of urea in the AGE1.HN cell line. Urea 
production was, however, not increased with increasing ammonia and seems to be correlated with the 
respective cell number in the cultivation. 
 
 
Fig. 5-3 Metabolic profiles of 
AGE1.HN.AAT cells in media with 
different ammonia concentrations. 
Time courses of selected metabolites 
and pH are depicted. Profiles of 
additionally measured metabolites 
are provided in Fig. S1 of the 
supplementary material. Glc glucose, 
Lac lactate, standard abbreviations 
for amino acids 
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5.4.3 Metabolic flux changes upon perturbation with increased ammonia 
concentrations 
Metabolic fluxes were calculated for the growth phase between 0 and 74 h. For phase II, no fluxes were 
calculated since due to different growth rates in phase I different starting conditions were prevalent at the 
beginning of phase II. The balances around the metabolites were zero in the range of the standard 
deviation indicating a good fit between data and model. Uptake and secretion rates for all measured 
metabolites are depicted in Table 5-1. Sensitivities of metabolic fluxes (FS) to increasing ammonia 
concentrations were calculated to identify significant changes in the metabolism (Eq. 3). FS > 1, i.e., flux 
change larger than standard deviation of that flux, was defined as significant change in metabolic flux. 
Most significant changes were found in the extracellular rates of alanine (FS = 6.06) followed by 
asparagine (FS = 3.01) and the branched chain amino acids isoleucine (FS = 2.72) and leucine (FS = 2.37). 
The rates of tyrosine (FS = 1.90), phenylalanine (FS = 1.84), valine (FS = 1.68), serine (FS = 1.58), glycine 
(FS = 21.51), and threonine (FS = 1.35) were also significantly reduced with increasing ammonia 
concentration in the medium. Specific glucose uptake rates were similar in the cultivations starting with 0 
and 2.5 mM ammonia, but in the 5 mM ammonia cultivation this rate was significantly higher. Specific 
production rates of urea and ammonia but also of A1AT were decreased with increasing ammonia 
concentration in the medium with FS ~ 1.  
Intracellular fluxes in the central energy metabolism of AGE1.HN were mostly similar in the different 
cultivations and seemed to be uninfluenced by the extracellular ammonia concentration as indicated by 
flux sensitivities below 1 (Table 5-2). However, glycolytic fluxes were slightly higher in the 5 mM 
ammonia cultivation compared to the other cultivations with FS close to 1. Selected fluxes taking part in 
the ammonia metabolism are additionally depicted in Fig. 5-4. It was observed that metabolic fluxes 
through different transaminases that require α-ketoglutarate as amino group acceptor were reduced with 
increasing ammonia concentration in the medium. On the other hand fluxes through alanine and 
phosphoserine transaminases (v49 and v64) catalyzing the formation of the respective amino acids were 
increased with increasing ammonia stress. Glutamate dehydrogenase (v55, Glu-AKGm) was working in the 
direction of α-ketoglutarate under reference conditions whereas in the cultivations with 2.5 mM and 5 mM 
ammonia start concentration in the medium this flux was reversed and increased with increasing initial 
ammonia concentration. 
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Table 5-1 Average specific extracellular rates in the first 74 h of the cultivation of AGE1.HN.AAT with different 
ammonia start concentrations (0 mM, 2.5 mM, 5 mM).  
  Flux [µmol g-1 h-1]   
  0 mM NH4+ 2.5 mM NH4+ 5 mM NH4+    
No. Metabolite Flux SD Flux SD Flux SD FS FC SDFC 
1 Glc -429.17 56.90 -377.19 30.91 -479.06 39.99 1.07 10.21 9.55 
2 Gal -37.56 6.06 -36.08 3.96 -36.54 4.65 0.09 -0.11 1.23 
3 Lac 639.75 2.84 546.76 45.56 682.46 56.90 0.58 -9.66 16.60 
4 Pyr -76.52 2.48 -64.73 5.53 -81.07 6.06 0.59 1.05 1.78 
5 Ala 20.57 0.51 27.39 2.16 39.29 2.84 6.06 -3.74 0.62 
6 Arg -12.39 4.35 -10.77 2.06 -9.04 2.48 1.03 -0.66 0.64 
7 Asn -7.26 1.01 -5.53 0.52 -4.87 0.51 3.01 -0.48 0.16 
8 Asp -16.23 1.54 -10.12 3.20 -11.54 4.35 0.79 -0.90 1.13 
9 Cys -0.21 6.55 1.11 0.79 -0.30 1.01 0.06 -0.02 0.27 
10 Glu 16.98 3.55 15.78 1.58 18.56 1.54 0.64 -0.30 0.47 
11 Gln -95.45 0.83 -88.64 6.64 -89.24 6.55 0.68 -1.31 1.92 
12 Gly 6.76 1.37 6.88 2.74 13.33 3.55 1.51 -1.35 0.90 
13 His -3.23 1.56 -3.47 0.68 -2.32 0.83 0.76 -0.17 0.22 
14 Ile -14.73 5.41 -10.21 1.21 -10.33 1.37 2.37 -0.89 0.38 
15 Leu -23.76 0.81 -18.89 1.60 -17.72 1.56 2.72 -1.21 0.44 
16 Lys -16.63 0.74 -14.83 4.18 -11.27 5.41 0.68 -1.00 1.47 
17 Met -6.55 4.48 -5.62 0.70 -5.28 0.81 1.07 -0.26 0.24 
18 Phe -6.27 2.92 -4.81 0.58 -4.26 0.74 1.84 -0.39 0.21 
19 Pro 13.37 1.26 22.22 3.35 19.81 4.48 1.09 -1.26 1.16 
20 Ser -33.41 0.63 -29.21 2.84 -27.06 2.92 1.58 -1.25 0.79 
21 Thr -7.98 0.97 -4.99 1.07 -5.53 1.26 1.35 -0.47 0.35 
22 Trp -0.79 1.85 -0.76 0.55 -0.55 0.63 0.29 -0.05 0.18 
23 Tyr -5.52 0.42 -3.45 0.86 -2.79 0.97 1.90 -0.53 0.28 
24 Val -14.15 0.02 -9.21 1.65 -9.88 1.85 1.68 -0.86 0.51 
25 Urea 6.11 24.67 5.05 0.38 5.40 0.42 1.14 -0.15 0.13 
26 A1AT 0.10 0.02 0.09 0.02 0.07 0.02 0.99 0.01 0.01 
27 NH3 91.67 11.32 66.67 16.03 56.37 24.67 1.34 -7.54 5.63 
Standard deviation (SD) was calculated using Monte Carlo simulation. Negative values indicate uptake. FS flux 
sensitivity (Eq. 3), FC flux change (Eq. 2), SDFC standard deviation of FC, Glc glucose, Gal galactose, Lac lactate, Pyr 
pyruvate, A1AT α1-antitrypsin, standard abbreviations for amino acids. 
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Table 5-2 Average specific intracellular fluxes in the first 74 h of the cultivation of AGE1.HN.AAT with different 
ammonia start concentrations (0 mM, 2.5 mM, 5 mM). 
  Flux [µmol g-1 h-1]      
  0 mM NH4+ 2.5 mM NH4+ 5 mM NH4+    
No. Reaction Flux  SD Flux  SD Flux  SD FS FC SDFC 
28 G6P-F6P 456.72 31.68 399.78 29.85 505.52 38.43 0.91 9.51 10.50 
29 F6P-GAP 453.79 31.69 397.21 29.93 503.39 38.41 0.98 9.90 10.15 
30 GAP-Pyr 905.70 63.37 792.48 59.85 1,005.12 76.82 0.97 18.46 19.12 
31 Pyr-Pyrm 299.15 86.92 260.42 76.23 341.45 96.14 0.27 7.28 27.00 
32 Pyrm-AcCm 350.82 88.23 283.38 77.26 377.35 97.51 0.24 6.31 26.83 
33 OAA/AcCm-Citm 377.07 89.37 294.58 80.02 393.25 101.17 0.14 3.57 26.30 
34 Citm-AKGm 330.69 89.49 247.10 80.13 352.61 101.18 0.20 5.60 27.47 
35 AKGm-SuCm 362.37 89.81 270.75 80.57 379.38 103.12 0.20 5.61 28.53 
36 SuCm-Fumm 375.73 90.68 273.59 81.35 387.84 104.17 0.15 4.06 27.50 
37 Fumm-Malm 376.32 90.85 272.64 81.79 387.43 105.04 0.07 2.05 28.15 
38 Malm-OAAm 371.03 88.77 297.15 79.41 392.18 101.19 0.19 5.04 26.62 
39 Malm-Pyrm 51.67 8.08 22.96 9.22 35.90 13.18 1.00 -3.16 3.17 
40 Citm-Citcc 46.38 2.38 47.48 0.96 40.64 0.81 2.29 -1.14 0.50 
41 Cit-AcC/Mal 46.38 2.38 47.48 0.96 40.64 0.81 2.15 -1.09 0.51 
42 Mal-Malm 46.38 2.38 47.48 0.96 40.64 0.81 2.22 -1.14 0.51 
43 G6P-P5P 4.39 0.19 4.52 0.07 3.88 0.06 2.70 -0.10 0.04 
44 NADH-OP 1,705.02 447.11 1,281.32 396.81 1,789.98 507.03 0.14 18.64 135.65 
45 FADH2-OP 390.60 91.77 278.23 82.69 397.73 105.84 0.07 2.05 29.80 
46 OP-ATP 4,848.44 1,254.90 3,620.64 1,115.40 5,071.53 1,425.34 0.25 85.58 344.04 
47 ATPwOP 726.13 152.19 508.85 145.37 939.17 173.29 0.86 38.85 45.36 
48 ATPtot 5,574.57 1,395.21 4,129.48 1,252.97 6,010.70 1,589.99 0.20 83.05 419.11 
49 Ala-Pyr -37.66 2.35 -42.49 2.55 -52.15 3.72 3.34 -2.85 0.85 
50 Arg-Glu -1.44 2.15 -1.10 2.15 -2.28 2.62 0.28 -0.17 0.62 
51 Asn-Asp -0.34 0.87 -2.14 0.68 -1.63 0.65 1.27 -0.26 0.21 
52 Asp-OAAm 6.04 3.89 -2.58 3.59 1.07 4.73 0.79 -0.98 1.23 
53 Cys-Pyrm -0.09 1.20 -2.47 1.13 -0.35 1.33 0.15 -0.05 0.36 
54 Gln-Glu 84.87 5.69 79.95 6.00 82.15 6.09 0.38 -0.61 1.60 
55 Glu-AKGm 7.05 9.65 -11.67 13.35 -24.27 19.54 1.41 -6.00 4.24 
56 Gly-Ser -23.67 3.21 -23.02 2.62 -27.24 3.52 0.80 -0.77 0.97 
57 His-Glu -1.98 1.71 0.07 1.81 -0.20 2.32 0.59 0.32 0.54 
58 Ile-AcCm/SuCm 6.50 1.63 2.92 1.47 4.23 1.61 0.97 -0.44 0.46 
59 Leu-AcCm 7.05 2.04 3.41 2.03 4.78 2.04 0.77 -0.44 0.58 
60 Lys-AcCm 2.58 3.68 2.78 3.98 1.32 4.93 0.21 -0.26 1.19 
61 Met/Ser-SuCm/Cys 3.48 0.89 2.52 0.78 2.67 0.83 0.59 -0.14 0.24 
62 Phe-Tyr -1.61 1.03 -1.89 1.06 -1.18 1.41 0.20 0.07 0.36 
63 Pro-Glu -20.95 3.31 -28.75 3.42 -25.41 4.38 0.80 -0.92 1.16 
64 Ser-Pyr -5.43 4.34 -7.47 4.09 -12.20 4.84 1.02 -1.26 1.24 
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65 Thr-SuCm -1.82 1.36 -3.72 1.38 -1.58 1.84 0.14 0.06 0.46 
66 Trp-AcCm/Ala -3.87 0.98 -2.81 1.09 -2.25 1.31 0.93 0.31 0.34 
67 Tyr-AcCm/Fumm 0.60 1.94 -0.95 1.93 -0.40 2.65 0.26 -0.18 0.68 
68 Val-SuCm 5.20 2.02 1.13 1.70 3.13 2.20 0.64 -0.38 0.60 
Standard deviation (SD) was calculated using Monte Carlo simulation. Negative values indicate reversed flux. FS flux 
sensitivity (Eq. 3), FC flux change (Eq. 2), SDFC standard deviation of FC, Pyr pyruvate, G6P glucose 6-phosphate, 
P5P pentose 5-phosphate, F6P fructose 6-phosphate, GAP glyceraldehyde 3-phosphate, AcC acetyl coenzyme A, Cit 
citrate, AKG α-ketoglutarate, SuC succinyl coenzyme A, Fum fumarate, Mal malate, OAA oxaloacetate, NADH 
nicotinamide adenine dinucleotide, FADH2 flavine adenine dinucleotide, ATP adenosine triphosphate, ATPwOP ATP 
production without oxidative phosphorylation, ATPtot total ATP production, OP oxidative phosphorylation, standard 
abbreviations for amino acids. Indices: m mitochondrial. 
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Fig. 5-4 Metabolic fluxes in the ammonia metabolism of AGE1.HN upon perturbation with different ammonia 
concentrations in the medium. Metabolic fluxes are given in µmol g-1 h-1 and the flux strength is additionally 
indicated by the arrow width. The total transamination flux (v49+v52+v58+v59+2v60+v64+v67+v68) represents the total net 
flux from glutamate (Glu) to α-ketoglutarate (AKG) which was required for transamination reactions. Flux numbers 
are given in the upper figure. AKA α-ketoacids, BCA branched-chain amino acids (Ile, Leu, Val), OAA oxaloacetate, 
MNH3 total ammonia produced from intracellular reactions, standard abbreviations for amino acids. Indices: ex 
extracellular. 
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5.5 Discussion 
In this study, the specific effects of elevated extracellular ammonia levels on growth, A1AT production, 
and metabolism of the new human cell line AGE1.HN were analyzed. Initial ammonia concentrations of 
2.5 mM and 5 mM as well as 0 mM as control were chosen because in reference cultivations of AGE1.HN 
ammonia concentrations of almost 5 mM were found at the end of the cultivation. 
5.5.1 Increased ammonia stress reduces growth rate and production of ammonia 
and A1AT  
It was found that initial concentrations of 2.5 mM ammonia already led to decreased maximum cell 
densities and that 5 mM ammonia slowed down growth significantly. Similar observations were made by 
Butler and Spier (Butler and Spier 1984) and Cruz et al. (Cruz et al. 2000) for BHK cells, where ammonia 
concentrations of 1 mM were found to reduce growth significantly. For channel catfish ovary (CCO) cells, 
similar values were found (Slivac et al. 2010) showing that 2.5 mM ammonia reduced growth by 44% and 
that 5 mM stopped growth almost completely. In contrast, for other cell lines like, e.g., some CHO cell 
lines, much higher ammonia concentrations up to 25 mM were tested and found to reduce growth only by 
25% (Yang and Butler 2000). Additionally, specific protein production rates were influenced by 
extracellular ammonia concentrations. In our study, it was observed that 2.5 mM ammonia did only 
slightly decrease specific productivity. 5 mM ammonia led to reduced specific A1AT production rates of 
about 30% (Table 5-1). The total amount of A1AT produced during the cultivation depends, amongst 
other factors, on specific productivity and on viable cell density. Therefore, even 2.5 mM ammonia 
reduced the final A1AT titer primarily through significant reduction of maximal viable cell density. For 
CHO TF-70 cells expressing t-PA, concentrations of 8 mM ammonia were found to reduce the t-PA 
production significantly (Hansen and Emborg 1994). In contrast, it was shown for another CHO cell line 
producing G-CSF that ammonia concentrations up to 25 mM did not reduce protein secretion indicating a 
high ammonia tolerance for this cell line (Andersen and Goochee 1995). Similar observations were made 
for BHK cells by Cruz et al. where it was shown that concentrations as high as 20 mM ammonia reduced 
the specific productivity by 50% (Cruz et al. 2000). 
Generally, the presented standard batch cultivation resulted in active titers of 0.63 g/l for the complex 
glycoprotein A1AT which was around 30% of the total cell biomass (~2 g/l) matching the expectations 
for an industrially relevant pharmaceutical producer cell line. The maximum product titer was reduced by 
nearly 20% when 5 mM ammonia was added at the beginning. 
5.5.2 Central energy metabolism remains robust with increasing ammonia stress 
The analysis of the metabolism of the AGE1.HN cell line under conditions of elevated extracellular 
ammonia concentrations revealed that the cell line´s central energy metabolism is quite robust against 
increased extracellular ammonia concentrations since no significant changes in glycolysis and TCA cycle 
were observed under the analyzed conditions. Only in the 5 mM ammonia cultivation, glycolytic fluxes 
seemed to be slightly higher than in the control cultivation. In contrast to many other cell lines like BHK 
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(Cruz et al. 2000), CHO K1 (Yang and Butler 2000), and hybridoma cells (Ozturk et al. 1992), only a slight 
increase in specific glucose and no change in the glutamine consumption rate were observed in the 
AGE1.HN cell line. This indicates that the applied extracellular ammonia concentrations, which are 
usually not higher in the cultivation process, do not increase energy demand in AGE1.HN cells as was 
proposed by Martinelle et al. (Martinelle et al. 1998) for myeloma and hybridoma cells to maintain pH 
homeostasis. These two findings indicate that the cells are able to maintain energy supply even under 
ammonia stress conditions. 
5.5.3 Ammonia stress results in global flux rearrangements in the amino acid 
metabolism of AGE1.HN 
In contrast to the relatively uninfluenced fluxes in the central energy metabolism of the cells, several 
interesting adaptations to increased ammonia stress were observed in the metabolism of amino acids. 
Under standard conditions, the glutamate dehydrogenase (GDH) was catalyzing the formation of α-
ketoglutarate producing ammonia (v55 in Table 5-2, Fig. 5-4). The net transamination flux was low and also 
produced α-ketoglutarate (Fig. 5-4). This flux direction was accomplished by the reaction of transaminases 
using pyruvate (alanine transaminase) or 3-phosphoglycerate (phosphoserine transaminase) as acceptor for 
the glutamate amino group producing, finally, the amino acids alanine and serine in the respective 
metabolic pathways. Fluxes through other transaminases involved in amino acid degradation pathways 
were high. The total flux distribution resulted in a relatively high ammonia production rate under standard 
conditions.  
Increased ammonia stress (2.5 mM and 5 mM start concentration in the medium) resulted in a global 
rearrangement of the amino acid metabolism to reduce ammonia production and, eventually, ammonia 
accumulation in the medium. This was accomplished through changes in different metabolic reactions 
involved in ammonia metabolism. Glutamate dehydrogenase flux was reversed consuming ammonia and 
resulting in an increased production of glutamate from α-ketoglutarate (AKG). This was compensated by 
a large increase in the net transamination flux from glutamate to AKG. Fluxes of transamination reactions 
transferring amino groups to AKG, e.g., branched-chain amino acid transaminase or aspartate 
transaminase catalyzed reactions, were reduced, whereas the metabolic fluxes through transaminases 
catalyzing the formation of amino acids, i.e., alanine and phosphoserine transaminase, were increased with 
increasing initial ammonia concentration. Miller et al. also reported changes in transaminase activities 
upon raised ammonia concentrations in hybridoma cells (Miller et al. 1988). Commensurate with the 
increased transaminase fluxes, the production rate of alanine was increased and uptake rate of serine 
decreased. In the 5 mM ammonia cultivation, alanine production rate was doubled compared to the 
control cultivation showing the importance of alanine in the detoxification of ammonia. The reduction of 
the fluxes through transaminases involved in amino acid degradation pathways is actually accomplished by 
reduced uptake of the respective amino acids. As denoted before, the change in the glutamate 
dehydrogenase flux direction at higher ammonia load was compensated by increased transamination to 
AKG with a corresponding transfer of the amino group to alanine or serine and of the carbons into the 
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TCA cycle. Glutamate production rate was not increased significantly (Fig. 5-4, Table 5-1) with increased 
ammonia stress indicating that this flux is not used by the cells to remove excess glutamate. Proline 
production flux was, however, slightly increased. In effect, the flux changes led to reduced ammonia 
production and showed that the cell can react to increased ammonia concentration in the environment. 
Bonarius et al. described the adaptation mechanism of hybridoma cells to toxic levels (10 mM) of 
ammonia (Bonarius et al. 1998a). They also found that ammonia accumulation was reduced by a change in 
the glutamate dehydrogenase flux and that the additionally produced glutamate is further metabolized by 
aminotransferases. Increased production rates of alanine and proline, both used as nitrogen sinks, were 
also observed by the same authors as well as by other groups (Hansen and Emborg 1994; Ozturk et al. 
1992; Schumpp and Schlaeger 1992). However, in hybridoma cells no changes in uptake rates of other 
amino acids were observed, e.g., branched chain amino acids that transfer intracellularly amino groups to 
AKG during their degradation. Additionally, we did not find any metabolic flux study investigating 
ammonia effects in which all transamination reactions taking place in amino acid degradation pathways 
were included in the metabolic flux model. However, as shown in this study, it is important to include and 
analyze these reactions since cells change fluxes through these amino acid degradation pathways as a 
response to increased ammonia stress thereby reducing the production of glutamate through 
transamination. It was very interesting to observe that the AGE1.HN cell line seems to be able to regulate 
the uptake rates of several amino acids and to adapt these to anabolic requirements. Under standard 
conditions, uptake of several amino acids, e.g., branched-chain amino acids, was higher than the anabolic 
demand for these biomass precursors. Higher ammonia concentration in the medium led to reduced 
uptake rates of amino acids getting closer to the demand for synthesis of biomass and A1AT production 
having lower fluxes through degradation pathways. 
5.5.4 Adaptation mechanism of AGE1.HN cells to increased ammonia 
concentrations 
A possible mechanistic explanation for the adaptive behavior described above is depicted in Fig. 5-5. 
Increased extracellular ammonia concentration leads to increased intracellular ammonia concentration. 
This might lead to a shift in the reaction equilibria of reactions where ammonia is involved towards 
fixation of free ammonia (e.g., α-ketoglutarate + ammonia → glutamate). The resulting increased 
glutamate concentration would shift the reaction equilibrium of selected transaminase reactions towards 
production of amino acids, e.g., alanine, recycling glutamate to α-ketoglutarate. In contrast, the equilibria 
of ammonia/glutamate producing reactions in some amino acid degradation pathways are shifted towards 
the amino acids leading to reduced degradation. The increased production or reduced degradation of 
several amino acids leads to increased secretion and/or reduced uptake of these amino acids as observed 
during the experiment. Hypothetically, these changes in uptake and secretion of certain amino acids might 
lead to changes in the intracellular concentrations which could be an explanation for reduced biomass and 
A1AT production based on amino acid limitation. 
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Fig. 5-5 Mechanistic explanation for the observed 
adaptation phenomema of the AGE1.HN cell line 
to increased extracellular ammonia concentrations. 
AKG α-ketoglutarate, AKA α-ketoacids, AA amino 
acid, standard abbreviations for amino acids, TA 
transaminase. Indices: TA amino acids produced 
by transamination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5.5 Urea production in AGE1.HN cells is not altered by increased addition of 
ammonia  
Interestingly, we found another possible nitrogen depository, i.e., urea. To our knowledge, this has not 
been reported or analyzed for any production cell line derived from non-liver tissue. A possible 
explanation for these findings in the neuronal cell line AGE1.HN is provided by the results from 
Braissant et al. and from Gotoh et al. who found that arginase II is expressed in almost all parts of the 
human brain (Braissant et al. 1999; Gotoh et al. 1997). Since the enzyme arginase catalyzes the degradation 
of arginine to ornithine and urea, this might be an explanation for the increasing urea concentrations 
found in the medium. The observation that the urea concentration is not increased with increasing 
ammonia supply in the medium indicates that urea is not used as nitrogen sink in AGE1.HN. This is 
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further supported by the fact that arginine which is taken up in excess and not needed for anabolic 
purposes is just converted via the enzyme arginase to urea and ornithine. The urea cycle seems to be 
inactive in AGE1.HN showing that urea is not used to remove excess ammonia. However, these findings 
might open up new possibilities to engineer this cell line towards even more efficient ammonia 
detoxification with minimal carbon wasting. This may be achieved through genetic engineering 
introducing the genes necessary to create fully functional urea cycle. Park et al. have introduced carbamoyl 
phosphate synthetase I and ornithine transcarbamoylase genes in CHO cells and found only a slight 
reduction in the ammonia production and a small increase in viable cell density (Park et al. 2000). 
However, for AGE1.HN cells the success of this strategy to decrease ammonia production as well as to 
increase A1AT production has to be tested.  
5.6 Concluding remarks 
In summary, the adaptation mechanism of the neuronal cell line AGE1.HN to cope with high ammonia 
concentrations was unraveled. The cell line adapts to high ammonia concentration by rearranging its 
amino acid metabolism towards lower ammonia production and increased ammonia fixation in amino 
acids. This indicates that the cell line has a kind of “NH3/NH4+ sensor”, in the simplest case just 
representing equilibrium effects, which enables the cell to sense changing conditions and furthermore to 
convert this information into described physiological adaptations. These adaptations mainly take place in 
amino acid metabolism and are based on regulatory changes in selected physiologically relevant processes. 
The uptake rates for specific amino acids are downregulated. Transaminase activities involved in amino 
acid degradation pathways are reduced, whereas activities of transaminases catalyzing the formation of 
amino acids are increased. In combination with a change in the glutamate dehydrogenase flux direction 
leading to the fixation of free ammonia, these adaptations lead to reduced ammonia accumulation and 
storage of excess ammonia in extracellular amino acids, mainly alanine. The fact that urea production only 
depended on cell number and arginine excess indicates that urea is not used to remove excess ammonia 
but indicates that arginase is expressed in AGE1.HN. From an engineering point of view, it can be 
concluded that further engineering of the cell line with the aim of increasing resistance to high ammonia 
conditions is of interest, particularly, if product titers should be further increased leading to an anticipated 
higher ammonia production. Possible targets are enzymes transferring amino groups that could be down-
regulated in the case of consumed amino acids and up-regulated in the case of alanine and serine. 
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The supplementary material for this chapter is given in the supplementary material section at the end of 
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6 Metabolism and metabolic burden by α1-antitrypsin production 
in human AGE1.HN cells 
6.1 Abstract 
The goal of this study was a detailed analysis of the metabolic burden on AGE1.HN cells imposed by the 
production of recombinant α1-antitrypsin (A1AT). This was accomplished by comparing the properties of 
a selected high-producing clonal cell line with the parental cell line. By analyzing growth and biomass 
dynamics, it was observed that RNA and lipid fractions were higher in the producer cell line. The 
differences found in the macromolecular composition were also reflected in the metabolism. Specific 
changes observed were, e.g., increased glycine and glutamate production in the producer, which could be 
explained by using a model describing the whole protein synthesis process. By simulating the theoretical 
metabolite demand for production of mature A1AT, it was found that the differences in metabolic 
profiles between producer and parental cells match the increased C1 unit and nucleotide demand in the 
producer. Comparison of metabolic fluxes revealed that energy metabolism was similar in both cell lines 
whereas fluxes in C1 and amino acid metabolism were changed and adapted to the different anabolic 
demand. The data indicate that the main cellular properties distinguishing the high producer from the 
parental cell population are, apart from production of A1AT, high RNA and lipid content. The increased 
lipid content points to an expanded secretion machinery in the producer cell line which might be an 
adaptation to high level secretion of A1AT or the specific property of this cell clone and the reason for its 
selection. Lipid metabolism and protein secretion seem important targets for further improvement of 
AGE1.HN. 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was submitted as 
Niklas J, Priesnitz C, Rose T, Sandig V, Heinzle E. Metabolism and metabolic burden by α1-antitrypsin 
production in human AGE1.HN cells. 
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6.2 Introduction 
Alpha1-antitrypsin (A1AT) deficiency is an inherited disease characterized by low serum levels of A1AT 
which can result in lung emphysema and liver dysfunction (Kelly et al. 2010; Petrache et al. 2009). The 
lack of protection against neutrophil elastase usually provided by A1AT leads to destruction of lung 
parenchyma and finally emphysema in the respiratory tract. The mortality rate of patients can be decreased 
by A1AT augmentation which is achieved by intravenous infusion of a purified preparation of human 
A1AT (A1AT-Group 1998). However, only human plasma-derived products are licensed by the US-FDA 
for intravenous treatment of A1AT deficiency in spite of many attempts to produce recombinant A1AT in 
prokaryotic and eukaryotic hosts (Karnaukhova et al. 2006). This fact makes the therapy currently very 
expensive and not cost-effective (Gildea et al. 2003) showing that an alternative source of A1AT would be 
important. Recently, it was shown that A1AT derived from the novel human cell line AGE1.HN has 
similar anti-inflammatory activity as plasma-derived A1AT (Blanchard et al. 2011) indicating that this cell 
line is a useful expression system for large scale production of this biopharmaceutical. Recent studies on 
growth, metabolism (Niklas et al. 2011b; Niklas et al. 2011c; Niklas et al. 2011d), and glycosylation 
properties (Blanchard et al. 2011) of this cell line have shown that AGE1.HN seems a favorable cell line 
for the production of glycoproteins requiring human-type post-translational modifications. Further 
improvement of the productivity might be achieved by a detailed understanding of the cellular protein 
production process. 
The development of mammalian cell lines suitable for the production of biopharmaceuticals typically 
requires an intense effort. This is mainly due to the low frequency of recombinant cell clones expressing 
high levels of the desired target protein. Therefore, identifying and understanding the physiological 
characteristics of a high producer cell offers great potential. Addressing the specific requirements of 
producer clones via genetic engineering or defined adjustment of media and feed compositions should 
simplify cell line development and generally enhance the yields in industrial production. 
Selected cellular principles underlying varying productivity were analyzed using different omics-
technologies (Alete et al. 2005; Hayduk and Lee 2005; Seth et al. 2007; Smales et al. 2004; Yee et al. 2009). 
In proteomic analyses of cells with varying secreted recombinant protein productivities, changes in, e.g., 
translation, energy metabolism, chaperones, and cytoskeletal proteins were observed (Alete et al. 2005; 
Hayduk and Lee 2005; Smales et al. 2004). Seth et al. analyzed changes in transcriptome and proteome in 
different producers and proposed that differences in protein synthesis and cell growth controlling 
networks might lead to high productivity (Seth et al. 2007). Another transcriptome study concluded that 
particularly vesicle trafficking, endocytosis, and cytoskeletal elements go along with increased specific 
productivity (Yee et al. 2009). Khoo et al. compared the transcriptome of producer and non-producer cell 
lines (Khoo et al. 2007). They found that the producer cells did not grow any slower indicating negligible 
metabolic burden in this case but, nevertheless, differences in metabolic activities were observed. It was 
concluded that slower growth, as a result of metabolic burden, might be negligible in cells that were 
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selected for high productivity as well as growth rate. To our knowledge, a detailed analysis on the 
metabolome level concerning differences in productivity has not yet been described.  
In this study, we analyzed the metabolic burden of α1-antitrypsin production in AGE1.HN. The goal was 
to compare growth, dynamics of biomass constituents, metabolite dynamics, and metabolic fluxes in the 
A1AT producing cell line AGE1.HN.AAT and its parental cell line. The following questions were 
addressed: (i) what are the differences in growth and biomass composition of both cell lines, (ii) what is 
changed in the cellular metabolism, (iii) what particularly distinguishes this clonal A1AT producing cell 
line from the parental cell population enabling this cell line to produce large quantities of the product, and 
(iv) can we identify potential targets for further improvement of the cell line by understanding the 
metabolic requirements of A1AT production and the adaptation of the cell to high-level glycoprotein 
secretion? 
6.3 Material and methods 
6.3.1 Cell line 
The cell line AGE1.HN® (ProBioGen, Berlin, Germany) originates from primary human brain cells. 
These were immortalized and improved using different adenoviral genes as described previously (Niklas et 
al. 2011d). The α1-antitrypsin (A1AT) producing cell line AGE1.HN.AAT was developed as follows. 
Parental cells were transfected with an expression vector containing the human A1AT gene driven by a 
human CMV/EF1 hybrid promoter (ProBioGen). High producing clones were established with 
puromycin drug selection. In a recent publication, it was shown that A1AT derived from AGE1.HN cells 
was highly active and showed a complex glycostructure (Blanchard et al. 2011). 
6.3.2 Analytical methods 
Cell counting was performed using an automated cell counter (Countess, Invitrogen, Karlsruhe, 
Germany).  
Cell dry weight. Cell suspensions containing exactly 3 or 4 × 106 cells were harvested (500 1/min, 5 min, 
25°C, Labofuge 400R Function Line, Heraeus Instruments, Hanau, Germany) and the pellets resuspended 
in 2 ml 37°C PBS. The suspensions were transferred into preweighed Eppendorf tubes and again 
centrifuged (4000 1/min, 5 min, 20°C, Picofuge, Heraeus Instruments, Hanau, Germany). The 
supernatant was discarded. The pellets were frozen at -70°C, lyophilized, and finally weighed. 
Intracellular and extracellular proteins. Cell pellets from the cell dry weight analysis were resuspended in 200 µl 
CelLytic™ M solution (Sigma-Aldrich, Steinheim, Germany) and incubated for 15 min at 20°C on a 
shaker (400 1/min, MS1 Minishaker, IKA, Staufen, Germany). After centrifugation (13,000 1/min, 10 
min, 4°C, Biofuge fresco, Heraeus Instruments, Hanau, Germany) the supernatants were transferred into 
new tubes. Proteins were quantified using Bradford assay (Bradford 1976) (reagent from Bio-Rad 
Laboratories, Munich, Germany). A series of BSA (bovine serum albumin) solutions was used for 
calibration. The absorption was measured at 540 nm (iEMS Reader MF, Labsystems, Helsinki, Finland). 
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The total extracellular protein concentration was directly analyzed in culture supernatants using the 
Bradford assay.  
RNA content was determined using the TRI Reagent® Solution from Applied Biosystems/Ambion (Austin, 
TX, USA) according to the manual. The RNA concentrations were determined spectrophotometrically 
(Genesys 10 Bio, Thermo Fisher Scientific, Waltham, MA, USA). 
Total lipid analysis. Cells were cultured in 250 ml shake flasks (Corning) and harvested in the exponential 
growth phase by centrifugation (1,200 1/min, 5 min, 20°C, Labofuge 400R Function Line, Heraeus 
Instruments, Hanau, Germany). The supernatant was discarded and lipids were extracted using a protocol 
published by Akopian et al. (Akopian and Medh, 2006). In brief, the pellet was resuspended in 
cyclohexane/isopropanol (3:2 v/v), vortexed, and incubated on ice. After another centrifugation (4500 
1/min, 10 min, Labofuge 400R Function Line, Heraeus Instruments, Hanau, Germany) the supernatant 
was transferred to a glass tube. After evaporation of the solvents the vessel was placed for drying at 80°C 
over night and then cooled down in a desiccator. Total extracted lipids were finally weighed. 
Alpha1-antitrypsin concentration and activity. A1AT (α1-antitrypsin) concentration was determined using an 
activity assay based on the inhibition of trypsin by A1AT. Calibration was done using standards with 
different A1AT concentrations (0.5-0.001 mg/ml in PBS; A1AT from human plasma was acquired from 
Sigma-Aldrich, Steinheim, Germany). Samples were appropriately diluted with PBS. Of the samples and 
standard solutions 50 µl were mixed with a trypsin solution (0.1 mg/ml in an activity buffer containing 15 
mM Tris, 100 mM NaCl, 0.01% (v/v) Triton X-100 at pH 7.6) and incubated for 10 min at 37°C. 10 µl of 
these solutions were pipetted into the wells of a 96-well plate. 90 µl of a BAPNA solution (Nα-Benzoyl-L-
arginine 4-nitroanilide hydrochloride, Sigma-Aldrich; 11 µl of BAPNA stock solution [500 mM in DMSO] 
were mixed with 1,989 µl activity buffer) was added to each well. The plate was incubated at 37°C for 1 h 
and the absorption was measured at 405 nm (iEMS Reader MF, Labsystems, Helsinki, Finland). 
Extracellular metabolites. Concentrations of extracellular metabolites were measured by different HPLC 
methods (Kromer et al., 2005; Niklas et al., 2009). 
6.3.3 Cell culture and experimental procedure 
The cells were cultured in an incubator supplied with a shaking unit (Innova 4230, New Brunswick 
Scientific, Edison, NJ, USA; 2 inches orbit) at 37°C and 5% CO2. The precultures were carried out in 250 
ml shake flasks (Corning, NY, USA). The cells from the precultures were transferred in Falcon tubes, 
centrifuged (500 1/min, 5 min, 20°C, Labofuge 400R Function Line, Heraeus Instruments, Hanau, 
Germany), the supernatant discarded, and the pellet resuspended in phosphate buffered saline (PBS). 
After another centrifugation, the pellets were resuspended in medium and the cell suspensions transferred 
in 125 ml shake flasks (Corning, NY, USA). The applied serum-free medium was 42-Max-UB medium 
(Teutocell, Bielefeld, Germany). Samples containing more than 4 × 106 cells were taken every day. Cell 
counting was performed. A part of the cell suspension was used for the analysis of cell dry weight and 
protein content. The rest was centrifuged and the supernatant transferred into fresh tubes. The samples 
were frozen and stored at -20°C for later analysis of extracellular components. Since higher cell amounts 
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were necessary for a reliable analysis of RNA dynamics, separate cultivations in 250 ml shake flasks 
(Corning) were performed using the same media and conditions as before. Samples containing more than 
3 × 106 cells were taken every 24 h. A part of this suspension was used for cell counting and an exactly 
defined volume was immediately centrifuged (8000 1/min, 5 min, 20°C, Biofuge pico, Heraeus 
Instruments, Hanau, Germany). The supernatant was discarded, the pellet resuspended in TRI Reagent® 
Solution (Applied Biosystems/Ambion, Austin, TX, USA) and stored at -70°C for later determination of 
RNA concentrations. 
6.3.4 Metabolic flux analysis 
Metabolic fluxes in the growth phase (days 0-4) of both cell lines were calculated using Matlab R2007b 
(The Mathworks, Natick, MA, USA) applying stationary metabolic flux analysis using metabolite balancing 
as described in literature (Niklas and Heinzle 2011; Niklas et al. 2011d; Stephanopoulos et al. 1998). The 
applied metabolic network model (Fig. 6-1) was set up using the Kyoto Encyclopedia of Genes and 
Genomes pathway database (www.kegg.com) for Homo sapiens. 
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Fig. 6-1 Metabolic network model for metabolic flux analysis. Single cell, three compartment model distinguishing 
selected cytosolic and mitochondrial reactions as well as the α1-antitrypsin (A1AT) glycosylation that takes place in 
the endoplasmic reticulum (ER) and Golgi apparatus (Golgi). Anabolic fluxes are indicated by dashed lines. The 
stoichiometry of the model is given in the supplementary material (Table S1). Abbreviations: BM biomass, Glc 
glucose, Gal galactose, Lac lactate, Pyr pyruvate, G6P glucose 6-phosphate, P5P pentose 5-phosphate, F6P fructose 6-
phosphate, GAP glyceraldehyde 3-phosphate, AcC acetyl coenzyme A, Cit citrate, AKG α-ketoglutarate, SuC succinyl 
coenzyme A, Fum fumarate, Mal malate, OAA oxaloacetate, TA transamination flux (TA = 
v52+v55+v61+v62+2v63+v67+v70+v71), Glc-NAc N-Acetylglucosamine, Man mannose, Fuc fucose, Neu5Ac N-
Acetylneuraminate, THF tetrahydrofolate, C1THF methylenetetrahydrofolate, standard abbreviations for amino 
acids. Indices, ex extracellular, m mitochondrial, ER localization in the ER or Golgi apparatus. 
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6.4 Results and discussion 
6.4.1 Biomass dynamics in parental and A1AT producing AGE1.HN cells 
The growth profiles of both cell lines are depicted in Fig. 6-2A. Cell growth and growth rate were similar 
in the first 120 h. After 120 h the A1AT producing AGE1.HN cells (AGE1.HN.AAT) were growing 
more slowly than the parental cell line (AGE1.HN) and the viability dropped faster in AGE1.HN.AAT. 
The time course of the dry weight was similar in both cell lines being initially slightly higher in 
AGE1.HN.AAT and after 48 h higher in the parental cell line. A1AT production was low in the first 48 h 
and then increasing up to a final concentration of ~0.4 g/l at the end of the cultivation. The time courses 
of selected biomass components were also analyzed (Fig. 6-2B). The total cell mass was increasing 
similarly in the first 96 h. After 96 h, AGE1.HN.AAT cell mass remained constant, whereas the 
extracellular protein concentration was increasing. This was different in the AGE1.HN cells where the cell 
mass was still increasing after 96 h and the increase in total extracellular protein mass was less. The total 
protein concentration in the culture (extracellular + cellular protein) remained almost constant after 96 h 
in AGE1.HN.AAT and after 120 h in AGE1.HN whereas cellular protein concentration was decreasing in 
AGE1.HN.AAT after 96 h. This indicates that specific cellular proteins might be degraded when there is a 
lack of protein building blocks to maintain the production of the recombinant glycoprotein A1AT which 
was high after 96 h. This was clearly different in the parental cell line where the total cellular protein 
concentration remained constant after 120 h. The total mass of the analyzed components at the end of the 
cultivation was similar in the cultivations of both cell lines being around 2.5 g/l. The final A1AT 
concentration, which was 0.4 g/l, was ~22% of the final cell mass and ~30% of the total protein in the 
culture. 
The total cellular RNA fraction during the growth phase was higher in AGE1.HN.AAT than in 
AGE1.HN (Fig. 6-2C). This might be explained by the fact that the A1AT gene is driven by a strong 
CMV/EF1 hybrid promoter which results in high levels of A1AT mRNA transcripts in AGE1.HN.AAT. 
Generally, high mRNA levels of the gene of interest are desirable. In a study on CHO producer cell lines, 
it was found that high mRNA levels were characteristic for the high-producing cells (Chusainow et al. 
2009). 
We measured also total lipid content in both cell lines. It was observed that the cellular lipid fraction was 
increased in AGE1.HN.AAT compared with the parental cell line (Fig. 6-2D). This points to an increased 
intracellular secretion machinery in the producing cell, which can be caused by high flux of the protein 
product through the secretory pathway forcing the cell to provide more endoplasmic reticulum (ER) and 
Golgi apparatus (Golgi). It might be also a particular characteristic of this specifically selected clone and 
might, amongst other properties, have led to the high level of A1AT production in this particular clone 
and, therefore, its selection. Seth et al. also speculated that the transformation from a host cell to a high 
producing cell might entail an expanded protein secretion machinery (Seth et al. 2006). The same group 
discovered in a transcriptome and proteome study comparing high and low producers that expression of 
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genes involved in protein synthesis pathways is altered in high producers (Seth et al. 2007). In another 
transcriptome study, it was reported that increased specific antibody productivity is accompanied by a 
difference in the expression of genes involved in secretory pathway and cytoskeletal elements (Yee et al. 
2009). In summary, increased secretion machinery might be one characteristic of a high producing cell. 
The differences in the RNA level and lipid content resulted, consequently, in a different anabolic demand 
of the producing and parental cells (Table 6-1) which should also result in specific signatures in 
metabolism and metabolic fluxes. 
 
Table 6-1 Anabolic demand of producer (AGE1.HN.AAT) and parental AGE1.HN cells. 
 AGE1.HN.AAT AGE1.HN 
 Anabolic demand [µmol/gbiomass] 
Proteins 7,462.6 7,344.2 
Lipids 202.9 170.7 
RNA 176.9 116.3 
DNA 45.3 45.3 
Carbohydrates 438.3 438.3 
RNA, lipid, and protein fractions in both cell lines were measured in this study. Carbohydrate and DNA data were 
taken from literature (Bonarius et al. 1996) and are therefore identical. 
 
6.4.2 Metabolite dynamics in both cell lines 
In order to explain the biomass and growth dynamics in both cell lines, time courses of extracellular 
substrate and product metabolites were analyzed (Fig. 6-3). In the growth phase from 0-96 h, similar time 
courses for most metabolites were observed. However, some specific differences were found. Glycine and 
glutamate production was higher in AGE1.HN.AAT compared to AGE1.HN whereas uptake of arginine 
and aspartate as well as alanine production was lower. Glutamine was depleted in the cultivations of both 
cell lines at ~96 h which resulted also in reduced growth (Fig. 6-2A). In particular, the increase in glycine 
and glutamate production points to an effect of the production of the glycoprotein A1AT on C1 
metabolism and on the cellular nucleotide demand. This will be explained in more detail in the next 
section. 
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Fig. 6-2 Growth and biomass dynamics in α1-antitrypsin (A1AT) producing (AGE1.HN.AAT) and parental 
AGE1.HN cells. A. Growth profile of AGE1.HN.AAT and AGE1.HN cells. Mean values and standard deviations 
of two cultivations, respectively. TCD total cell density, VCD viable cell density. B. Dynamics of biomass 
components in both cell lines. Mean values and standard deviations of two cultivations. C. RNA fraction in both cell 
lines from day 1 to day 4 of the cultivation. Mean values and standard deviations of two cultivations. D. Total lipid 
fraction in AGE1.HN.AAT and AGE1.HN during growth phase. Mean values and standard deviations from five 
independent measurements using different biological samples. 
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Fig. 6-3 Time course of extracellular metabolites during cultivation of AGE1.HN.AAT and AGE1.HN cells. Mean 
values and standard deviations of two cultivations. Glc glucose, Gal galactose, Lac lactate, Pyr pyruvate, standard 
abbreviations for amino acids. 
6.4.3 Modeling of the theoretical metabolic burden of A1AT production 
The differences that can be seen in the metabolism upon production of the glycoprotein can be best 
explained and understood by using an appropriate model of the theoretical anabolic demand that is 
needed to produce fully active α1-antitrypsin.  
At first sight one might be puzzled to see an increase in the production of the amino acids glycine and 
glutamate upon A1AT production since both amino acids are needed in the amino acid chain of this 
particular protein. However, considering just the amino acids and energy needed for assembly of the 
amino acid chain is clearly underestimating the real anabolic demand of A1AT. The whole cellular 
production process of a glycoprotein includes expression (transcription), synthesis of the amino acid chain 
(translation), posttranslational modification in endoplasmic reticulum (ER) and Golgi apparatus (Golgi), 
and secretion of the mature protein. The modeling of this complex process comprises different parts of 
the cellular metabolism. Whereas the amount of building blocks needed to synthesize mature A1AT is 
fairly well known, some important parameters in the process are not that clear and their modeling is more 
challenging. Nucleotides are needed for the synthesis of mRNA and activated sugars. However, their 
turnover and stability are not known precisely which results in an unknown precursor demand. 
Nucleotides can be de novo synthesized or can be produced by reutilization and phosphorylation of 
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nucleoside monophosphates (NMPs). Since the reactions in the whole glycoprotein synthesis process take 
place in different compartments, transport reactions might play an important role and can also be limiting 
to a certain extent. Another parameter that is not known is the number of A1AT proteins that are 
translated from one mRNA molecule. Stability of the mRNA is another factor that can improve the 
protein production in a cell (Hung et al. 2011), as long as other factors are not limiting, reducing at the 
same time the burden on the transcription machinery. The total cellular content of glycosylated protein 
might also be significantly increased in a producing cell resulting in a significant increase in the 
glycosylation demand. 
The biochemical equations of the different parts in the metabolism that are involved in the synthesis of 
the glycoprotein are presented below. The stoichiometry was taken from the Kyoto Encyclopedia of 
Genes and Genomes pathway database (www.kegg.com).  
Depending on the mRNA stability, transcription of A1AT mRNA might be an additional metabolic 
burden for the cell since many NTPs are needed for mRNA synthesis. However, many proteins can be 
translated from just one mRNA. We don’t know a priori how many mRNAs are synthesized and if this is 
really a significant burden for the cell. There is also the question of whether the cell will react by 
synthesizing more NTPs for RNA synthesis. In our simulations, we will assume different numbers of 
protein which can be synthesized per mRNA. 
Translation of A1AT mRNA into raw protein is clearly a burden for the cell since the amino acids and 
energy that is needed to assemble the protein is an additional amount of substrates that cannot be used for 
synthesis of cell biomass. Protein biosynthesis is a most energy-intensive process.  
The reactions of the glycosylation machinery take place in the endoplasmic reticulum and Golgi apparatus 
of the cell. In our model, both organelles were lumped and just the final glycosylation pattern was 
modeled. The stoichiometry that is needed to synthesize the glycans on the 3 N-glycosylation sites of 
A1AT was taken from literature (Kolarich et al. 2006). Transport of activated sugars into the Golgi 
apparatus is carried out by antiporters by an exchange with the corresponding nucleotide monophosphate, 
which requires no energy. 
The model for the synthesis of A1AT derived from the biochemical equations is shown in Fig. 6-4.  
6.4.3.1 Biochemical equations 
Nucleotide biosynthesis 
ATP: R5P + 7 ATP + 2 Gln + Gly + 2 C1THF + 2 Asp + GTP  = ATP + 2 Glu + 2 Fum + 1 AMP + 1 
PPi + 6 ADP + 5 Pi + 2 THF + CO2 + GDP 
GTP: R5P + 8 ATP + 3 Gln + Gly + 2 C1THF + Asp + NAD = GTP + 3 Glu + Fum + NADH + 2 
AMP + 2 PPi + 6 ADP + 4 Pi + 2 THF + CO2 
UTP: R5P + 5 ATP + Gln + Asp + HCO3- = UTP + Glu + 4 ADP + AMP + 2 Pi + PPi + CO2 
CTP: UTP + ATP + NH3 =CTP + ADP + Pi  
C1 metabolism 
C1THF: Ser + THF = Gly + C1THF 
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Transcription of A1AT mRNA 
mRNAA1AT: 2543 UTP + 2577 CTP + 2514 ATP + 2592 GTP = mRNAA1AT 
Translation of A1AT mRNA into raw protein 
A1ATraw: 26 Ala + 7 Arg + 19 Asn + 24 Asp + 3 Cys + 32 Glu + 18 Gln + 24 Gly + 13 His + 20 Ile + 51 
Leu + 34 Lys + 10 Met + 27 Phe + 19 Pro + 25 Ser + 30 Thr + 27 Trp + 3 Tyr + 6 Val + 1672 ATP = 
A1ATraw 
N-glycosylation of A1AT 
Biosynthesis of activated sugars 
UDP-GlcNAc: Gln + F6P + AcC + UTP = Glu + UDP-GlcNAc + CoA + PPi 
CMP-Neu5Ac: UDP-GlcNAc + PEP + CTP = CMP-Neu5Ac + UDP + Pi + PPi 
GDP-Man: F6P + GTP = GDP-Man +PPi 
GDP-Fuc: GDP-Man + NADPH = GDP-Fuc + NADP+ 
UDP-Gal: G6P + UTP = UDP-Gal +PPi 
N-glycosylation 
A1ATmat: A1ATraw +  12.69 UDP-GlcNAc + 9 GDP-Man + 6.69 UDP-Gal + 6.681 CMP-Neu5Ac + 0.321 
GDP-Fuc = A1ATmat + 12.69 UDP + 9 GDP + 6.69 UDP + 6.681 CMP + 0.321 GDP 
 
The balance equations for the different parts of the model are presented in matrix form in the 
supplementary material (Table S2).  
The nucleotide pools in the cell can be refilled by salvage nucleotides that are recycled from nucleoside 
diphosphates or monosphosphates which needs just energy in the form of ATP. However, the cells are 
proliferating and the nucleotide pools have to be filled, additionally, with newly synthesized species. In our 
model, we included both possibilities. The relative fraction of new nucleotides and recycled ones is 
defined by the parameters f1 and f2. The parameters t1-4 define the amount of the respective nucleotide that 
is needed to synthesize one mol of A1AT mRNA (mRNAA1AT, Fig. 6-4). Precursor metabolites required 
for the synthesis of nucleotides, sugars, activated sugars, and protein were included in the model. It is 
assumed in the model that all raw A1AT proteins (A1ATraw) are glycosylated and secreted. The parameters 
s1-5 define the amount of the respective activated sugar needed for glycosylation of A1AT (Fig. 6-4). 
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Fig. 6-4 Model to simulate the theoretical metabolic burden of A1AT production in human cells. This model 
describes in detail the theoretical metabolite demand that is needed to synthesize one mol of mature α1-antitrypsin 
(A1AT). The different parts of the model and the stoichiometry are described in the text. Abbreviations: Standard 
abbreviations for nucleotides and amino acids, NTPrec recycled nucleoside triphosphate pool, NTPcom combined 
nucleoside triphosphate pool, NTPnew pool of newly synthesized nucleoside triphosphate, AA amino acid, Glc 
glucose, G6P glucose 6-phosphate, F6P fructose 6-phosphate, PEP phosphoenolpyruvate, AcC acetyl coenzyme A, 
Glc-NAc N-Acetylglucosamine, Man mannose, Fuc fucose, Neu5Ac N-Acetylneuraminate, Gal galactose, THF 
tetrahydrofolate, C1THF methylenetetrahydrofolate. Specific metabolite indices, mat mature, ext extracellular, dem 
demand, raw raw. Rate names are given at the respective arrow. The stoichiometry of the model is additionally 
presented in the supplementary material (Table S2). 
6.4.4 Simulated metabolite demand for A1AT production 
Simulations were carried out using the model (Fig. 6-4) described in the previous section. Assuming 
metabolic steady state and using the average A1AT production rate, rA1AT2, from two cultivations (Fig. 6-
2) which was 0.0454 µmol/gbiomass/h, the theoretical anabolic metabolite fluxes required for A1AT 
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synthesis were calculated. There are some parameters in the model that are not known. The first one is the 
relative fraction of new NTPs, f1, the second one the fraction of recycled NTPs, f2, and the third one the 
amount of mRNA per translated A1AT protein, m. These parameters were varied and the effects of 
changes were analyzed. 
The calculated demand of selected metabolites depending on f1 and m is depicted in Fig. 6-5. It was 
observed that glutamate and glycine are increasingly produced (negative demand) with increasing f1 
(fraction of new NTPs) and m (mRNA/A1AT). The demand for serine or aspartate rises with increasing 
nucleotide demand. These results indicate that one would expect an increase in the production of 
glutamate and glycine with increasing intracellular nucleotide demand, which was actually observed for 
AGE1.HN.AAT (Fig. 6-2). Aspartate and serine uptake was, however, not significantly higher in the 
producing cell line and even lower for aspartate. The applied model describes the theoretical metabolite 
demand and does not describe what might happen if, e.g., production of specific metabolites like 
glutamate or glycine is increased intracellularly. Increased intracellular production of glutamate has to be 
compensated by the cell. The adaptation might be an increased secretion of glutamate but also increased 
flux through transamination reactions might be an adaptation. Hereby, the glutamate amino group is 
transferred to an α-ketoacid producing an amino acid and α-ketoglutarate. This might be the case for 
aspartate but also for serine. Increased intracellular glutamate levels might lead, e.g., to higher intracellular 
production of aspartate from oxaloacetate leading to lower demand for extracellular aspartate. In order to 
understand the differences of producing and parental cell line on metabolic flux level, metabolic flux 
analysis using metabolite balancing was carried out as described in the next paragraph. 
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Fig. 6-5 Theoretical demand of selected metabolites upon A1AT production. The theoretical demand for selected 
metabolites depending on (i) the number of A1AT proteins that are translated per mRNA (mRNA/A1AT) and (ii) 
the relative intracellular fraction of newly synthesized nucleoside triphosphates (NTPs) is depicted. The demand is 
given as a theoretical rate in µmol/g/h and was calculated using the observed mean A1AT production rate in the 
AGE1.HN.AAT cultivations (Fig. 6-2) which was 0.0454 µmol/g/h. 
6.4.5 Comparison of metabolic fluxes in parental and A1AT producing AGE1.HN 
cells 
Selected metabolic fluxes are depicted in Fig. 6-6. A list of all fluxes is given in the supplementary material 
section (Table S3). It was observed that fluxes in the central energy metabolism (glycolysis, TCA cycle) 
were similar (Fig. 6-6). However, significant differences were found in other parts of the metabolism. The 
flux through glycine hydroxymethyltransferase (Fig. 6-6, GHMT, v59) producing C1 units and glycine was 
higher in AGE1.HN.AAT concurrently with an increased glycine production rate (Fig. 6-6, v12). Another 
change was observed in the glutamate metabolism and in the fluxes through different transaminases. 
Glutamate dehydrogenase was catalyzing the formation of glutamate in both cell lines, however, this flux 
was higher in AGE1.HN.AAT. This led to a higher flux into intracellular glutamate pool which was 
compensated in AGE1.HN.AAT by increased production of glutamate and increased transamination 
activity (TA). Aspartate and phosphoserine transaminases (Fig. 6-6, Table S3; v55 and v67, respectively) 
were catalyzing the formation of the respective amino acid consuming excessive glutamate. On the other 
hand activities of other transaminases involved in amino acid degradation pathways, e.g., branched chain 
amino acid transaminases (Table S3, degradation of isoleucine, v61, leucine, v62, valine, v71), were lower in 
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the producing cell resulting in lower glutamate production in these reactions. Alanine transaminase flux 
was, however, almost similar in both cell lines (Table S3, v52) whereas alanine production was higher in the 
parental cell line (Fig. 6, v5). 
The sugar demand in ER/Golgi required for glycosylation was only calculated for A1AT production in 
the producing cell line. These fluxes were lower than 1% of the glucose uptake rate (Table S3) and sugar 
supply for glycosylation is presumably not a significant burden for the cell. 
In summary, it was shown by the metabolic flux analysis that the differences in the anabolic demand of 
the producing cell line resulted in specific adaptations in intracellular fluxes in the amino acid metabolism 
and C1 metabolism whereas energy metabolism remained similar.  
The higher RNA concentration of AGE1.HN.AAT is most likely due to the recombinant A1AT RNA 
itself and an increased pool of endogenous RNAs encoding for intracellular proteins directly or indirectly 
involved with high level A1AT expression. In addition, the higher lipid content can be interpreted as a 
specific adaptation of the cellular secretion machinery to the burden of processing and secreting high 
amounts of recombinant A1AT. 
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Fig. 6-6 Selected metabolic fluxes in AGE1.HN.AAT and AGE1.HN. Fluxes are given in µmol/gbiomass/h. 
Abbreviations and flux numbers as specified in the metabolic network model in Fig. 6-1 and in the representation of 
the stoichiometry of the metabolic network in the supplementary material (Table S1). TA transaminase flux. 
Glycosylation fluxes (Glyco) were only calculated for the product A1AT. In the parental cell (AGE1.HN) these were 
neglected. All calculated extracellular and intracellular fluxes are presented in Table S3 of the supplementary material. 
6.4.6 Targets for improvement of biopharmaceutical production in AGE1.HN 
Growth, metabolism, metabolic shifts, as well as metabolite channeling in AGE1.HN were analyzed and 
described in other recent publications (Niklas et al. 2011b; Niklas et al. 2011c; Niklas et al. 2011d) and 
promising targets for the improvement of energy metabolism and metabolic efficiency in the cells were 
identified, i.e., reduction of substrate load and improved connectivity between cytosolic and mitochondrial 
pyruvate pools. In this study, we will discuss other engineering possibilities which can be deduced from 
the specific differences between the selected producer and the parental cells. 
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Product titers in mammalian cell culture processes have tremendously increased in the past decades, which 
was mainly achieved by optimization of culture media and process control as well as genetic engineering 
of host cells. Engineering strategies applied in the past are summarized in several excellent reviews (Dinnis 
and James 2005; Kuystermans et al. 2007; Lim et al. 2010; Seth et al. 2006). The engineering of protein 
secretion and lipid metabolism represents one strategy to optimize the secretion of recombinant proteins 
(Lim et al. 2010; Seth et al. 2006). It is supposed that high level synthesis of glycoproteins is associated 
with a certain stress to the secretory machinery of the producer (Lim et al. 2010). In transcriptional 
analyses, several ER- and Golgi-localized proteins were found to be differently expressed and associated 
with enhanced productivity (Doolan et al. 2008). Translation or post-translational events like, e.g., 
modification and secretion via ER and Golgi, might be bottlenecks when the protein load exceeds the 
available capacity. In cells with high expression level, it was reported that productivity was not associated 
with mRNA level or transgene copy number indicating bottlenecks downstream in the process (Barnes et 
al. 2006; Ku et al. 2008; Lim et al. 2010). In particular, in cells where a secretory bottleneck was supposed, 
overexpression of XBP-1, a global regulator of the unfolded protein response, was enhancing productivity 
(Ku et al. 2008; Tigges and Fussenegger 2006). Earlier, it was suggested by Sriburi et al. that XBP-1 
overexpression links the unfolded protein response to phospholipid biosynthesis and ER biogenesis 
(Sriburi et al. 2004). Shaffer et al. showed that XBP-1 induces expansion of the ER and other organelles in 
plasma cell differentiation leading to increased protein synthesis resulting in the characteristic phenotype 
of secretory cells (Shaffer et al. 2004). The specific differences between the selected clonal producer and 
the parental AGE1.HN cell population described in this study pointed to the fact that the most important 
cellular properties of the producer are high RNA levels and increased cellular lipid content. This resulted 
also in specific changes in the metabolism. While transcription and RNA level are not expected to limit 
A1AT expression when highly efficient promoters and selection strategies are applied, engineering of the 
secretion apparatus might be a promising strategy for further improving productivity in AGE1.HN. As 
shown in the aforementioned literature, overexpression of XBP-1 in AGE1.HN might push the cellular 
phenotype closer to the phenotype of a professional secretory cell and improve production. Engineering 
could be performed directly in parental AGE1.HN cells, which might lead to a new parental cell line with 
improved protein secretion properties and, presumably, later to better producers. Also, targeted feeding of 
specific lipid mixtures could further increase cellular phospholipid content leading to an expanded 
secretory apparatus in the cell, which might further enhance the yields. The effects of different lipid 
supplements in specific mammalian cell culture processes have also been analyzed and discussed in the 
literature (Jenkins et al. 1994; Nguyen et al. 1993; Seamans et al. 1994). Generally, we suggest genetic 
engineering of the lipid metabolism and the secretory pathway in AGE1.HN in order to further improve 
performance and productivity of this cell line. 
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7 Quercetin treatment changes fluxes in the primary metabolism 
and increases culture longevity and recombinant α1-antitrypsin 
production in human AGE1.HN cells 
7.1 Abstract 
Addition of the flavonoid quercetin to cultivations of the α1-antitrypsin (A1AT) producing human 
AGE1.HN.AAT cell line resulted in alterations of the cellular physiology and a remarkable improvement 
of the overall performance of these cells. In a first screening in 96-well plate format, toxicity and the effect 
of quercetin on the lactate/glucose ratio were analyzed. It was found that quercetin treatment reduced 
lactate/glucose ratio dose-dependently. An increase in culture longevity, viable cell density (160% of 
control), and A1AT concentration (195% of control) was observed in batch cultivation with 10 µM 
quercetin compared to control. Detailed analysis of quercetin effects on primary metabolism revealed 
dose-dependent alterations in metabolic fluxes. Quercetin addition resulted in an improved channeling of 
pyruvate into mitochondria accompanied by reduced waste product formation and stimulation of TCA 
cycle activity. The observed changes in cellular physiology can be explained by different properties of 
quercetin and its metabolites, e.g., inhibition of specific enzymes, oxidation of cytoplasmic and 
mitochondrial NADH resulting in reduced NADH/NAD+ ratio, and cytoprotective activity. The present 
study shows that addition of specific effectors to the culture medium represents a promising strategy for 
improving the cellular metabolic phenotype and the production of biopharmaceuticals. The provided 
results contribute, additionally, to an improved understanding of quercetin action on the metabolism of 
human cells. 
 
 
 
 
 
 
 
 
 
 
 
This chapter was submitted as 
Niklas J, Nonnenmacher Y, Rose T, Sandig V, Heinzle E. Quercetin treatment changes fluxes in the 
primary metabolism and increases culture longevity and recombinant α1-antitrypsin production in human 
AGE1.HN cells.  
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7.2 Introduction 
The human cell line AGE1.HN was specifically designed for the production of complex 
biopharmaceuticals requiring human-type glycosylation. One of these glycoproteins of interest is α1-
antitrypsin (A1AT) which is required in the clinic to treat patients suffering from A1AT deficiency. This 
hereditary disorder can result in lung emphysema and liver dysfunction (Kelly et al. 2010; Petrache et al. 
2009). The mortality risk can be significantly reduced by A1AT augmentation therapy (A1AT-Group 
1998), however, this therapy is very expensive and not cost-effective (Gildea et al. 2003) particularly as so 
far all licensed A1AT-products are only derived from human plasma (Karnaukhova et al. 2006). 
Production of recombinant A1AT in several hosts was not successful. However, A1AT produced from 
AGE1.HN cells is biologically active and has similar anti-inflammatory activity as commercial A1AT 
(Blanchard et al. 2011) showing that AGE1.HN is a suitable expression system. 
For further targeted improvement of the biopharmaceutical production in AGE1.HN, growth and 
metabolism of this cell line were analyzed in recent studies. In a first study of the metabolism and 
metabolic shifts of AGE1.HN during the cultivation, it was proposed that high substrate levels in the 
beginning of the cultivation might lead to energy spilling waste product formation (Niklas et al. 2011d). In 
a subsequent study, it was confirmed that reduced pyruvate load leads to improved metabolic efficiency 
and, ultimately, increased A1AT titers (Niklas et al. 2011b). Using detailed 13C tracer studies and 13C 
metabolic flux analysis, it was further revealed that mitochondrial pyruvate transport and the connectivity 
between TCA cycle and glycolytic metabolites is low during exponential growth in AGE1.HN (Niklas et 
al. 2011c). In summary, optimization of AGE1.HN’s metabolism towards improved metabolic efficiency 
and balanced substrate use should be performed to improve biopharmaceutical production in this cell line. 
The optimization of cellular metabolism concerning efficient use of nutrients represents an issue that was 
addressed in several mammalian production cells in the past. Altamirano et al. showed that the 
replacement of the substrates glucose and glutamine by the slowly metabolized compounds galactose and 
glutamate resulted in a very efficient metabolism with minimal formation of the waste products lactate and 
ammonium (Altamirano et al. 2000). Genetic engineering of the sugar transport was another strategy that 
was successfully applied to decrease sugar uptake and waste product formation increasing final cell 
concentration (Wlaschin and Hu 2007).  
Besides the modification of substrate availability and substrate concentrations and the targeted genetic 
engineering of producer cells, addition of specific substances having positive effects on growth, product 
titers, or specific productivity represents a very promising strategy for improving the cell culture process. 
It was reported that the addition of, e.g., DMSO, glycerol, or sodium butyrate can enhance the production 
of biopharmaceuticals in different mammalian cells (Cherlet and Marc 2000; Liu and Chen 2007; Oh et al. 
2005; Rodriguez et al. 2005). Despite an increase in specific productivity in many producers, treatment 
with these chemicals results usually in a reduced growth rate which can reduce the final product titer 
compared to untreated cells (Rodriguez et al. 2005). It is likely that other substances can increase 
metabolic efficiency and can be used as media additives to reduce waste product formation and improve 
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culture longevity and productivity. Recently, it was reported that verapamil can almost completely stop 
lactate production in HL-1 cells without noticeably influencing cell growth (Strigun et al. 2011a) which is a 
sought-after cellular phenotype in cell culture processes. 
In preceding work, we screened a number of compounds with a view to assessing their ability to increase 
metabolic efficiency or to improve α1-antitrypsin production in AGE1.HN cells. Quercetin was found to 
be one of the most promising candidates. This naturally occurring flavonoid, which is present in many 
plants, was reported to have many beneficial effects on human health, e.g., anti-tumor, anti-inflammatory, 
and anti-oxidant activity (Middleton et al. 2000). Additionally, quercetin was found to inhibit a number of 
enzymes and to modify important physiological parameters related to primary metabolism. It was reported 
that lactate dehydrogenase, pyruvate kinase (Grisolia et al. 1975), malate dehydrogenase (Seddon and 
Douglas 1981), or sugar transport (Martin et al. 2003; Salter et al. 1978; Shisheva and Shechter 1992) are 
inhibited by quercetin. Since the improvement of metabolic efficiency and a better balanced substrate use 
were optimization targets defined for AGE1.HN in recent publications (Niklas et al. 2011b; Niklas et al. 
2011c; Niklas et al. 2011d), the reported beneficial and inhibitory activities of quercetin might be 
appropriate for improving the metabolism in AGE1.HN. 
In this study, we analyze in detail the effects of quercetin on growth, metabolism, and α1-antitrypsin 
production in AGE1.HN. The results obtained are, on the one hand, useful for an improvement of 
biopharmaceutical production in mammalian cells and, on the other hand, important for an improved 
understanding of the effect of quercetin on the metabolism in human cells and on human health in 
general. 
7.3 Material and methods 
7.3.1 Cell line and cultivation 
The α1-antitrypsin (A1AT) producing cell line AGE1.HN.AAT® (ProBioGen AG, Berlin, Germany) 
originates from primary human brain cells which were immortalized and engineered using selected 
adenoviral genes. The A1AT gene in this cell line is driven by a human CMV/EF1 hybrid promoter 
(ProBioGen AG). A more detailed description of the cells can be found in recent publications (Niklas et 
al. 2011b; Niklas et al. 2011c; Niklas et al. 2011d). Cultivations were carried out in an incubator supplied 
with a shaking unit (Innova 4230, New Brunswick Scientific, Edison, NJ, USA; 2 inches orbit) at 37°C and 
5% CO2 using 125 ml shake flasks (Corning, NY, USA) and serum-free 42-Max-UB medium (Teutocell 
AG, Bielefeld, Germany). 
7.3.2 Analytical methods 
Cell counting was performed using an automated cell counter (Countess, Invitrogen, Karlsruhe, 
Germany). Toxicity screening was performed using respiration measurements in 96-well OxoPlates 
(PreSens GmbH, Regensburg, Germany (Deshpande et al. 2005; John et al. 2003)) applying the equipment 
and procedures as described in recent publications (Niklas et al. 2009; Noor et al. 2009). A1AT (α1-
Chapter 7 Quercetin treatment changes primary metabolism in AGE1.HN 
 124 
antitrypsin) concentration was measured as described recently (Niklas et al. 2011b) using an activity assay 
based on the inhibition of trypsin by A1AT. Concentrations of extracellular metabolites (sugars, organic 
acids, amino acids) were measured using different HPLC methods (Kromer et al. 2005; Niklas et al. 2009). 
7.3.3 Screening in 96-well plates 
Toxicity was assessed using respiration measurements in 96-well plates. Cells from the preculture were 
transferred into Falcon tubes, centrifuged (500 1/min, 5 min, 20°C, Labofuge 400R Function Line, 
Heraeus Instruments, Hanau, Germany), the supernatant discarded, and the pellet resuspended in 
medium. After cell counting and appropriate dilution, 198 µl of the cell suspension were pipetted into 
each well of the 96-well plate having a final cell density of 0.4 × 106 cells/ml. 100× stock solutions of the 
compounds were prepared in DMSO and 2 µl of the respective stock solution was finally added to the 
cells. Respiration was monitored for 24 h using a fluorescence reader (BMG Labtechnologies, Offenburg, 
Germany) with shaking unit (300 1/min) set at 37°C and enclosed in a chamber ensuring 5% CO2 supply. 
After the respiration measurement, the cell suspension was centrifuged (8,000 1/min, 5 min, 20°C, 
Biofuge pico, Heraeus Instruments, Hanau, Germany), the supernatant transferred into fresh tubes, and 
frozen for later analysis of extracellular metabolites. EC50 (effective concentration that elicits a half-
maximal reduction of respiration) for quercetin was calculated as described recently (Niklas et al. 2009). 
7.3.4 Study of effects of quercetin on growth, metabolism, and α1-antitrypsin 
production in AGE1.HN 
The cells were taken from the preculture and centrifuged (500 1/min, 5 min, 20°C, Labofuge 400R 
Function Line, Heraeus Instruments, Hanau, Germany). The supernatant was discarded and the pellet 
resuspended in fresh medium. After cell counting the cells were seeded into 50 ml bioreactor filter tubes 
(TPP, Trasadingen, Switzerland). Quercetin (CAS 117-39-5, Sigma-Aldrich, Steinheim, Germany; stock 
solution 1 mM in DMSO) was added to a final concentration of 10 µM. The control cultivation was 
performed with the same final DMSO concentration (1% v/v). Samples were taken every day. Cell 
counting was performed and extracellular metabolite concentrations as well as A1AT concentrations were 
measured in the culture supernatants. 
7.3.5 Study of dose-dependent effects of quercetin on AGE1.HN 
The experiment was started as described in the foregoing study having also the same materials. Tested 
quercetin concentrations were 0.1, 1, and 10 µM. 100× stock solutions were prepared in DMSO and 
added to the cultures. The control cultivation without quercetin was carried out with 1% (v/v) DMSO in 
the medium as it was also present in the quercetin cultivations. Growth was monitored for all cultivations. 
A1AT and extracellular metabolite concentrations in the culture supernatants were measured. 
Chapter 7 Quercetin treatment changes primary metabolism in AGE1.HN 
 125 
7.3.6 Metabolic flux analysis 
Metabolic fluxes were calculated using Matlab R2007b (The Mathworks, Natick, MA, USA) applying 
stationary metabolic flux analysis using metabolite balancing as described in literature (Niklas and Heinzle 
2011; Niklas et al. 2011d; Stephanopoulos et al. 1998). The stoichiometry of the applied metabolic 
network model (Fig. 7-1) for the AGE1.HN.AAT cell line is given as stoichiometric matrix in the 
supplementary material (Table S1). 
 
 
Fig. 7-1 Metabolic network model for metabolic flux analysis in AGE1.HN.AAT. The stoichiometric matrix of the 
model is given in Table S1 of the supplementary material. Dashed lines indicate fluxes to biomass. Abbreviations: 
A1AT α1-antitrypsin, ER endoplasmic reticulum, Golgi Golgi apparatus, BM biomass, Glc glucose, Gal galactose, Lac 
lactate, Pyr pyruvate, G6P glucose 6-phosphate, P5P pentose 5-phosphate, F6P fructose 6-phosphate, GAP 
glyceraldehyde 3-phosphate, AcC acetyl coenzyme A, Cit citrate, AKG α-ketoglutarate, SuC succinyl coenzyme A, 
Fum fumarate, Mal malate, OAA oxaloacetate, TA transamination flux (TA = v52+v55+v61+v62+2v63+v67+v70+v71), Glc-
NAc N-Acetylglucosamine, Man mannose, Fuc fucose, Neu5Ac N-Acetylneuraminate, THF tetrahydrofolate, C1THF 
methylenetetrahydrofolate, standard abbreviations for amino acids. Indices ex extracellular, m mitochondrial ER 
localization in the ER or Golgi apparatus. 
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7.4 Results 
7.4.1 Toxicity- and metabolic screening of effectors in 96-well plates 
A number of chemicals influencing cellular glucose uptake, as reported in literature, were tested in 
different concentrations concerning toxicity on AGE1.HN.AAT cells (not shown). Additionally, 
metabolite profiling was carried out to identify promising candidates as well as the best concentrations 
fulfilling objectives that were defined as follows: (i) no toxic effects, (ii) reduction of lactate/glucose ratio. 
From a number of candidates quercetin was one of the most promising substances. In a respiration assay, 
an EC50 value of 48 µM (Fig. 7-2A) was observed. In the metabolite analysis, reduction of lactate/glucose 
ratio was detected for all tested concentrations showing a dose dependent decrease of the ratio (Fig. 7-2B). 
 
 
Fig. 7-2 Screening in 96-well plate. A. Concentration response curve for quercetin on AGE1.HN.AAT cells in 
respiration assay after 24 h (n=3). The dissolved oxygen (pO2) is given as % air saturation. B. Lactate/glucose ratio 
(∆Lac/∆Glc) after 24 h in AGE1.HN.AAT cells treated with different quercetin concentrations 
7.4.2 Quercetin treatment increases culture longevity, maximal cell density, and 
A1AT production 
Cultivations of AGE1.HN.AAT cells were carried out using selected subtoxic concentrations of the 
effectors as identified in the toxicity and metabolite screening. For quercetin, a concentration of 10 µM 
was chosen which was clearly below EC50 value showing at the same time a reduction in the Lac/Glc 
ratio. It was observed that the culture longevity was increased in the quercetin cultivation (Fig. 7-3). The 
maximal viable cell density that was reached during the process was much higher compared to the control 
with maximal viable cell densities of 5.5 × 106 cells/ml and 3.4 × 106 cells/ml for treated cells and control, 
respectively. The concentration of the product A1AT was 0.76 g/l at the end of the quercetin cultivation 
compared to an A1AT concentration of 0.39 g/l in the control (Fig. 7-4).  
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Fig. 7-3 Growth profile of AGE1.HN.AAT cells cultured without (control) and with 10 µM quercetin. TCD total 
cell density, VCD viable cell density. 
 
 
Fig. 7-4 Time course of α1-antitrypsin (A1AT) in the control cultivation and in the cultivation with 10 µM quercetin 
in the medium. Same experiment as in Fig. 7-3. 
 
Chapter 7 Quercetin treatment changes primary metabolism in AGE1.HN 
 128 
7.4.3 Changes in extracellular metabolic profiles upon quercetin treatment 
Time courses of extracellular metabolites during the cultivations are depicted in Fig. 7-5. Profiles for most 
metabolites were similar in the exponential growth phase until 120 h. Total alanine production was higher 
in the first 120 hours of the cultivation in quercetin treated cells. Lactate production as well as glucose 
uptake was only slightly reduced in the quercetin cultivation. After glutamine depletion at ~140 h, alanine 
was taken up in both cultivations. Glutamate was only taken up in the quercetin cultivation. In the control 
culture, reduced growth and decreasing viability were observed after glutamine depletion explaining the 
low substrate uptake. In contrast, increased culture longevity in the quercetin cultivation led to further 
consumption of substrates. Glucose and amino acids, like glutamate and aspartate, were completely 
consumed. Uptake of branched chain amino acids (e.g., Ile, Fig. 7-5) and asparagine remained high after 
glutamine was consumed.  
 
 
Fig. 7-5 Time courses of extracellular metabolites during the cultivations. Same experiment as in Figs. 7-3 and 7-4. 
Glc glucose, Lac lactate, Pyr pyruvate, standard abbreviations for amino acids 
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7.4.4 Quercetin treatment leads to metabolic flux changes in the beginning of the 
cultivation 
For a detailed understanding of the influence of quercetin on the central metabolism in this cell line, 
metabolic flux analysis was carried out for different metabolic phases observed during cultivation. We 
divided the cultivations into the following phases. Phase 1 (0-72 h) is characterized by highest waste 
product formation and ends at 72 h where also pyruvate is consumed. Phase 2 (72-144 h) starts with the 
pyruvate depletion in the medium and ends when glutamine is consumed.  
The most important fluxes calculated by stationary metabolic flux analysis for the different phases are 
depicted in Fig. 7-6. 
In phase 1, the glucose uptake rate and glycolytic rates (e.g., v32 and v33) were reduced upon quercetin 
treatment (86% of control) accompanied by reduced production rates for the waste metabolites lactate 
(83% of control, v3) and alanine (84% of control, v5). Flux of cytosolic pyruvate into TCA cycle was 
increased in the quercetin treated cells (231% of control, v34). The increased flux through pyruvate 
dehydrogenase was supported by higher anaplerotic fluxes that were additionally feeding into TCA cycle 
intermediates. Flux from glutamate to α-ketoglutarate (v58 and TA) was higher in quercetin treated cells 
which was mainly accomplished by a reduction of the production and secretion of excess glutamate and 
proline (v10 and v19). Degradation of branched chain amino acids (Ile, v61; Leu, v62; Val, v71) to TCA cycle 
intermediates additionally contributed to replenishing the TCA cycle metabolite pools. In summary, 
metabolic efficiency, i.e., reduced waste product formation and increased TCA cycle activity, was increased 
by quercetin treatment. 
In phase 2, metabolism of control and treated cells was almost identical in this experiment (Fig. 7-6). 
7.4.5 Dose-dependent effects of quercetin on central metabolism in AGE1.HN 
In order to verify the metabolic effects that were found for the cultivation with 10 µM quercetin and to 
analyze which of these effects observed in the exponential growth phase are dose-dependent, we 
performed additional cultivations with different quercetin levels. Growth parameters and time courses of 
extracellular metabolites in the growth phase were measured and metabolic fluxes were calculated. The 
most important fluxes selected are shown in Fig. 7-7. It was observed that the glucose uptake rate and 
glycolytic rates (e.g., v32 and v33) were slightly reduced compared to control (84-90% of control) at all 
applied quercetin concentrations ranging from 0.1 µM to 10 µM. Production of waste metabolites (lactate, 
v3; alanine, v5; glutamate, v10; proline, v19) was decreased with increasing quercetin concentrations. In 
particular, lactate production rate (v3) was dose-dependently decreased from 87% of control on 0.1 µM 
quercetin to 79% and 74% of control on 1 µM and 10 µM quercetin treatment, respectively. According to 
the reduced channeling of pyruvate carbons to waste metabolites, flux of pyruvate into TCA cycle (v34) 
was dose-dependently increased with increasing quercetin treatment (107%, 140%, 227% of control on 0.1 
µM, 1 µM, and 10 µM quercetin, respectively). Anaplerotic fluxes feeding the TCA cycle were higher when 
quercetin was applied as observed in the experiment described before (Fig. 7-6). 
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Fig. 7-6 Metabolic flux distribution of AGE1.HN.AAT cells in different growth phases and upon different 
treatment. The most important fluxes selected are depicted. Same experiment as in Figs. 7-3, 7-4, and 7-5. Growth of 
AGE1.HN.AAT was divided into distinct metabolic phases and fluxes were calculated for each phase. Phase 1 is 
ranging from 0-72 h, phase 2 from 72-144 h. C1, fluxes in phase 1 for the control cultivation; Q1, fluxes in phase 1 
for the quercetin cultivation; C2, fluxes in phase 2 for the control cultivation; Q2, fluxes in phase 2 for the quercetin 
cultivation. Flux numbers and abbreviations are defined in Fig. 7-1 (metabolic network model) and in Table S1 of the 
supplementary material. BCA branched chain amino acid. 
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Fig. 7-7 Dose-dependent effects of quercetin on metabolic fluxes in AGE1.HN.AAT. Selected fluxes during the 
exponential growth phase are depicted. C, control cultivation; Q 0.1, cultivation with 0.1 µM quercetin; Q 1, 
cultivation with 1 µM quercetin; Q 10, cultivation with 10 µM quercetin. Flux numbers and abbreviations are defined 
in Fig. 7-1 (metabolic network model) and in Table S1 of the supplementary material. BCA branched chain amino 
acid. 
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7.5 Discussion 
At the start of this study, we analyzed the toxicity of quercetin using a respiration assay (Noor et al. 2009) 
to determine the subtoxic concentration range. This procedure is similar to the one which was also applied 
recently to identify subtoxic effects of drugs (Niklas et al. 2009). The EC50 for quercetin which was 48 µM 
is similar to literature values for other human cells. In human lung embryonic fibroblasts and in human 
umbilical vein endothelial cells a 50% lethal concentration of 303 µM and 61 µM was reported, 
respectively (Matsuo et al. 2005). A 50% inhibitory concentration for inhibition of proliferation of 178 µM 
was found for quercetin on pancreatic tumor cells (Harris et al. 2011).  
The reported inhibitory activity of quercetin on cellular sugar transport (Martin et al. 2003; Salter et al. 
1978; Shisheva and Shechter 1992) and, particularly, the inhibition of GLUT1 (Martin et al. 2003) as well 
as the inhibition of lactate dehydrogenase (Grisolia et al. 1975) were promising properties and the reason 
why we decided to test this compound on AGE1.HN. In recent studies on primary metabolism of 
AGE1.HN cells under various conditions, one of the conclusions was that a reduction of substrate uptake 
and an improvement of the connectivity between glycolysis and TCA cycle are promising optimization 
targets (Niklas et al. 2011b; Niklas et al. 2011c; Niklas et al. 2011d). It was suggested that changing these 
cellular properties might finally lead to higher metabolic efficiency and improved production. In the first 
screening of quercetin, we observed a dose dependent reduction of the lactate/glucose ratio (Fig. 7-2B) 
indicating an influence of quercetin on glucose transport or intracellular lactate production as reported in 
literature (Grisolia et al. 1975; Martin et al. 2003). 
In the cultivation of AGE1.HN cells with 10 µM quercetin, a remarkable increase in cell number and 
product titer at the end of the cultivation was observed. This shows that quercetin has beneficial effects 
for biopharmaceutical production in AGE1.HN. In the flux analysis, it was observed that quercetin 
treatment was improving the metabolic phenotype especially at the beginning of the cultivation (Fig. 7-6). 
While glucose and lactate uptake fluxes slightly decreased, the flux of pyruvate carbons into TCA cycle 
doubled. The fact that fluxes were mostly different in phase 1 of the cultivation points to a direct 
influence of quercetin at the beginning of the cultivation. It is possible that quercetin is rapidly taken up 
and metabolized by the cells. Boulton et al. examined the elimination of quercetin in HepG2 cells 
(Boulton et al. 1999). They observed that quercetin is rapidly metabolized. Quercetin itself and the 
different quercetin metabolites might have specific biological actions. This was also confirmed in other 
studies in which bioactivity and, in particular, cytotoxicity and cytoprotective effects of quercetin and its 
major in vivo metabolites were investigated (Spencer et al. 2003). Since it would be desirable to prolong the 
positive effect of quercetin on metabolic efficiency observed at the beginning of the cultivation, further 
studies investigating the metabolic effect of controlled quercetin feeding during cultivation would be 
interesting. However, as observed in this study, the improved metabolic phenotype and increased culture 
longevity for AGE1.HN upon a single dose of quercetin at the cultivation start was already remarkable.  
The observed dose-dependent effect of quercetin on specific metabolic fluxes, i.e., decreased waste 
product formation rates and increased flux into TCA cycle, might be caused by an inhibitory effect of 
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quercetin on lactate dehydrogenase (Grisolia et al. 1975) or by other effects that this compound or derived 
metabolites exert inside the cell. It has been shown that quercetin can be transported and accumulated in 
mitochondria preventing mitochondrial damage (Fiorani et al. 2010), but it was also reported that active 
forms of this compound can oxidize mitochondrial as well as cytosolic NADH (Buss et al. 2005; Chan et 
al. 1999; Gasparin et al. 2003a; Metodiewa et al. 1999). This leads to a reduced NADH/NAD+ ratio and 
shifts the cellular conditions to a more oxidized state. In the isolated perfused rat liver, it was shown that 
quercetin stimulates TCA cycle activity which is probably caused by an increased mitochondrial NAD+ 
availability (Buss et al. 2005). Gasparin et al. reported that quercetin inhibits lactate production and 
decreases cytosolic NADH/NAD+ ratio (Gasparin et al. 2003b). Reduced lactate production was also 
observed in our study on neuronal AGE1.HN cells. An increased oxidation of cytosolic NADH and, 
therefore, increased NAD+ availability which can be induced by quercetin could lead to a shift in the 
reaction equilibrium of the lactate dehydrogenase catalyzed conversion in the direction of pyruvate. The 
cellular metabolism has to adapt to the situation which can be accomplished by increased channeling of 
pyruvate into mitochondria as observed for AGE1.HN upon quercetin treatment. This higher flux into 
mitochondria and, finally, TCA cycle might be even facilitated by specific changes in mitochondrial 
physiology induced by quercetin. Mitochondrial oxidation of NADH can reduce the efficiency of the TCA 
cycle and stimulate its overall activity since higher activity is necessary to provide the same energy level. 
This would consequently result in an increased metabolite demand for the TCA cycle and higher 
anaplerotic fluxes. Interestingly, this was exactly what was observed for AGE1.HN. Flux of pyruvate into 
mitochondria and into TCA cycle was increased in quercetin treated AGE1.HN cells accompanied by an 
increase in anaplerotic fluxes feeding the cycle.  
The increase in culture longevity could be on the one hand due to the improved metabolism with reduced 
waste product formation. On the other hand, it is also possible that the reported cytoprotective activity of 
quercetin plays an important role in prolonging cell growth in the cultivation process keeping the viability 
high. Many studies reported protective effects of quercetin and excellent reviews explain the various 
functions of flavonoids including the flavonol quercetin in detail (Middleton et al. 2000; Ren et al. 2003). 
It was also shown that quercetin can be taken up and can accumulate in mitochondria and might help to 
prevent mitochondrial damage (Fiorani et al. 2010). Ishige et al. found that flavonoids can protect 
neuronal cells from oxidative stress by different mechanisms (Ishige et al. 2001). Quercetin alters 
glutathione metabolism and acts as antioxidant at the same time. This protective effect of quercetin might 
be another reason for the increased culture longevity of the neuronal AGE1.HN cell line when the 
compound is added to the medium. 
7.6 Concluding remarks 
In summary, we found that quercetin addition to the culture medium resulted in many beneficial effects 
on cultivation of the neuronal AGE1.HN cell line. An increase in culture longevity, viable cell density, and 
final A1AT titer was observed when quercetin was added to the medium accompanied by improved 
channeling of pyruvate into mitochondria having red
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cycle activity. We postulate that these effects might be induced by (i) inhibitory action of quercetin on 
specific enzymes, (ii) quercetin induced oxidized state with reduced NADH/NAD+ ratio, and 
(iii) cytoprotective activity. Testing of quercetin on other mammalian cells and testing of other flavonoids 
would be very interesting and might lead to the discovery of further interesting media additives for cell 
culture processes. The provided results in this study contribute, additionally, to an improved 
understanding of the effect of quercetin on human cells in general. 
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8 Outlook and future prospects 
8.1 Improvement of biopharmaceutical production in the AGE1.HN cell line 
The results presented in this thesis provide detailed insights into the primary metabolism of AGE1.HN 
and its adaptation to changing conditions. By interpreting the data, we were able to develop several ideas 
for improving the cell line or the cultivation conditions. Selected strategies, e.g., reduced substrate levels, 
were also tested in this thesis and the impact is described. Further genetic engineering of selected targets 
in AGE1.HN might lead to substantial improvement of the performance of this cell line. Generally, 
various cellular characteristics can be associated with high productivity (Seth et al. 2006), however, only 
specific engineering might be appropriate for a particular cell line.  
We think that one interesting strategy for improving AGE1.HN may be increasing the connectivity of 
TCA cycle and glycolysis, as supported by the results presented in chapters 2-4. This might help lower 
overflow metabolism by reducing the cytosolic pyruvate load and increasing TCA cycle activity. As 
discussed earlier in the thesis, this strategy implies that additionally produced NADH/FADH2 can be used 
and that oxidative phosphorylation activity is not the bottleneck. As shown in chapter 7, addition of 
quercetin resulted in reduced lactate production and increased channeling of pyruvate into mitochondria. 
However, we suggest that the increased TCA cycle activity might have been facilitated by prooxidant 
activity of quercetin which reduces NADH/NAD+ ratio. The energy level might have been similar in 
control and quercetin treated cells since cell growth was also similar. The effect of genetically modified 
connectivity between glycolysis and TCA cycle in AGE1.HN has still to be tested. Overexpression of a 
pyruvate carboxylase gene can be a promising strategy to increase pyruvate flux into mitochondria. This is 
further supported by the fact that we found low intercompartmental pyruvate transport and a high 
channeling of pyruvate carbons via oxaloacetate into TCA cycle (chapter 3).  
Improving the substrate use and decreasing the energy spilling can also be accomplished by a reduction of 
substrate uptake, in an ideal scenario down to the uptake rate that is just needed for growth and product 
formation. This issue is discussed in detail in chapter 4, where we were able to show that a reduction in 
substrate levels improves metabolic efficiency. In fed-batch processes, low concentrations of the main 
carbon sources, i.e., glucose and glutamine, can be applied which might force the cellular metabolism to 
operate economically. Other possibilities include specific inhibition of the substrate uptake, e.g., by using 
inhibitors, genetic engineering of the cellular sugar transport (Wlaschin and Hu 2007), or specific 
alterations in the medium (Altamirano et al. 2000). 
Resistance to high ammonia concentrations or lowering the ammonia formation during the cultivation are 
issues that have to be addressed mainly in fed-batch processes in which a high cell density and high 
ammonia concentration are reached. The adaptation of the cellular metabolism to increased ammonia 
stress is presented in detail in chapter 5. Generally, ammonia formation during fed-batch cultivation of 
AGE1.HN cells can be fairly well controlled through low feeding of glutamine. Therefore, engineering of 
AGE1.HN towards lower ammonia formation and increased ammonia fixation should not have priority 
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over the other strategies discussed in this chapter. However, if this engineering direction is of interest, 
specific manipulations in the amino acid metabolism might be promising. Ammonia formation could be 
lowered through increased fixation of free ammonia and storage in extracellular amino acids. 
Downregulation of the activity of amino acid consuming pathways and upregulation of the activity of 
transaminases producing amino acids would be a strategy leading to lowered ammonia formation in the 
process. 
Engineering and improvement of protein secretion is another possibility of improving AGE1.HN. 
Shifting the cellular phenotype closer to one of a professional secretory cell might be accomplished by 
targeted genetic modifications. In earlier work on regulators of the unfolded protein response, 
phospholipid biosynthesis, and related ER biogenesis, it was shown, e.g., that overexpression of a global 
regulator of the unfolded protein response, i.e., X-box binding protein 1 (XBP-1), resulted in ER 
expansion and increased protein synthesis (Ku et al. 2008; Shaffer et al. 2004; Sriburi et al. 2004; Tigges 
and Fussenegger 2006). Similar modifications could also be performed in parental AGE1.HN cells which 
might lead to a new, improved parental cell line with better protein secretion properties and later to better 
producers. Another direction that would be interesting to follow may be the feeding of specific media 
additives with high lipid/phospholipid content. This might also facilitate ER biogenesis and, eventually, 
protein production and secretion. 
8.2 Improved metabolic flux studies in mammalian cells 
The available methods for metabolic flux analysis in mammalian cells can be applied to provide fascinating 
insights into numerous biological systems. However, there is still much room for improvement. The 
information about genomic sequences and the increasing availability of reconstructed genome scale 
metabolic networks tremendously improve metabolic flux studies and help to set up own models, also, for 
13C flux analysis. However, even if the reconstructed metabolic networks rely on accurate genomic 
information combined with a huge amount of published knowledge, it may still be necessary to study the 
network topology of a biological system of interest separately, since some genes might not be expressed 
and the expression of numerous genes might differ, e.g., caused by epigenetic mechanisms. To create a 
thorough knowledge of active enzymes and pathways, different methods can be applied, e.g., in vitro 
enzyme activity measurements, tracer studies, or proteomic analyses. The acquired information may also 
be combined to set up a relevant metabolic network model which comes as close as possible to the real 
situation. The fact that mammalian cells are compartmentalized is another issue so far only rudimentarily 
considered in metabolic flux studies. However, especially detailed 13C metabolic flux analysis has the 
potential to unravel fluxes even in a system with several different compartments having different 
intracellular pools of the same metabolite. The development of new and improved methods makes it 
possible to determine enzyme activities in different compartments (Niklas et al. 2011a) and future 
methods might even enable to measure intracellular metabolite concentrations and their labeling in 
different cell compartments. These improved methods can facilitate in-depth insights into fluxes in and 
between different cellular compartments and in the underlying regulation (Wahrheit et al. 2011). The 
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measurement of intracellular metabolite concentrations as well as the labeling patterns of intracellular 
metabolites seems well established for adherent cells (Ahn and Antoniewicz 2011; Hofmann et al. 2008). 
For suspension cells, this is still an open question as it is doubtful whether the published methods for 
intracellular metabolite measurements are really robust enough to permit realistic studies uncorrupted by 
errors resulting, e.g., from insufficient quenching, cell leakage, or mixing of intracellular metabolites with 
extracellular species. Different results reported by different groups are confusing and hamper the choice 
of method (Dietmair et al. 2010; Sellick et al. 2011; Volmer et al. 2011). However, reliable methods for 
intracellular metabolite extraction would greatly contribute to obtaining further detailed insights into 
cellular metabolism of industrially relevant suspension cells by metabolic flux analysis. Another very 
interesting advance would be the aforementioned possibility of measuring metabolites and their labeling 
even in different cellular compartments. Suitable methods of measuring intracellular metabolite 
concentrations in different compartments are so far mainly established for plants (Krueger et al. 2011; 
Ratcliffe and Shachar-Hill 2001). Selective permeabilization (Niklas et al. 2011a) and the development of 
microfluidic devices (Wurm et al. 2010) might be promising starting points for developing methods for 
making this possible in suspension-cultured mammalian cells. Transient 13C flux analysis represents a very 
promising approach to obtain flux estimates on a very short time scale and is, theoretically, well suited to 
characterize fluxes of mammalian cells in batch and fed-batch processes (Maier et al. 2008). However, 
reliable data of concentrations and labeling of intracellular metabolites would be required which is still 
challenging for suspension-cultured cells as discussed before and the computational and modeling part is 
much more sophisticated compared to the stationary 13C based flux analysis methods.   
8.3 Application of the presented metabolic flux analysis methods 
The metabolic flux analysis methods that are described in this thesis can be applied to answer scientific 
questions related to cell metabolism not only in the biotechnological field but also in medical, 
toxicological, and pharmacological research.  
Improved understanding of the metabolism of cell lines in cell culture processes should be a desirable goal 
since it can speed up and simplify the process development substantially. In general, the important 
variables in a cell culture process are cell line, media, and process parameters, and all influence 
productivity and yield. Ultimately, their optimal interplay determines the level of performance. Optimized 
processes can be achieved through a system-wide understanding, e.g., accomplished by integration of 
different omics data (Schaub et al. 2011) in which metabolic flux data plays an important role. This 
understanding and the ability to predict the consequences of specific perturbations on cell physiology and 
cell culture process can reduce time-consuming “trial and error-” strategy still commonly employed in the 
development of bioprocesses. Fluxome data for various conditions can be combined with other omics 
data to provide in-depth insights into cellular physiology and its regulation. 
The combined analysis of calculated flux changes over time with measured changes of in vitro enzyme 
activities during cultivation represents an interesting application providing insights into the regulation of in 
vivo enzyme activities. Dynamic flux changes can be calculated by using the presented time resolved flux 
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analysis method (chapter 2) and subcellular enzyme activities can be determined, e.g., by applying the 
recently developed selective permeabilization methodology (Niklas et al. 2011a). 
The dynamic flux analysis method described in chapter 2 may also be applied for studying dynamic 
responses of the cellular metabolism to specific perturbations. In this case, metabolite measurements 
should be performed in short time intervals ensuring reliable monitoring of the metabolic response. 
Interesting applications are, e.g., the dynamic response of the cellular metabolism to specific effectors or 
the alterations in the metabolism upon treatment with chemicals or drugs. The application of a time 
resolved method may be appropriate for many experimental setups in which the metabolism changes 
dynamically over time and metabolic steady state conditions are not fulfilled.  
For detailed insights into cellular metabolism at metabolic steady state, the application of (i) 13C tracers for 
monitoring the fate and distribution of substrate carbons in the cellular metabolism and (ii) 13C flux 
analysis using multiple parallel labeling experiments is well suited as presented in chapter 3. Tracing of 
substrate carbons using 13C labeled substrates can also be performed in situations in which the metabolism 
changes. In particular, the monitoring of concentration changes of single mass isotopomers is in this case 
very useful and specific information can be obtained depending on the tracer. Inherent challenges that 
limit the applicability of stationary 13C metabolic flux analysis on suspension-cultured mammalian cells are 
attaining metabolic steady state and obtaining reliable and sufficient labeling information. The 
measurement of intracellular metabolite labeling would be desirable but the available methods of 
separating cells and medium as well as of quenching are not validated enough and are also not yet 
routinely applied. Measurement of the labeling in secreted, extracellular metabolites is, therefore, still a 
good option. However, industrially relevant media are very complex and also usually contain all amino 
acids severely reducing the number of extracellular metabolites of which the labeling information can be 
directly applied for stationary 13C metabolic flux analysis, as discussed in chapter 3. Parallel labeling 
experiments and measurement of the labeling in extracellular metabolites that are not present at the 
beginning of the cultivation, e.g., lactate, is in this case a solution. Since lactate is derived from the central 
metabolic hub, i.e. pyruvate, its labeling is very valuable for 13C flux analysis. The missing labeling 
information from other metabolites can be compensated for by applying parallel labeling experiments with 
multiple tracers, significantly increasing the information and reducing the uncertainties in calculated flux 
estimates. This approach has also been applied by Henry and colleagues to analyze the metabolism in 
HEK-293 cells (Henry and Durocher 2011; Henry et al. 2011).  
The presented metabolic flux analysis methods and adapted versions of the metabolic network models 
have already been applied in additional studies. In particular, stationary 13C flux analysis was well suited to 
unravel drug induced alterations in the central metabolism of HL-1 cells (Strigun et al. 2011a; Strigun et al. 
2011b).  
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Summary 
There is a growing recognition that systems biology studies combining large sets of experimental data with 
theoretical modeling can contribute tremendously to our understanding of how biological systems 
function. This integrative strategy can also be applied to improve mammalian cell culture processes based 
on a thorough understanding of cellular physiology and its regulation. The integration of different omics 
data and the development of integrated models of production cells might make it easier to predict how 
cells perform under varying conditions and to design optimized cell culture processes and cell lines in the 
future. This thesis focused on generating a detailed quantitative description of the primary metabolism of 
the novel human production cell line AGE1.HN with the aim of applying the acquired knowledge to 
improve biopharmaceutical production. To this end, experimental methods were developed and 
established, experimental data sets were generated, different methods for metabolic flux analysis including 
computational tools were developed and established, metabolic network models were set up, and 
metabolic fluxes were calculated and analyzed for various conditions. Overall, this thesis contains a broad 
and deep characterization of cell physiology and primary metabolism of the human cell line AGE1.HN 
and highlights future prospects for improved biopharmaceutical manufacturing. The main findings 
obtained and the conclusions drawn from the various studies can be summarized as follows. 
The metabolism of mammalian cells in a cell culture process usually changes over time by adapting to 
different environmental conditions. Analyzing and understanding these metabolic dynamics is important 
for a targeted optimization of the process conditions or the production cell line. Metabolism of 
AGE1.HN and metabolic shifts during batch cultivation were quantitatively characterized in the study 
described in chapter 2. Stationary metabolic flux analysis was applied for calculating mean fluxes for 
distinct metabolic phases. Additionally, a time resolved flux analysis method was developed which makes 
describing metabolic flux changes over time possible. This method represents a valuable tool to support 
the development of cell culture media and processes in the future. For the AGE1.HN cell line, it was 
found that the primary metabolism switched from an inefficient overflow metabolism at the beginning of 
the cultivation to a very efficient metabolism with low energy spilling during the batch process. It was 
concluded that the high substrate levels result in a high channeling of pyruvate to lactate. This metabolic 
inefficiency might be improved, e.g., by the reduction of substrate levels or by genetic engineering.  
Detailed insights into the channeling of metabolite carbons and into the metabolic fluxes during overflow 
metabolism were obtained by applying 13C tracer experiments and 13C metabolic flux analysis. The data are 
presented in chapter 3. The different tracer experiments made possible the unraveling of metabolic 
connections. Flux from TCA cycle metabolite carbons to glycolytic metabolites was observed. 
Additionally, we found that lactate and alanine originate from the same pyruvate pool, which is in contrast 
to certain published hypotheses. The applied 13C metabolic flux analysis approach, in which the data from 
parallel tracer experiments were combined, proved effective in estimating fluxes in the applied 
compartmented metabolic network for AGE1.HN. We found that pentose phosphate pathway activity 
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was low being just around 2 % of the glycolytic flux. This might be compensated for by high malic 
enzyme flux producing NADPH. Direct transport of pyruvate into mitochondria was almost zero. The 
pyruvate carbons were mainly channeled via oxaloacetate into mitochondria entering the TCA cycle, 
which was mainly fed via α-ketoglutarate and oxaloacetate during the overflow metabolism phase 
investigated. The applied 13C flux analysis method allows a detailed determination of metabolic fluxes in 
the primary metabolism of mammalian cells and can be used for studying related biological questions. In 
order to improve metabolic efficiency in the AGE1.HN cell line, engineering strategies focusing on 
improved metabolite transfer between cytosolic and mitochondrial pyruvate pools could be applied 
accompanied by improved control and targeted reduction of substrate availability and uptake.  
The metabolism in standard batch processes was investigated in the studies presented in chapters 2 and 3. 
As discussed in chapter 2, the metabolism of AGE1.HN switched from an inefficient metabolic state with 
high waste product formation to a very efficient metabolic state with favorable flux distribution during the 
cultivation. It was proposed that the reduction in substrate levels including pyruvate depletion might be 
responsible for this metabolic shift. However the question was raised: what is the direct adaptation of the 
metabolism upon perturbation with different substrate load? Understanding the metabolic response of 
AGE1.HN to various substrate levels was the issue addressed in chapter 4. The adaptation of the 
metabolism to varying pyruvate and glutamine concentrations was investigated using full factorial design. 
Correlations between changed levels of these two metabolites and several other metabolic parameters 
were found. One of the most interesting findings was the increasingly inefficient substrate use 
accompanied by reduced cell growth when the pyruvate level in the medium was increased. In different 
fed-batch cultivations of an α1-antitrypsin producing AGE1.HN cell line, it was observed that the highest 
viable cell density and product titer were reached when the pyruvate load was minimized, which was 
accomplished by maintaining low glucose level and no feeding of pyruvate. By using metabolic flux 
analysis, we were able to show that reduced intracellular pyruvate load resulted in lower waste product 
formation and higher metabolic efficiency. The higher sensitivity to high pyruvate load and different 
adaptation of AGE1.HN compared to, e.g., CHO cells might be caused by the generally lower activity of 
enzymes involved in pyruvate metabolism, as measured in this study. The results presented in chapter 4 
prove the hypotheses that have been developed in chapters 2 and 3. The efficiency of the metabolism and, 
ultimately, the overall performance of AGE1.HN were improved by reducing the substrate levels. 
Generally, specific differences in the metabolic behavior of AGE1.HN compared to other commonly 
employed production cell lines were observed, mainly, in the pyruvate metabolism. These differences in 
the metabolism and in the metabolic machinery of different production cell lines might derive from their 
specific origin. Depending on the organism and tissue type from which the cell lines are derived, enzyme 
and transporter properties as well as metabolic requirements might be constrained, e.g., by epigenetic 
mechanisms.  
Another property that varies between cell lines is the response and resistance to high ammonia 
concentrations in the medium. This toxic metabolite accumulates during cell culture processes and can 
limit productivity and influence product quality. The alterations imposed by ammonia stress as well as the 
Summary 
 141 
adaptation mechanism of the α1-antitrypsin producing AGE1.HN cell line were analyzed in detail in the 
study described in chapter 5. Growth and product formation were slightly decreased with increasing 
ammonia concentration. By using metabolic flux analysis, it was observed that the fluxes in the central 
energy metabolism were similar at different levels of ammonia stress, whereas specific fluxes in the amino 
acid metabolism were significantly and dose-dependently changed. We were able to show that the 
AGE1.HN cell line adapts to high ammonia concentrations by rearranging its amino acid metabolism 
towards increased fixation of free ammonia and less ammonia production resulting, eventually, in reduced 
ammonia accumulation in the medium. Fluxes through transaminases in amino acid degradation pathways 
were reduced along with a reduced uptake of the respective amino acids. Activities of transaminases 
producing amino acids, e.g., alanine transaminase, were increased leading to the increased storage of 
excess nitrogen in extracellular amino acids. Glutamate dehydrogenase was increasingly catalyzing the 
formation of glutamate with increasing ammonia concentration in the medium leading to increased 
fixation of free ammonia. Additionally, urea production was observed in the AGE1.HN cell line, which is, 
presumably, solely carried out by arginase II and, therefore, not relevant to the removal of excess 
ammonia. In summary, the results indicate the existence of an “ammonia sensor” in these cells which 
might be, in the simplest case, just equilibrium effects leading to the observed adaptations in the 
metabolism. A mechanistic explanation for the metabolic behavior of this cell line is provided in that same 
chapter.  
The development of high-producing cell lines for biopharmaceutical production is typically impeded by 
the low frequency of recombinant cell clones producing high levels of the target protein. Identifying the 
specific properties of the high producers as well as the metabolic and cellular requirements for high-level 
glycoprotein production might facilitate cell line development and help identify possible genetic 
engineering targets. This issue is addressed in chapter 6 in which the changes in the metabolism and the 
metabolic burden imposed by α1-antitrypsin production in AGE1.HN were analyzed. In this study, we 
compared the properties of a specifically selected high-producing cell line with the parental cell line. By 
comparing time courses of cellular biomass, metabolites, and selected macromolecules, we were able to 
identify specific differences between both cell lines. In particular, RNA and lipid fractions were higher in 
the producer. These specific alterations result, as a consequence, in different anabolic requirements and in 
specific changes in the metabolism of the cells. Since the cellular glycoprotein synthesis is fairly complex, a 
network model was set up comprising the whole process. By performing simulations, it was observed that 
the simulated theoretical metabolite demand corresponds with the observed changes in metabolic profiles, 
e.g., increased glycine and glutamate production. The increased production of these specific amino acids 
can be explained by the increased C1 unit and nucleotide demand in the producer, which is due to higher 
lipid and RNA content in this cell line. Comparison of the metabolic fluxes in both cell lines revealed that 
the central energy metabolism was similar in both cell lines. However, fluxes in the amino acid metabolism 
and C1 metabolism were changed according to the altered anabolic demand. In summary, we were able to 
show that the main cellular properties distinguishing the producer from the parental cell line are increased 
lipid and RNA fractions resulting in specific metabolic adaptations. The increased RNA content in the 
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producer is probably due to high levels of the recombinant α1-antitrypsin mRNA and, presumably, an 
increased pool of RNAs encoding for proteins involved in high-level α1-antitrypsin production. The 
increased lipid content points to an expanded secretion machinery in the producer. This might be an 
adaptation to high-level glycoprotein production or a specific feature of this cell clone which might have 
led to its selection. This study indicates that the engineering of lipid metabolism and secretory apparatus 
might be a promising strategy for further improvement in the performance of this cell line.   
The findings in chapters 2-4 highlight the possibility of improving biopharmaceutical production in 
AGE1.HN by optimizing the metabolism towards improved metabolic efficiency and balanced substrate 
use. In chapter 7, it is shown that treatment with the flavonoid quercetin induces changes in the primary 
metabolism of AGE1.HN resulting in lowered waste product formation, increased TCA cycle fluxes, and, 
ultimately, increased culture longevity and α1-antitrypsin titer. The improved channeling of pyruvate into 
mitochondria accompanied with a stimulation of TCA cycle activity upon quercetin treatment can be 
explained by different properties of quercetin and its metabolites. The results provided in chapter 7 show 
that the application of specific effectors might be a promising strategy for improving the metabolism and 
for enhancing the yields in cell culture processes.  
Finally, an outlook for the future is provided in chapter 8. Possibilities of improving the performance of 
the AGE1.HN cell line are discussed and the future prospects for applying and improving metabolic flux 
analyses in mammalian cells are presented. 
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Fig. S1. Metabolic profile of all analyzed metabolites and pH in three different cultivations of AGE1.HN.AAT cells 
with different ammonia start concentrations (0 mM, 2.5 mM, 5 mM). Glc glucose, Gal galactose, Lac lactate, Pyr 
pyruvate, standard abbreviations for amino acids. 
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Table S3 Metabolic fluxes in AGE1.HN.AAT and parental AGE1.HN cells. 
    AGE1.HN.AAT   AGE1.HN   
Flux no. Flux description Flux [µmol/g/h] SD [µmol/g/h] Flux [µmol/g/h] SD [µmol/g/h] 
    Extracellular fluxes       
1 Glc 216.14 6.27 217.32 0.83 
2 Gal 19.08 3.43 21.83 2.18 
3 Lac -302.99 16.94 -299.39 0.65 
4 Pyr 32.99 2.25 31.72 0.66 
5 Ala -0.70 0.02 -3.66 0.80 
6 Arg 6.54 0.45 8.41 0.55 
7 Asn 4.26 0.10 3.94 0.38 
8 Asp 8.23 0.74 10.10 1.44 
9 Cys 0.42 0.42 -0.02 0.78 
10 Glu -4.71 0.16 -3.29 0.40 
11 Gln 25.68 0.85 26.57 0.12 
12 Gly -3.40 0.42 -1.32 0.12 
13 His 1.70 0.14 1.67 0.15 
14 Ile 7.67 0.02 8.41 0.50 
15 Leu 11.02 0.41 11.33 0.44 
16 Lys 6.38 0.44 6.82 0.12 
17 Met 3.19 0.18 3.45 0.19 
18 Phe 3.36 0.09 3.21 0.39 
19 Pro -2.79 0.55 -4.15 0.98 
20 Ser 16.18 0.69 15.06 1.15 
21 Thr 4.19 0.06 4.34 0.65 
22 Trp 1.09 0.11 1.14 0.06 
23 Tyr 2.76 0.70 4.01 0.85 
24 Val 7.82 0.08 8.50 0.77 
25 A1AT 0.05 0.00 0.00 0.00 
    Anabolic fluxes       
26 Carbo 6.65 0.39 7.27 0.82 
27 DNA 0.69 0.04 0.75 0.08 
28 RNA 2.68 0.16 1.93 0.22 
29 Lip 3.08 0.18 2.83 0.32 
30 Prot 113.17 6.67 121.77 13.75 
    Intracellular fluxes       
31 G6P-F6P 224.90 10.28 229.20 4.14 
32 F6P-GAP 223.59 10.22 229.20 4.14 
33 GAP-Pyr 444.69 20.59 456.13 8.54 
34 Pyr-Pyrm 152.14 37.64 166.14 10.87 
35 Pyrm-AcCm 144.52 40.52 171.65 11.60 
36 OAA/AcCm-Citm 129.81 44.78 172.79 15.03 
37 Citm-AKGm 73.27 47.93 122.23 20.74 
38 AKGm-SuCm 68.26 50.10 121.97 22.11 
39 SuCm-Fumm 68.67 51.14 125.73 22.35 
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40 Fumm-Malm 69.74 50.69 128.27 21.65 
41 Malm-OAAm 133.90 44.66 173.31 15.21 
42 Malm-Pyrm -7.62 2.88 5.51 0.73 
43 Citm-Citc 56.54 3.15 50.55 5.71 
44 Citc-AcC/Mal 56.54 3.15 50.55 5.71 
45 Mal-Malm 56.54 3.15 50.55 5.71 
46 G6P-P5P 3.37 0.20 2.68 0.30 
47 NADH-OP 451.64 237.57 679.88 91.21 
48 FADH2-OP 68.47 52.70 130.26 23.39 
49 OP-ATP 1,231.80 672.97 1,895.11 263.10 
50 ATPwOP -5.69 100.57 134.17 89.86 
51 ATPtot 1,226.10 773.55 2,029.28 352.96 
52 Ala-Pyr -12.38 0.63 -13.67 0.41 
53 Arg-Glu 0.34 0.78 2.08 0.17 
54 Asn-Asp -1.80 0.36 -1.66 0.25 
55 Asp-OAA -4.09 0.13 -0.52 0.18 
56 Cys-Pyr -2.07 0.03 -2.05 0.35 
57 Gln-Glu 11.73 1.59 14.10 1.53 
58 Glu-AKGm -36.84 7.51 -20.44 4.84 
59 Ser-Gly 12.47 0.79 10.43 1.04 
60 His-Glu -1.38 0.26 -1.01 0.15 
61 Ile-AcCm/SuCm 1.67 0.24 2.93 0.11 
62 Leu-AcCm -1.14 0.88 0.73 0.75 
63 Lys-AcCm -3.65 0.87 -2.32 0.91 
64 Met/Ser-SuCm/Cys 0.81 0.27 1.38 0.04 
65 Phe-Tyr -1.93 0.28 -1.18 0.11 
66 Pro-Glu -8.18 0.32 -9.02 0.43 
67 Ser-Pyr -7.78 1.72 -6.60 0.96 
68 Thr-SuCm -2.72 0.21 -1.63 0.02 
69 Trp-AcCm/Ala -1.38 0.12 -0.20 0.10 
70 Tyr-AcCm/Fumm -1.46 0.30 0.52 0.48 
71 Val-SuCm 0.64 0.32 1.07 0.07 
72 G6P-GalER 0.30 0.01 0.00 0.00 
73 F6P/AcC-GlcNAcER 0.88 0.04 0.00 0.00 
74 GlcNAcER/PEP-Neu5AcER 0.30 0.01 0.00 0.00 
75 F6P-ManER 0.42 0.02 0.00 0.00 
76 ManER-FucER 0.01 0.00 0.00 0.00 
  TA AKGm-Glu -31.84 5.35 -20.18 3.47 
Mean values and standard deviations (SD) of two cultivations. Abbreviations as described in Fig. 6-1. NADH nicotinamide 
adenine dinucleotide, FADH2 flavin adenine dinucleotide, ATP adenosine triphosphate. Fluxes through electron transport chain 
and oxidative phosphorylation (47-51, not specified in Fig. 6-1): NADH-OP (47), NADH flux into electron transport chain, 
FADH2-OP (48) FADH2 flux into electron transport chain, OP-ATP (49) ATP produced in oxidative phosphorylation, ATPwOP 
(50) ATP excess from pathways other than oxidative phosphorylation, ATPtot (51) total cellular ATP excess. 
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